Nouvelles transformations énantiosélectives dirigées par des cyclodextrines : applications pour la préparation de briques moléculaires d’intérêt biologique by Mansour, Ali Taher
HAL Id: tel-02343180
https://tel.archives-ouvertes.fr/tel-02343180
Submitted on 2 Nov 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
New enantioselective transformations induced by
cyclodextrins : applications in the preparation of
molecular building blocks of biological interest
Ali Taher Mansour
To cite this version:
Ali Taher Mansour. New enantioselective transformations induced by cyclodextrins : applications in
the preparation of molecular building blocks of biological interest. Organic chemistry. Université
Paris-Saclay; Université libanaise, 2018. English. ￿NNT : 2018SACLS186￿. ￿tel-02343180￿
  New Enantioselective 
Transformations Induced by 
Cyclodextrins: Applications in the 
Preparation of Molecular Building 
Blocks of Biological Interest 
 
 
Thèse de doctorat de l'Université Libanaise et de l'Université Paris-
Saclay, préparée à l’Université Paris Sud 
 
 
    École doctorale n°571 sciences chimiques : molécules, matériaux, 
instrumentation et biosystèmes (2MIB) 
 
   Ecole doctorale des sciences et technologie de l’Université 
Libanaise (EDST) 
 
Spécialité de doctorat: Chimie 
 
 
Thèse présentée et soutenue à Beyrouth, le 5 Juillet 2018, par 
 
 M. Ali Taher Mansour  
 
Composition du Jury : 
 
 
M. Kamal Bouhadir 
Professeur, American University of Beirut   Président 
M. Olivier Piva  
Professeur, Université Claude Bernard (– SURCOOF)  Rapporteur 
M. Mahmoud Faraj 
Professeur, Lebanese International University  Rapporteur 
M. David J. Aitken  
Professeur, Université Paris Sud (– CP3A)   Directeur de thèse 
M. Daoud Naoufal 
Professeur, Université libanaise (– LCIO)   Directeur de thèse 
Mme Sylvie Robin 
Maître de conférences, Université Paris Descartes (– CP3A) Co-encadrante 
Mme Ogaritte Yazbeck 
Assistante Professeur, Université libanaise (– LCIO)  Co-encadrante
N
N
T
 :
 2
0
1
8
S
A
C
L
S
1
8
6
 
  
 
 
  
 
 
  
  
 
 
  
 
Acknowledgments 
First, I would like to express my gratitude to Pr. Mahmoud Faraj, the person who triggered 
my interest in organic chemistry, and Pr. Olivier Piva, for being reporters for my PhD 
thesis; and to Pr. Kamal Bouhadir for being the examiner. I am honored to have all of you 
as jury members. 
I would also like to express my gratitude to my research supervisors; Dr. Ogaritte Yazbeck 
who always believed in my potentials, and tough me how to have the spirit of a researcher; 
Dr. Sylvie Robin who patiently followed my work on daily basis; Pr. David J. Aitken who 
provided top class scientific supervision, and Pr. Daoud Naoufal who was especially helpful 
in setting up a wok place for organic chemistry in his lab, here in Lebanon. You were all 
encouraging, supportive, and vital for the success of this research.  
A special thanks goes to all the personnel at the Chimie Peptidomimétique Photochimie, 
Procédés Alternatifs (CP3A) group, from permanents to students, for their hospitality and 
scientific guidance, especially Ms. Florence Charnay-Pouget for her help with the HPLC, 
Mr. Jean-Pierre Baltaze for his help with the NMR experiments, Dr. Thomas Boddaert for 
his help with the photoreactor setup, Dr. Julien Buendia for his technical advices and Elodie 
Tran whose masters 1 work was integrated within this thesis. It has been a great pleasure, I 
learned enormously from each one of you.  
I would also like to show my appreciation to Dr, Ali Hachem and all his research group 
(LCMPN), especially my colleagues, Layal Haris, Tourin Bziea, Ranin Kawtharani, and Ali 
Solaiman. 
I am also grateful to the CIOES for their financial support, and to my family, and friends, 
who stood by me throughout this doctoral research. 
 
  
 
 
  
 
 Contents 
Chapter 1: Introduction ........................................................................................................ 1 
1.1 Photochirogenesis ............................................................................................................ 1 
1.1.1 Non-supramolecular photochirogenesis ......................................................................... 2 
1.1.1.1 Photochirogenesis via a chiral photosensitizer ............................................................ 2 
1.1.1.2 Photochirogenesis via a chiral auxiliary ...................................................................... 4 
1.1.2 Supramolecular Photochirogenesis ................................................................................ 6 
1.1.2.1 Chiral templates ........................................................................................................... 6 
1.1.2.2 Supramolecular photochirogenesis with cyclodextrins ............................................... 9 
1.2 Study of CD complexes ................................................................................................. 16 
1.2.1 Complex stoichiometry ................................................................................................ 16 
1.2.1.1 Determination of a CD complex stoichiometry ......................................................... 17 
1.2.2 1D NMR studies of CD complexes .............................................................................. 18 
1.2.3 Determination of the binding constant Kb .................................................................... 19 
1.2.3 2D NMR in the characterization of CD host/guest complexes .................................... 20 
1.3 γ-Amino acids ................................................................................................................. 23 
1.3.1 GABA and constrained analogs ................................................................................... 23 
1.3.1.1 Constrained -amino acids ......................................................................................... 24 
1.3.1.2 GABA analogs in the field of foldamers ................................................................... 25 
1.3.2 Literature synthesis of cis- and trans-2,3CB-GABA ..................................................... 26 
1.3.3 Literature synthesis of cis- and trans-3,4CB-GABA ..................................................... 28 
1.4 Aims of this project ....................................................................................................... 31 
  
 
 
  
 
Chapter 2: The Photochemical Reactivity of N-Allyl-N-(4-methoxyphenyl)acrylamide
 ............................................................................................................................................... 33 
2.1 Introduction ................................................................................................................... 33 
2.2 Results and discussion ................................................................................................... 35 
2.2.1 Synthesis of N-allyl-N-(4-methoxyphenyl)acrylamide 1 ............................................. 35 
2.2.2 The β-CD/ N-allyl-N-(4-methoxyphenyl)acrylamide 1 complex ................................. 37 
2.2.2.1 Formation of the β-CD/1 complex ............................................................................ 37 
2.2.2.2 Evidence of complexation by powder X-ray diffraction ........................................... 37 
2.2.2.3 Determination of the complex stoichiometry ............................................................ 38 
2.2.2.4 1D NMR studies of the β-CD/1 complex .................................................................. 39 
2.2.2.5 Determination of the binding constant Kb ................................................................. 42 
2.2.3 The photochemical reactivity of compound 1 .............................................................. 42 
2.2.3.1 Photoreactivity of compound 1 in solution, without β-CD ....................................... 42 
2.3 Conclusion ...................................................................................................................... 46 
Chapter 3: The Photochemical Reactivity of 1,3-dihydro-2H-azepin-2-one .................. 47 
3.1 Introduction ................................................................................................................... 47 
3.2 Results and discussion ................................................................................................... 49 
3.2.1 Synthesis of azepinone 8 .............................................................................................. 49 
3.2.2 Photoelectrocyclization of azepinone 8 in the absence of β-CD .................................. 50 
3.2.2.1 Photoelectrocyclization of azepinone 8 in solution ................................................... 50 
3.2.2.1.1 Photoelectrocyclization of azepinone 8 in ether .................................................... 50 
3.2.2.1.2 Photoelectrocyclization of azepinone 8 in water .................................................... 50 
3.2.2.2 Photoelectrocyclization of azepinone 8 in solid state ................................................ 51 
  
 
 
  
 
3.2.3 Analysis of the enantiomeric excess in photoadduct 9 ................................................. 51 
3.2.4 The β-CD/azepinone 8 complex ................................................................................................... 52 
3.2.4.1 Formation of the β-CD/azepinone 8 complex: ....................................................................................... 52 
3.2.4.2 Evidence of complexation by powder X-Ray diffraction ...................................................................... 53 
3.2.4.3 Determination of the complex stoichiometry ......................................................................................... 54 
3.2.4.3.1 The azepinone 8 to β-CD ratio in the precipitate ............................................................................... 54 
3.2.4.3.2 The Job’s method of continuous variation: ......................................................................................... 55 
3.2.4.4 1D NMR studies of the β-CD/azepinone 8 complex ............................................................................. 56 
3.2.4.5    Determination of the binding constant Kb ........................................................................................... 59 
3.2.4.6 2D ROESY NMR studies of the complex.............................................................................................. 60 
3.2.5 Photoelectrocyclization of azepinone 8 in the presence of β-CD ....................................... 63 
3.2.5.1 Recovery of the photoadduct 9 .............................................................................................................. 63 
3.2.5.2 Reduction of photoadduct 9 ................................................................................................................... 64 
3.2.5.3 Analysis of the enantiomeric excess compound (±)-10 ......................................................................... 65 
3.2.6 Photoelectrocyclization/Reduction of azepinone 8 in presence of β-CD .......................... 66 
3.2.6.1 Irradiation of β-CD/azepinone 8 complex in fluid state ......................................................................... 66 
3.2.6.1.1 Experiment A: “1:1 Hot solution” ...................................................................................................... 66 
3.2.6.1.2 Irradiation of 1 β-CD/azepinone 8 in Suspension ............................................................................... 68 
                 3.2.6.1.2.1 Experiment B: “1:1 β-CD/azepinone 8, Cold suspension” ................................................. 68 
                 3.2.6.1.2.2 Experiment C: “3:1 β-CD/azepinone 8 Cold suspension” ................................................... 69 
3.2.6.2 Irradiation of β-CD/azepinone 8 complex in solid state ........................................................................ 70 
3.2.6.2.1 Irradiation of β-CD/azepinone 8 complex in solid state powder form ................................................ 70 
                 3.2.6.2.1.1 Experiment D: Mechanically ground mixture of β-CD and azepinone 8 .......................... 70 
                 3.2.6.2.1.2 Experiment E: “β-CD/8 complex, filtered then irradiated in powder form”.................... 71 
3.2.6.2.2 Irradiation in thin film form ................................................................................................................ 73 
  
 
 
  
 
                 3.2.6.2.2.1 Experiment F: “1:1 film from 15 mM suspension” .............................................................. 73 
                 3.2.6.2.2.2 Experiment G: “2:1 film from 15 mM suspension” .............................................................. 75 
                 3.2.6.2.2.3 Experiment H: “1:1 film from 5 mM clear solution” ........................................................... 75 
3.2.7 The β-CD/8 complex film texture ................................................................................................ 76 
3.2.7.1   Scanning electron microscopy (SEM) of β-CD/azepinone 8 complex films ....................................... 78 
3.2.8 The absolute configuration of compound 10 ............................................................................. 78 
3.3 Chiral resolution of ()-cis-3,4CB-GABA by HPLC .............................................................. 81 
3.3.1 Preparation of the Boc protected amino acid ()-12 ............................................................... 81 
3.3.1.2 Photoelectrocyclization of azepinone 8 in ether .................................................................................... 81 
3.3.1.3 Catalytic hydrogenation of photoadduct (±)-9 ....................................................................................... 82 
3.3.1.4 Activation of the 2-azabicyclo[3.2.0]heptan-3-one (±)-10 .................................................................... 82 
3.3.1.5 Basic hydrolysis of (±)-11 ..................................................................................................................... 83 
3.3.2 Chiral HPLC resolution of N-Boc amino acid (±)-12............................................................. 83 
3.3.3 Switching to the N-Boc benzylic ester (±)-13 ........................................................................... 85 
3.3.3.1 Preparation of N-Boc benzyl ester (±)-13 .............................................................................................. 85 
3.3.3.2 Chiral HPLC resolution of N-Boc benzylic ester (±)-13 ........................................................................ 86 
3.4 Conclusion ............................................................................................................................................. 89 
Chapter 4: Synthesis and Folding Pattern of γ/α-Hybrid Peptides ................. 90 
4.1 Introduction .......................................................................................................................................... 90 
4.1.1 The Three dimensional conformation of polypeptides ........................................................... 91 
4.1.1.1 The conformation of the peptide link ..................................................................................................... 91 
4.1.1.2 The conformation around the peptide bond ........................................................................................... 92 
4.1.2 The folding pattern in natural peptides ....................................................................................... 93 
4.1.2.1 The Ramachandran diagram .................................................................................................................. 93 
  
 
 
  
 
4.1.2.2 Conformation of natural peptides .......................................................................................................... 94 
4.1.2.2.1 The α-helix “natural helix” ................................................................................................................ 95 
4.1.3 The folding pattern in unnatural peptides .................................................................................. 96 
4.1.3.1 Folding pattern in homo-peptides .......................................................................................................... 97 
4.1.3.1.1 β-Peptides ........................................................................................................................................... 97 
                 4.1.3.1.1.1  Example and application of the β-Peptides .......................................................................... 98 
4.1.3.1.2 γ-peptides ............................................................................................................................................ 99 
                 4.1.3.1.2.1 Examples and application of the γ-peptides ......................................................................... 100 
4.1.3.2 Folding pattern in hybrid peptides ....................................................................................................... 101 
4.1.3.2.1 Mixed α/β-peptides ............................................................................................................................ 102 
                 4.1.3.2.1.1 Examples of α/β-peptides and applications ......................................................................... 102 
4.1.3.2.2 Mixed β/γ-peptides ............................................................................................................................ 103 
                 4.1.3.2.2.1 Examples of β/γ and applications .......................................................................................... 103 
4.1.3.2.3 Mixed α/γ-peptides ............................................................................................................................ 104 
                 4.1.3.2.3.1 Examples and applications ...................................................................................................... 105 
4.1.3.3 Stereochemistry effect on the peptide secondary structure .................................................................. 109 
4.1.4 Objectives of this work .................................................................................................................. 111 
4.2. Results and discussion ................................................................................................................... 113 
4.2.1 The starting amino acids: Enantiomerically pure protected γ- and α-amino acids ...... 113 
4.2.1.1 The enantiomerically pure Boc-cis-3,4CB-GABA-OBn ....................................................................... 113 
4.2.1.2 The Enatiomerically pure D-Alanine ................................................................................................... 114 
4.2.2 The general Synthetic method ..................................................................................................... 115 
4.2.2.1 The activation/ coupling strategy ......................................................................................................... 115 
4.2.2.2 Choice of the coupling agent ............................................................................................................... 116 
4.2.2.3 Convergent peptide synthesis .............................................................................................................. 118 
  
 
 
  
 
4.2.3 Synthesis of Boc-(S,S)-cis-3,4CB-GABA/(R)-Ala-OBn peptides ...................................... 119 
4.2.3.1 Synthesis of the Boc-[(S,S)-cis-3,4CB-GABA/(R)-Ala]-OBn peptide p1 ............................................. 120 
4.2.3.2 Synthesis of the Boc-[(S,S)-cis-3,4CB-GABA/(R)-Ala]2-OBn peptide p2 ............................................ 120 
4.2.4 Synthesis of Boc-(R,R)-cis-3,4CB-GABA/(R)-Ala-OBn peptides ..................................... 121 
4.2.4.1 Synthesis of the Boc-(R,R)-cis-3,4CB-GABA-(R)-Ala-OBn peptide p3 ............................................... 122 
4.2.4.2 Synthesis of the Boc-[(R,R)-cis-3,4CB-GABA-(R)-Ala]2-OBn peptide p4 ........................................... 123 
4.2.5 Structural and Conformational analysis in solution .............................................................. 123 
4.2.5.1 General methods for structural and conformational analysis ............................................................... 123 
4.2.5.1.1 Structural analysis ............................................................................................................................ 123 
4.2.5.1.2 DMSO-d6 NMR titration experiments ............................................................................................... 124 
4.2.5.1.3 Conformational analysis ................................................................................................................... 124 
4.2.5.1.4 Molecular modeling .......................................................................................................................... 124 
4.2.5.2 Determining the linear structure of the peptides p2 and p4 ................................................................. 125 
4.2.5.2.1 DMSO-d6 titration experiment .......................................................................................................... 125 
4.2.5.3 Conformational analysis of the peptides p2 and p4 ............................................................................. 126 
4.2.5.3.1 2D ROESY NMR experiment ............................................................................................................ 126 
4.2.5.3.2 Molecular modeling .......................................................................................................................... 127 
4.2.6 Boc-(S,S)-cis-3,4CB-GABA/(R)-Ala-NHBn peptides ............................................................................. 130 
4.2.6.1 Synthesis of the Boc-(S,S)-cis-3,4CB-GABA-(R)-Ala-NHBn peptide p5................................................ 131 
4.3 Conclusion ........................................................................................................................................... 133 
Perspective and Overall Conclusion .................................................................................... 134 
Experimental Part ............................................................................................................................. 137 
Index............................................................................................................................................................ 184 
Thesis Summary in French (Résumé français)............................................................................188 
  
 
 
  
 
Bibliography .......................................................................................................................................... 216 
Abstract .................................................................................................................................................... 224 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Page | 1  
  
Chapter 1: Introduction 
1.1 Photochirogenesis 
The majority of natural and biologically relevant chiral molecules on Earth have a defined 
configuration which is linked to their molecular function. It is marvelous how living 
organisms have the ability to preferentially choose or selectively biosynthesize only a single 
enantiomer of a given molecule.1 Chemists are envious of this and seek to imitate biological 
systems; thus, the asymmetric synthesis of organic compounds has become a popular 
playground for research.2 Selective preparation of molecules in single enantiomer form also 
has industrial importance, due to the requirement of stereochemically  pure molecules in the 
field of medicine and material science. 
 Over the last few decades, the asymmetric synthesis of organic compounds has been 
conventionally achieved by either catalytic3 or enzymatic4 transformations, and a wide range 
of methods have been developed in order to gain stereochemical control over a variety of 
chemical transformations. Photochemistry has proven itself to be a versatile tool in organic 
synthesis,5, 6 and it is receiving even more attention today since it qualifies as a method for 
the preparation of new materials in an “environmentally friendly” context, referred to as 
green chemistry.7 Nonetheless, asymmetric photochemical transformations are not widely 
studied. The term “photochirogenesis” is rather new. It was coined in 1996, and is 
conceptually synonymous to more traditional “asymmetric photochemistry” or “chiral 
photochemistry” with the emphasis on the creation of molecular chirality through the use of 
a photon.8 
Asymmetric induction from the excited electronic state is hard to achieve due to 
fundamental factors that make conventional approaches difficult to apply in photochemical 
reactions.9 For instance, a chiral catalyst in thermal reactions often functions by decreasing 
the reaction activation barrier and channels the reaction profile towards an enantioselective 
pathway; whereas in a photochemical reaction, the irradiated molecules gain sufficient 
energy to undergo fast subsequent reactions, which do not require further catalysis. So, the 
biggest challenge in photochirogenesis relates to the inherent high-energy nature of the 
electronical excited state. Indeed, the much smaller activation parameters for excited-state 
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(as opposed to ground-state) reactions leave little space for energetically differentiating the 
diastereomeric transition states leading to a pair of enantiomers. So how can chirality be 
controlled in the highly reactive, short lived excited state? 
Photochirogenesis research has made great progress both quantitatively and qualitatively 
due to new methodologies developed for controlling the processes involved. Essentially, in 
order to achieve stereochemical control over a photochemical reaction, one must make sure 
that the substrate molecule already resides in a chiral environment during the excitation 
step.10 In this regard, photochirogenesis can be convenienttly split into two major categories. 
The first includes reactions in which chirality is transferred to a reacting molecule due to the 
presence of a chiral substituent, covalently or ionically connected to the reactant. Chirality, 
with such an approach, can be induced through the intramolecular interaction between the 
chiral center, acting as a “chiral auxiliary”, and the reacting moiety. The second category, 
supramolecular photochirogenesis, can be described as a host-guest interaction between the 
reactant, as the guest, and a host molecule that provides a chiral environment for the 
photochemical reaction to proceed in an asymmetric manner. Here, chirality is transferred 
from one molecule to another through intermolecular interactions between the substrate and 
a neighboring molecule bearing some chiral properties.  
1.1.1 Non-supramolecular photochirogenesis 
1.1.1.1 Photochirogenesis via a chiral photosensitizer 
Hammond and Cole,11 were the first to exploit chiral photosensitizers for asymmetric 
induction in photochemistry. They studied the geometrical photoisomerization of racemic 
1,2-diphenylcyclopropane sensitized by a chiral (R)-N-acetylnaphthylethylamine (see 
Scheme 1). By monitoring the development of the optical activity during the course of the 
photoisomerization, they established a photostationary state at a cis/trans ratio of 1.03 with 
an enantiomeric excess of 7% of the chiral trans-isomer, thus showing the potential of using 
a chiral photosensitizer to induce chirality in a photoreaction.  
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Scheme 1: The asymmetric photoisomerization of 1,2-diphenylcyclopropane sensitized by a 
chiral naphthylethylamine derivative. 
However, after 20 year of rather slow progress; the unprecedentedly high 53% ee achieved 
by the Inoue group,12 in a systematic study of the enantiodifferentiating isomerization of 
cyclooctenes sensitized by chiral polyalkyl benzene(poly)carboxylates (see Scheme 2), 
triggered a boost of interest in photochirogenesis. 
 
Scheme 2: The asymmetric photoisomerization of cyclooctene sensitized by chiral polyalkyl 
benzene(poly)carboxylates. 
Most recently the Inoue group13 exploited chiral methyl (R)-[10]paracyclophane-12-
carboxylate as a sensitizer, to achieve an enantiomeric excess of 87% in the 
photoisomerization of  (Z,Z)-1,5-cyclooctadiene (see Scheme 3). In this system the 
decamethylene bridge provided a shield on one of the enantiotopic faces of the chiral 
cyclophanes sensitizer. This shielding was attributed by the authors to both enthalpically 
and entropically factors, which makes the approach, and subsequently the isomerization of 
the substrate more enantioselective. 
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Scheme 3: The asymmetric photoisomerization of cyclooctadiene sensitized by (R)-
[10]paracyclophane-12-carboxylate derivative. 
Aside from this quite unique example of enantioselective photosensitized isomerization of 
cyclooctadiene, it had pretty much been established that conventional photochirogenesis 
induced via chiral sensitizers alone are generally considered not very efficient. The exciplex 
between an excited chiral sensitizer and a ground-state substrate, despite being at lower 
energy than the exited state alone, still has large conformational freedom which minimizes 
the prospects for chiral induction.14 
1.1.1.2 Photochirogenesis via a chiral auxiliary 
After the mid-1990’s, with more understanding of chirality transfer, much greater 
stereoselectivity was reported in photochemical reactions. Griesbeck and coworkers studied 
the photodecarboxylation of N-phthaloylanthranilic acid derivatives (see Scheme 4).15 
Photodecarboxylation of the corresponding chiral potassium salt allowed access to the 
pentacyclic pyrrolo[1,4]benzodiazepine photo-adduct with a diastereoselectivity greater 
than 98% and an enantiomeric excess up to 86%. 
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Scheme 4: The asymmetric photodecarboxylation of N-phthaloylanthranilic acid 
derivatives. 
At around the same period, the Mariano group studied the [2+2] photocycloaddition of 
chiral pyrolidino-cyclohexeniminium perchlorates (see Scheme 5).16 The presence of the 
chiral pyrrolidine makes the photocycloaddition facially selective favoring the anti 
transition state that gives rise to an enantiomeric excess of up to 82%. 
 
Scheme 5: The asymmetric photocycloaddition of chiral pyrrolidino-cyclohexeniminium 
perchlorate. 
Later, much higher enantiomeric excess was found through photochirogenesis using chiral 
auxiliaries. Scheffer and Wang studied the photochemical synthesis of β-lactams via the 
asymmetric Norrish Type II photochemical reaction of salt crystals formed from ionic chiral 
auxiliaries and 4-(2-(diisopropylamino)-2-oxoacetyl)benzoate (see Scheme 6).17 Irradiation 
of the chiral crystals in the solid state yielded the target photoadduct in ee up to 99%. The 
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high enantioselectivity was attributed by the authors to the ability of the chiral salt substrate 
to crystallize into a single conformational enantiomer.  
 
Scheme 6:The asymmetric Norrish Type II photochemical reaction of chiral salts of 4-(2-
(diisopropylamino)-2-oxoacetyl)benzoate,  forming a β-lactam derivative. 
1.1.2 Supramolecular Photochirogenesis 
Supramolecular photochirogenesis18 is an evolving field of research implicating 
photochemistry, asymmetric synthesis, and supramolecular chemistry. Stereochemical 
control in supramolecular photoreactions is mostly attributed the non-covalent interactions 
between the host and the substrate; by confining a prochiral substrate in a chiral 
supramolecular environment prior to photo-excitation, there is more likelihood of effective 
chirality transfer in the excited state. The substrate is likely to have a preferred 
conformation within the host cavity; this is conveyed to the product chirality upon 
irradiation. Also, confinement extenuates the difference in free energy of activation between 
two diasteromeric transition states, thus facilitating their discrimination, and boosting 
enantioselectivity. Several macromolecules have been used as hosts in asymmetric 
photosynthesis, including zeolite, urea clatharates, cucurbiturils, octaacids, metal 
nanocages, chiral organic templates, and cyclodextrins (CDs). There are a number of 
excellent recent reviews on supramolecular photochirogenesis;19 here we shall illustrate 
some of the more recent studies or examples with fairly high enantioselectivity. 
1.1.2.1 Chiral templates 
Chiral templates are among the best supramolecular hosts utilized in the field of asymmetric 
photochemistry. Several chiral templates have been used to induce high enantioselectivity. 
Chiral templates possess a well-defined three-dimensional space to confine a guest 
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substrate; they do not have a cavity, but achieve chirality transfer by directly interacting 
with substrates through strong and directional non-covalent interactions, such as hydrogen-
bonding and/or electrostatic interactions. In their interactions they are considered 
supramolecular hosts, even though they are more “molecular” due to their size and 
architectural simplicity. Several chiral templates have been used to induce high 
enantioselectivity. 
The Lipkowska group utilized chiral diols as templates to perform enantioselective 
photocyclizations of 1-alkyl-2-pyridones in inclusion crystals, to give β-lactams in good 
yield with ee up to 99% (see Scheme 7).20 The high enantioselectivity was attributed to the 
spatial situation of the pyridone derivative substrate relative to the template molecule in the 
solid crystal form, which sterically allows the formation of one enantiomer. 
 
Scheme 7: The asymmetric photocyclizations of an 1-alkyl-2-pyridone into a β-lactam 
derivative. 
A similar approach was later studied by the Bach group who developed a lactam/xanthone 
based template for the intramolecular [2+2]-photocycloaddition of prochiral 4-(but-3-
enyloxy)quinolone (see Scheme 8 ).21 The template allowed high directionality in the 
binding of its lactam segment to a photoreactive substrate, making only one enantiotopic 
face available for the [2+2]-cycloaddition reaction to proceed. This was validated by the 
high enantioselectivity of the reaction, with ee values up to 94%. 
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Scheme 8: The asymmetric photocyclization of 4-(but-3-enyloxy)quinolone. 
The same research group also utilized thiourea based molecules as templates to host, by the 
same logic, another enantioselective intramolecular [2+2] photocycloaddition reaction with 
ee up to 91% (see Scheme 9).22 
 
Scheme 9: The asymmetric photocycloaddition of a 2,3-dihydropyridone-5-carboxylate 
derivative. 
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1.1.2.2 Supramolecular photochirogenesis with cyclodextrins  
Cyclodextrins (CDs) are macrocyclic nano-buckets that are capable of forming stable 
inclusion complexes with many molecules. Due to this property, CDs have many 
applications in supramolecular chemistry,23, 24 in the catalysis of organic reactions,25 and in 
encapsulation of pharmaceuticals in order to serve as drug delivery agents.26, 27 CDs also 
play a prominent role in the field of supramolecular photochirogenesis, as we shall illustrate 
below. 
Before discussing asymmetric photochemistry induced by cyclodextrins, one must 
appreciate the structural features of these molecules.  Natural CDs are cyclic oligomers 
comprised of 6, 7, or 8 D-glucopyranose units (corresponding to α-, β-, and γ-CD 
respectively), that are linked through α-(1,4) glycosidic bonds. Due to the chair 
conformation of the glucopyranose units the CD is shaped like a truncated cone rather than 
a perfect cylinder (see Figure 1).28 The internal cavity of the truncated cone is lined by the 
H3 and H5 protons and the lone pair of the glycosidic oxygen atoms, thus rendering the 
interior of the structure lipophilic; this allows CDs to form host-guest complexes with a 
variety of organic and inorganic molecules. On the other hand, the hydroxyls on C-2, C-3, 
and C-6 are directed towards the exterior, thus rendering the outer face hydrophilic. As a 
combined effect of this arrangement of atoms, CDs are soluble in polar (e.g. physiological) 
media and at the same time can carry lipophilic molecule in their cavity.29 
 
Figure 1: Glucopyranose unit (left), the β-CD torus (middle), and the orientation of the CD 
protons relative to its cavity (right).  
CDs are transparent in the UV-vis region of electromagnetic radiation and are inherently 
chiral and compatible with many electronically excited species, making them among the 
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most frequently employed supramolecular hosts for mediating photochirogenic reactions.30 
In the past 30 years, the CD cavity has provided a chiral environment for a wide range of 
photochemical reactions, including photolysis reactions,31, 32 unimolecular 
photoelectrocyclizations, intermolecular33 and intramolecular photocycloadditions,34, 35 as 
well as photocyclodimerization reactions.36, 37, 38 Since CDs can be chemically modified,39 
sensitizer-grafted CDs can be envisaged as supramolecular photosensitizing systems for 
better enantiodifferentiation. 
In 1980, Takeshita and coworkers studied the intramolecular photochemical 
electrocyclization of tropolone and its methyl ether derivative in the presence of α- or β-
CDs, in water, methanol, acetone, or hexane (see Scheme 10).40 The authors did not report 
ee values for the photoproducts; rather, they validated the occurrence of enantioselective 
transformations through optical rotation measurements. They also noted that the amplitude 
of the optical rotation was largest in photoadducts obtained from irradiation in aprotic 
solvents in the presence of β-CD compared to those obtained in the presence of α-CD.  
 
Scheme 10: The intramolecular  photochemical electrocyclization of tropolone and its 
methyl ether derivative in the presence of CDs. 
Twenty years later, the Ramamurthy group conducted new studies on the photochemical 
electrocyclizations of tropolone alkyl ethers bearing different alkyl substituents, in the 
presence of α, β and γ-CDs, both in solution and in the solid state.41 observed a near zero ee 
in solution and a moderate ee (20-30%) in solid state, suggesting that the rigidity of the 
medium is an important parameter for the chiral induction during this photoreaction. 
Moreover, they suggested that a tight-binding complexation between the reactant and the 
CD host is a requirement for a good enantioselectivity. 
Subsequently, the same group studied the photochemical electrocyclization of N-alkyl 
pyridines in the presence of β-CD (see Scheme 11).42 Enantiomeric excesses 60% was 
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obtained by irradiating a mechanically ground mixture of the β-CD host and the pyridone 
guest in solid state. 
 
Scheme 11: The photochemical electrocyclization of N-alkyl pyridones in the presence of β-
CD. 
Despite the higher ee, the authors were unable to exceed a conversion of 15% even when 
controlling the wavelength of the irradiation, an observation which was attributed to the 
photoreversibility of the reaction. 
Chirally modified CDs were utilized as hosts for Norrish Type II / Yang cyclization 
reactions of chiral derivatives of N,N-diisopropyl-2-oxo-2-arylacetamides, in aqueous 
solutions as well as in sloid state (see Scheme 12).43 Although an increase of the 
enantiomeric (up to 21% ee and 47% de) was noted when either the host or the guest were 
chirally modified; neither a reliable model that would help to predict the outcome of the 
chiral induction in a photochemical reaction, nor an understanding of the effect of the chiral 
center in the substrate emerged from this investigation. 
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Scheme 12: Asymmetric Norrish Type II / Yang cyclization reaction of chiral N,N-
diisopropyl-2-oxo-2-arylacetamide derivatives in the presence of β-CD and chirally 
modified β-CD.  
Inoue and coworkers investigated the photoisomerization of Z-cyclooctene in the presence 
of native β-CD44 and functionalized α, β, and γ-CDs bearing a photosensitizer on the 
primary face.45, 37 They observed an improvement in the ee from near 0% with native β-CD 
to 24% with a sensitizer functionalized β-CD (see Scheme 13). The authors pointed out the 
importance of the “fit” between the CD cavity and the guest for  the enantioselectivity. The 
same photoisomerization reaction was further investigated in aqueous methanol by Li and 
coworkers.46 This group showed that, in the presence of a sensitizer functionalized β-CD, 
the ee and the photostationary E/Z ratio are dependent on the solvent composition. They 
reported ee values up to 47% through optimization of the methanol/H2O ratio and the 
temperature of the reaction mixture (See Scheme 13). 
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Scheme 13: The photoisomerization of Z-cyclooctene in the presence of native or 
functionalized β-CDs.  
CDs have also been employed as hosts for bimolecular photoreactions. For instance, Luo 
and coworkers studied the photocyclodimerization of methyl 3-methoxynaphthalene-2-
carboxylate inside a γ-CD host (see Scheme 14).47 The authors reported an ee of 48% in 
aqueous solution, at 0.5 oC, which was the highest value achieved for the asymmetric 
photodimerization in solution at that time. 
 
Scheme 14: The photocyclodimerization of methyl 3-methoxynaphthalene-2-carboxylate in 
the presence of  γ-CD. 
 Inoue’s research group has extensively studied the chiral photocyclodimerization of 2-
anthracenecarboxylates (ACs) in the presence of native γ-CD and 6A-2(2-
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(dimethylamino)ethylamino)-6A-deoxy-γ-CD (DMAEA-γ-CD)3 (see Scheme 15).36, 48 In the 
case of native γ-CD, the head to tail enantiomer b was the major compound, obtained with 
an ee of 32% at 25 °C. This was improved to an ee of 41% when the reaction temperature 
was lowered to 0 °C. On the other hand, when DMAEA- γ-CD was used as the chiral host, 
ionic interactions between the carboxylate part of the ACs and the ammonium part the 
DMAEA-γ-CD led to substrate reorientation inside the CD cavity such that the head to head 
enantiomer c became the major compound, still with 41% ee. 
 
Scheme 15: The chiral photo-cyclodimerization of 2-anthracenecarboxylate inside γ-CDs. 
Later, the same group devised a novel, “dual chiral, dual-supramolecular” system in which 
they anchored two AC acid molecules to the primary face of an α-CD in order to pre-orient 
the two photosubstrates before adding the γ-CD as the chiral confining host. This duel 
system allowed selective access to the major cyclodimer c in 98% yield and unprecedented 
99% ee (see Scheme 16).49 
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Scheme 16: The dual-supramolecular system for a chiral photocyclodimerization of 2-
anthracenecarboxylate. 
Continuing their research, Inoue’s group recently published the cyclodimerization of ACs 
encapsulated by two 6A,6C-dideoxy-6A,6C-triethylammonium derivatives of β-CD  (see 
Scheme 17).50 In this 2:2 AC/β-CD complex, two ACs moieties are partially stacked to each 
other exclusively in a head-to-tail fashion which allowed access to the non-conventional 
slipped cyclodimer with an ee of 71% under optimized conditions. 
 
Scheme 17: Formation of the non-conventional slipped cyclodimer as a product of the 
photocyclodimerization of the 2:2 AC/β-CD complex. 
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1.2 Study of CD complexes 
1.2.1 Complex stoichiometry 
When studying a molecular inclusion complex, a key matter is to determine its 
stoichiometry (see Figure 2). For CD complexes several host:guest ratios have been 
reported, among which the most commonly observed is the 1:1 complex, wherein one CD 
molecule includes only one guest inside its cavity.51 Nevertheless, other ratios are known, 
e.g. 1:2, where two guest molecules are (totally or partially) included inside the same CD 
cavity;52 2:1, where two CD molecules encapsulate a single guest;53 or a 2:2 complex made 
of 2 CD molecules and 2 Guest molecules.54 
 
Figure 2: The most common binding stoichiometries between CDs and guest molecules.55 
Three-component CD complexes are also known. These ternary complexes are usually 
composed of the CD, a guest, and an alcohol that serves to optimize the fit of the guest in 
the CD cavity.51  
Interestingly, the stoichiometry in a CD complex can be temperature dependent. For 
instance, the 1:1 stoichiometry of a β-CD/1-adamantanecarboxylic acid complex at 25 oC 
changes to a 1:2 stoichiometry when the temperature is lowered to 0 oC.56 
  
Page | 17  
  
1.2.1.1 Determination of a CD complex stoichiometry 
One of the frequently applied procedures to determine the stoichiometry of a molecular 
complex is the Job’s method of continuous variation.29 In a typical experiment, a physical 
property that is sensitive to complex formation is recorded while the relative proportions of 
the host and the guest are varied in a solution in which the total solute concentration is kept 
constant.57 
The most common variable used for a Job’s plot is UV-vis absorbance, but any property 
that correlates linearly with the concentration of complex formation, including kinetics, 
conductivity, NMR spectroscopy etc., can be used.58 The collected data are usually plotted 
in the form of the molar fraction () of one species (host or guest) multiplied by the induced 
change in the observed property (P), against that molar fraction (), where  =
[𝑠𝑝𝑒𝑐𝑖𝑒𝑠 𝒂]
[𝑠𝑝𝑒𝑐𝑖𝑒𝑠 𝒂]+[𝑠𝑝𝑒𝑐𝑖𝑒𝑠 𝒃]
 (see Figure 3). 
The position of the maximum in a Job’s plot identifies the stoichiometric ratio of the formed 
complex. Although the data obtained is not convenient for estimating the binding constant,57 
the shape of the Job’s plot curve provides qualitative insight into the magnitude of the 
binding constant. Strong binding (Kb >> 1) affords a more angular plot, whereas a lower 
bonding constant affords a gentle curvature.58 
 
Figure 3: A general form of a Job’s plot for a 1:1 complex showing the difference in 
curvature shape when Kb << 1 and , Kb>> 1. 
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 1.2.2 1D NMR studies of CD complexes 
The simplest NMR experiment for studying an inclusion complex is to monitor the changes 
in the proton chemical shifts between the free host and guest species and the putative 
complex. Thakkar and Demarco described an NMR method for examining the mode of 
interaction of CDs with a variety of aromatic substrates.59, 60 Their method is based upon the 
rationale that when an aromatic guest is incorporated inside the cavity of the CD molecule, 
protons located within the cavity (H3, H5 and, possibly, H6), (see Figure 4), undergo a 
noticeable shift in their 1H NMR signals due to the anisotropy of the aromatic moiety. On 
the other hand, protons which are oriented toward the outside of the CD cavity (H1, H2, and 
H4), are relatively unaffected. These induced variations in the chemical shifts could provide 
evidence for the formation of an inclusion complex in solution.61, 62 
 
Figure 4: Orientation of CD protons with respect to the cavity. 
Apart from qualitative information, NMR titration experiments can lead to valuable 
information not just for how the host and guest(s) interact, but can also be used to quantitate 
how strong this interaction is. Indeed, values exceeding 105 for the equilibrium binding 
constant Kb can be estimated using modern NMR instruments from the observed induced 
chemical shifts (Δδ).63 The induced chemical shift is defined as the difference in the 
chemical shift of a proton belonging to one molecule, in the presence and absence of 
another molecule.64 In our case, the induced shifts were calculated by the following 
equation: Δδ = δ(free) - δ(complexed). In this convention, a positive sign of Δδ designates an 
upfield shift in the presence of another molecule. 
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1.2.3 Determination of the binding constant Kb 
 The equilibrium constant (K) for a complex formed between a host (H) and a guest 
(G) can be formulated from the general equilibrium reaction: 
 
When the stoichiometry of a β-CD/guest complex is 1:1, the desired equilibrium (in this 
case binding) constant Kb is given by: 
        𝐾𝑏 =
[𝐻𝐺]
[𝐻][𝐺]
                      (1) 
Where [G] is the concentration of free guest, [H] is the concentration of free host, i.e. β-CD, 
and [HG] the concentration of the formed host/guest complex.  
Because the complexation phenomenon is a dynamic equilibrium, the individual 
concentration of each species is not readily measurable. Instead of measuring separate 
concentrations, a well-known approach to determine the binding constant is to generate the 
binding curve then to deduce Kb via a regression analysis based on the Benesi-Hildebrand 
equation.65, 66 A plot of 1/Δδ vs [G] establishes a straight line whose slop is directly related 
to the value of Kb, for a 1:1 - Guest:Host complex (see Figure 5). (For more detailes see 
ndex -A) 
 
Figure 5: A plot of 1/Δδ vs 1/[G], based on the Benesi-Hildebrand equation.  
  
Page | 20  
  
1.2.3 2D NMR in the characterization of CD host/guest complexes 
In order to investigate the geometry of a complex and to propose a mode of complexation 
between CD and a guest, 2D ROESY NMR experiments are very useful. At the level of 
NMR spectroscopy, nuclear spins can interact via both through-bond phenomena (spin-spin 
coupling) and through-space phenomena (dipolar coupling). The through-bond interaction is 
commonly observed as a split in the NMR signal and characterized by the coupling constant 
J. On the other hand, the through-space dipolar interactions do not split the NMR signal 
since the effect is completely averaged by the normal tumbling of molecules in isotropic 
solutions. Nevertheless, these dipolar interactions manifest themselves indirectly, 
generating the Nuclear Overhauser Effect (NOE).29 
NOE magnitudes depend, among others, on the effective correlation times τeff characterizing 
overall molecular tumbling and intramolecular motions. CD complexes with molecular 
masses around 1-2 kDa display τeff of a fraction of a nanosecond and are placed near the 
transition between positive and negative NOEs. Fortunately NOE in the rotating frame 
(ROE) is always positive, (see Figure 6), thus becoming a method of choice in the studies of 
medium-sized molecules and complexes.67Consequently the (ROESY) pulse sequence is 
typically the NOE-based experiment of choice for CD complexes.68  
 
Figure 6: The variation of the 1H/1H nuclear Overhauser effect (NOE) and rotating-frame 
Overhauser effect (ROE) with respect to correlation time τc. 
In Rotating-frame Overhauser Effect Spectroscopy (ROESY) experiment, the spatial 
proximity between atoms of the host and guest molecules is obtained by observing the 
intermolecular dipolar cross-correlations. The intensities of the cross peaks are proportional 
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to 1/r6, where r is the mean distance between the protons in dipolar interaction.69 A NOE 
cross-peak between a proton of a guest molecule and a proton of the CD moiety will be 
observed in a ROESY spectrum if these two protons are closer than 4 Å through space. 
Therefore, if the guest molecule is included in the CD cavity, NOE correlations between the 
protons of the guest and the protons (H3, H5, or H6) that appear in the CD inner cavity will 
be observed.62  
Although 1D NMR titration experiments could provide evidence on the formation of an 
inclusion complex between two molecules, 2D NOESY or ROESY experiments are 
essential to understand the dynamics and the overall geometry of the inclusion complex.64 
Several research groups have relied on interpretation of 2D as well as the 1D (selective) 
ROSEY spectra to extract valuable information on the mode of complexation of various 
organic guest molecules inside CD cavities. 
For instance, Forgo and D’Souza used 1D ROE experiments to study the host-guest 
interactions of β-CD with p-nitrophenol (see Figure 7).70 The selective excitation of H3’ and 
H5’ of p-nitrophenol shows a ROE correlation with H3 and H5 of the β-CD indicating that 
former set of protons are in close proximity to both H3 and H5, placing this part of the p-
nitrophenol molecule deep inside the β-CD cavity (see Figure 7 spectrum B). On the other 
hand, selective excitation of H2’ and H6’ of the p-nitrophenol shows a correlation only with 
H3 indicating that this part of the p-nitrophenol molecule is located in a more shallow 
manner, towards the secondary face of the β-CD. (see Figure 8 spectrum C). 
 
Figure 7: The proposed β-CD/p-nitrophenol complex (left), 1D selective ROE spectra 
(right). 
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Similarly, Korytkowska-Wałach and coworkers,71 studied the inclusion complexes formed 
between β-CD and vanillylmandelic acid (VMA), homovanillic acid (HVA) and vanillin 
(VA). The ROE correlations extracted from a 2D ROESY experiment allowed the authors 
to distinguish between partial and deep inclusion loci of the guest inside the CD, as well as 
on the face from which the guest enters the cavity (see Figure 8). 
 
Figure 8: The proposed inclusion complexes formed between β-CD and vanillylmandelic 
acid VMA (left), and the 2D ROESY spectrum leading to this proposal (right) 
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1.3 γ-Amino acids 
Amino acids are elementary building blocks of the biological system. From a structural 
point of view, amino acids can be classified as α, β, γ, etc., depending on the relative 
position of the amino group (-NH2) with respect to the carbocyclic acid (-COOH) on the 
common carbon chain (see Figure 9). 
 
Figure 9: The α-, β- and γ-amino acid backbones. 
While β- and γ-amino acids are non-proteinogenic, they have a great importance in the field 
of biology and in medicinal chemistry.72, 73 
 
1.3.1 GABA and constrained analogs 
Structurally, -amino acids are sub-classified according to the position of the substituents 
they bear. For example, a γ-amino acid which is monosubstituted at the C-2 position is 
labelled a γ2-amino acid, while a a γ-amino acid which is disubstituted at its C-2 and C-3 
positions is considered a γ2,3-amino acid (see Figure 10). 
 
Figure 10: Three different structural sub-classes of γ-amino acids. 
In the human body, -amino acids operate mainly as neurotransmitters. In particular, the 
parent compound γ-aminobutyric acid (GABA) serves as the principle inhibitory 
neurotransmitter of the central nervous system.74 GABA also has an influence on different 
biological events during the nervous system development.75 Abnormal levels of GABA in 
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the human brain have been correlated with serious neurological disorders such as epilepsy, 
anxiety,76 schizophrenia,77 and Alzheimer’s disease.78 Due to their potential significance in 
human biology and their potential applications in pharmacology,79 GABA analogs have 
gained considerable attention over the past decades and a large number of strategies have 
been developed for their stereoselective synthesis.80  
1.3.1.1 Constrained -amino acids 
-Amino acids can be considered as doubly-homologated α-amino acids, and as such the 
two extra carbons between the amine and carboxyclic acid functions provide the backbone 
with more flexibility when compared to α- and β-amino acids. Consequently, GABA can 
adopt many low-energy conformations, each one having its own specific biological 
relevance. 
In order to acquire analogs that mimic a particular bioactive conformation of GABA, the 
synthesis of conformationally restricted GABA analogs has been of recent interest.81 
Various types of GABA analogs, both acyclic,82 and cyclic,81 have been reported in the 
literature. Figure 11 shows some of these analogs that act as agonists for specific GABA 
receptors. For example, trans-4-aminocrotonic acid (TACA) was more potent than GABA 
as a ligand for the ionotropic receptors GABAA and GABAC, but less potent for the 
metabotropic receptor GABAB.
83, 84. The cis-isomer (CACA) showed preferred binding to 
the GABAC receptor over GABAA, whereas 4-aminotetrolic acid (ATA) had the opposite 
selectivity profile.82 cis-2-(Aminomethyl)cyclopropanecarboxylic acid ((+)-CAMP) was 
found to be a selective agonist of GABAC.
85 Gabapentin (GBP, Neurontin®) is a 
GABAergic agonist that has important anticonvulsant,86 and analgesic87 properties; on the 
other hand, Gabapentin lactam (GBP-L) is neuroprotective in retinal ischemia.88  
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Figure 11: The parent γ-amino acid GABA and some of its bioactive constrained analogs. 
1.3.1.2 GABA analogs in the field of foldamers 
Aside from their biological importance as discrete molecules, -amino acids are also 
becoming increasingly popular as building blocks for peptidomimetics, in the form of γ-
oligopeptides or of mixed α,- or β,- hybrid peptides, because of the distinct, well-defined 
3D folding patterns that these compounds can adopt (as will be discussed in more detail in 
Chapter 4).89, 90  
Here again, -amino acids with cyclic constraints are of particular interest since their rigid 
backbones provide the severe conformational restrictions needed to impose well-defined 
low-energy conformations in α,- and β,-hybrid peptides.91, 92 Figure 12 shows examples of 
three,93 four,94 five,95 and six96 membered ring cyclic constrained -amino acids which have 
been employed as building blocks for oligo-peptides that adopt well-defined 3D 
structures.90 
 
Figure 12: Example of different sized cyclic-constrained -amino acids used as building 
blocks for peptide foldamers. 
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1.3.2 Literature synthesis of cis- and trans-2,3CB-GABA 
In this section we will focus our attention on two cyclobutane constrained -amino acids: 2-
(aminomethyl)cyclobutanecarboxylic acid (2,3CB-GABA) and 2-(2-aminocyclobutyl)acetic 
acid (3,4CB-GABA) (see Figure 13). 
 
Figure 13:The constrained -amino acids of interest: 2,3CB-GABA and 3,4CB-GABA 
The synthesis of cis-2,3CB-GABA in enantiomerically pure form was described in 1999 by 
the Orena group following a lengthy procedure (more than 8 steps), starting from (S,E)-
ethyl 4-(3-methoxy-3-oxo-N-(1-phenylethyl)propanamido)but-2-enoate (see Scheme 18).97 
 
Scheme 18: The Orena group’s access to both enantiomers of cis-2,3CB-GABA. Conditions: 
a) NaH, THF, -78 °C; b) NaOEt, EtOH, -78 °C; c) DMF, NaCl, 80 °C; d) LiBH4, THF, 0 
°C; e) MsCl, Et3N, DMAP, CH2Cl2, 0 °C; f) NaI, acetone, r.t; g) LiHMDS, THF, -15 °C, 12 
h; h) Li-NH3, -78 °C i) 1M HCl, 82 °C, 12 h. 
Later, the Ley group used polymer supported enzymes and reagents in order to access only 
the (1S,2R) enantiomer of the cis-2,3CB-GABA starting from (1R,2S)-dimethyl cyclobutane-
1,2-dicarboxylate (see Scheme 19).98 
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Scheme 19: The Ley group’s access to (1S,2R)-cis-2,3CB-GABA. 
More recently, the Aitken group established a synthetic route that allowed access to both 
enantiomers of cis- and both enantiomers of trans-2,3CB-GABA.99, 100 The synthesis began 
with via a the photochemical [2+2]-cycloaddition reaction of (R)-1-(1-phenylethyl)-2,5-
dihydro-1H-pyrrole with ethylene, which provided the bicyclic photoadduct with an 
exclusive cis geometry and as a mixture of two diastereoisomers which were separated by 
chromatography. Each of the two compounds obtained was transformed in three steps into 
N-Boc-cis-2,3CB-GABA in single enantiomer form. In turn, each cis derivative was 
subjected to an epimerization protocol to furnish the corresponding trans compound, in 
enantiomerically pure form (see Scheme 20). 
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Scheme 20: The Aitken group’s access to all four stereoisomers of 2,3CB-GABA. Conditions: 
a), hν, acetone, 9 h; b) (i) Na, NH3 (l), t-BuOH; (ii) Boc2O, DMAP, CH3CN; c) (i) LiOH, 
H2O, THF; (ii) H3O+; d) 6 M NaOH, MeOH, Δ, 16 h e) (i) TFA, CH2Cl2; ii) Dowex-H+  
1.3.3 Literature synthesis of cis- and trans-3,4CB-GABA 
In the literature, access to cis- and trans-3,4CB-GABA, each in racemic form, was described 
in 1982 by Kennewell and co-workers through a lengthy procedure starting from cis and  
trans-cyclobutane-1,2-dicarboxylic acids, respectively.101 More recently, in order to 
improve the availability of these conformationally restricted cyclobutane analogues of 
GABA, our groups jointly reported two complementary synthetic routes that provided 
practical access to both enantiomers of cis-3,4CB-GABA (see Scheme 21).102 
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Scheme 21: The two routes to both enantiomers of cis-3,4CB-GABA. Conditions: a) hν, 
acetone, rt, 4 h; b) NaOH (3M), rt, 14 h; c) DCC, DMAP, MeOH, 0 °C to r.t., 20 h; d) 
NaBH4, EtOH, 1 h, reflux; e) MsCl, Et3N, Et2O, 24 h, rt; f) NaCN, DMSO, 3 d, < 40 °C; g) 
NaOH, EtOH, 3.5 h, reflux; h) hν, quartz EtOH, rt, 3 h; i) H2 Pd/C, EtOH, 16 h, rt; j) 
Boc2O, DMAP, CH3CN, 16 h, rt; k) LiOH, THF/H2O 16 h, rt; l) (i) PivCl, Et3N, THF, 1h, 0 
oC; (ii) n-BuLi, THF, 1h, -75 oC; m) (i) separation on silica; (ii) LiOH, H2O2, THF/H2O, 16 
h, rt n) (i) TFA, CH2Cl2; ii) Dowex-H
+ 
The first route involved a homologation strategy that started with the photochemical [2+2]-
cycloaddition reaction of Boc-uracil with ethylene, which provided a single bicyclic 
photoadduct with an exclusive cis geometry. Basic hydrolysis of this photoadduct led to the 
known N-Boc derivative of ()-cis-2-aminocyclobutanecarboxylic acid.103 This cyclic β-
amino acid derivative was then homologated in five steps to provide the N-Boc derivative of 
()-cis-3,4CB-GABA. The second route started with the known photochemical 4π-
electrocyclization of azepinone (see Scheme 21).102 The photoadduct was then transformed 
in three steps into the same N-Boc derivative of () cis-3,4CB-GABA that was obtained from 
the first route. The second route employed fewer steps and had a better overall yield than 
the first one. 
The chiral resolution of ()-N-Boc-cis-3,4CB-GABA was then described, using (4S,5R)-4-
methyl-5-phenyloxazolidin-2-one as a chiral auxiliary (See Scheme 21).102 This endeavor 
required considerable effort; it was first necessary to identify the satisfactory chiral 
auxiliary, which then had to be prepared synthetically. The resolution protocol itself 
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required three steps: coupling of the racemic -amino acids derivative with the 
oxazolidinone, tedious chromatographic separation of the two diastereoisomeric adducts, 
then cleavage of the chiral oxazolidinone from each, to provide both enantiomers of N-Boc-
cis-3,4CB-GABA.   
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1.4 Aims of this project 
In this work we sought to explore alternative synthetic strategies which might provide more 
convenient and/or efficient access to cis-2,3CB-GABA and cis-3,4CB-GABA in 
enantiomerically pure form. It was our intention to use these molecules as building blocks 
to prepare new mixed peptide sequences and to study these peptides for their foldamer 
behavior. 
We indicated above that photochemical strategies, used in conjunction with covalently 
attached chiral motifs, can provide access to enantiopure cis-2,3CB-GABA and cis-3,4CB-
GABA. In these preparations, chiral information is employed either in an “early-stage” role, 
such as in the synthesis presented in Scheme 20, or in a “late-stage” role, such as in the 
resolution protocol in Scheme 21. However, in each case the chiral fragment is 
(temporarily) attached covalently to the requisite -amino acid fragment, which implicates 
the formation of diastereoisomer mixtures at some point in the synthesis and the consequent 
requirement of diastereoisomeric separation by chromatography.  
We considered that the enantioselective synthesis of cis-2,3CB-GABA and cis-3,4CB-GABA 
derivatives warranted study. The clear advantage of this approach would be that the 
covalent attachment (and subsequent removal) of chiral auxiliaries would not be required, 
nor would chromatographic separation of diastereoisomeric pairs be necessary. Towards 
this objective, as a contribution to the growing area of photochirogenesis, we decided to 
investigate the use of β-CD as a readily-available, chiral supramolecular host for pertinent 
enantioselective photochemical transformations (see Scheme 22). The intramolecular 
photochemical [2+2]-cycloaddition of an N-allyl N-aryl acrylamide in the presence of β-CD 
might provide access to a bicyclic adduct in enantioenriched form, leading to 
enantioenriched cis-2,3CB-GABA. The photochemical 4π-electrocyclization of azepinone in 
the presence of β-CD might provide access to the known bicyclic adduct in enantioenriched 
form, leading to enantioenriched cis-3,4CB-GABA. 
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Scheme 22: The proposed photochirogenic reactions in the presence of β-CD, leading 
towards cis-2,3CB-GABA (top) and cis-3,4CB-GABA (bottom) in enantioenriched form. 
We proposed to use the enantiomerically-pure CB-GABA derivatives obtained above to 
prepare γ/α-hybrid peptides and study their conformational behavior in solution. 
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Chapter 2: The Photochemical Reactivity of N-
Allyl-N-(4-methoxyphenyl)acrylamide 
2.1 Introduction 
Organic chemists are constantly on the lookout for new methodologies for the synthesis of 
compounds with biological significance. N-allylacrylamide derivatives have been studied 
for the construction of heterocyclic compounds with multiple stereocenters, of interest as 
drugs or bioactive reagents, using  regioselective ring-closing metathesis reactions 
(RCM)104 or palladium-catalyzed tandem cyclization reactions.105 Enantioselective 
photochemical cycloaddition reactions of N-allylacrylamide derivatives have not been 
previously studied, but might constitute a “green” synthetic methodology for preparing 
heterocyclic compounds. Bicyclic lactams, such as the particular intermediate we target 
below, are of considerable synthetic interest in this respect. 
  In this chapter we set out to establish a new synthetic access to cis-2,3CB-GABA 
derivatives, based on the anticipated enantioselective intramolecular photochemical [2+2]-
cycloaddition of an N-allylacrylamide derivative hosted inside the chiral cavity of β-CD. 
The selected N-allylacrylamide derivative was N-allyl-N-(4-methoxyphenyl)acrylamide, 1 
(see Scheme 23). The methoxyphenyl group was chosen in order to favor the inclusion of 
compound 1 inside the hydrophobic (and asymmetric) cavity of the β-CD.  
 
Scheme 23: The proposed enantioselective intramolecular [2+2]-photocycloaddition of 
compound 1 in the presence of β-CD. 
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 In our work, it was expected that, following the [2+2] photocycloaddition, the 
methoxyphenyl group could be easily removed.106  Compound 2 should therefore be 
transformed in only a few steps  into the known N-Boc protected derivative of cis-2,3CB-
GABA (see Scheme 24). 
 
Scheme 24: Transformation of the anticipated photoadduct 2 into a cis2,3CB-GABA 
derivative. 
Our first objective in this chapter was to synthesize N-allyl-N-(4-
methoxyphenyl)acrylamide. Thereafter, a study of its host-guest interactions with β-CD was 
envisaged, followed by an assessment of its photochemical reactivity: both alone and in the 
presence of β-CD. Finally, the transformation of the anticipated cycloadduct to provide 
enantioenriched cis-2,3CB-GABA would be carried out. 
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2.2 Results and discussion  
2.2.1 Synthesis of N-allyl-N-(4-methoxyphenyl)acrylamide 1 
A short synthesis of N-allyl-N-(4-methoxyphenyl)acrylamide 1 has been described, 
requiring  as a starting material the unstable, not readily-available, toxic reagent acryloyl 
chloride.104We preferred to circumvent use of this reagent, and applied instead a variation of 
the literature procedures described by Bonete,107 and Wang,108 following the retrosynthetic 
approach depicted in Scheme 25.  
 
Scheme 25: Retrosynthetic analysis for the preparation of N-allyl-N-(4-
methoxyphenyl)acrylamide 1. 
The first step was the Michael addition of benzenesulfinate anion to acrylic acid, performed 
by stirring the reagents together in water overnight (see Scheme 26). In the literature 
procedure, 90% ethanol had been used as the solvent, however we encountered solubility 
problems in various ethanol/water mixtures. The use of water as the solvent greatly 
simplified the reaction. After the reaction time, the suspension was acidified with 2 M HCl 
and the desired product, 3-(phenylsulfonyl)propanoic acid 3, was extracted using diethyl 
ether. The organic layer was concentrated to give compound 3 as a white solid with a yield 
of 75%. The product 3 was used in the next step without further purification.  
 
Scheme 26: Synthesis of 3-(phenylsulfonyl)propanoic acid, 3, from sodium benzenesulfinate 
and acrylic acid. 
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The second step involved the conversion of the carboxylic acid group of 3 into an acyl 
chloride by refluxing it overnight with a large excess of thionyl chloride in dry 
dichloromethane (see Scheme 27). The solvent along with the excess of thionyl chloride 
were then distilled out under vacuum. The remaining yellowish solid, crude 3-
(phenylsulfonyl)proanoyl chloride, was used without isolation or further purification and 
was reacted with p-anisidine in the presence of triethylamine in dry dichloromethane at 0 oC 
to give N-(4-methoxyphenyl)-3-(phenylsulfonyl)propanamide 4 in 85% yield over the two 
steps. Compound 4 was pure enough to be used in the next step without any purification. 
 
Scheme 27: The synthesis of N-(4-methoxyphenyl)-3-(phenylsulfonyl)propanamide  from 3-
(phenylsulfonyl)propanoic acid. 
Making use of the phenylsulfonyl group as leaving group, the third step involved a one pot 
elimination in the presence of potassium tert-butoxide (Scheme 28), followed by addition of 
allyl bromide in a nucleophilic substitution to give crude compound 1, N-allyl-N-(4-
methoxyphenyl)acrylamide. The final product was purified by silica gel chromatography, 
and isolated with an overall yield of 60%. 
 
Scheme 28: The synthesis of N-allyl-N-(4-methoxyphenyl)acrylamide, 1, from N-(4-
methoxyphenyl)-3-(phenylsulfonyl)propanamide, 4. 
  
Page | 37  
  
It is important to note that compound 1 showed a tendency to polymerize into an insoluble 
hard solid, so it was important for it not to be in contact with traces of acids, nor be heated 
above 25 oC while evaporating the solvent after chromatography. 
2.2.2 The β-CD/ N-allyl-N-(4-methoxyphenyl)acrylamide 1 complex  
2.2.2.1 Formation of the β-CD/1 complex 
Unlike common examples of β-CD complex formation,109 mixing N-allyl-N-(4-
methoxyphenyl)acrylamide 1 with β-CD in water at a 15 mM concentration, did not result 
in the formation of a precipitate. In order to prepare a β-CD/1 complex, we therefore added 
one equivalent of solid compound 1 to a clear (5 ml, 15 mM, 1 eq) aqueous solution of β-
CD.  The mixture was heated to 35-40 oC and left to stir for 5 min, during which time 1 
dissolved completely. The resulting clear solution was stirred at room temperature for 2 
hours then spread on a glass plate and left to evaporate to give a white clear film (see Figure 
14). 
 
Figure 14: The white film (complex) of N-allyl-N-(4-methoxyphenyl)acrylamide with β-CD. 
2.2.2.2 Evidence of complexation by powder X-ray diffraction 
In order to confirm the formation of a complex between 1 and β-CD, a powder X-ray 
diffraction analysis was done. Three samples were compared: β-CD alone, compound 1 
alone, and the white film (β-CD/1 complex), as shown in Figure 17. 
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Figure 15: Powder X-ray diffraction spectra of β-CD, compound 1, and β-CD/1 complex 
The powder X-ray diffraction data obtained for the β-CD/1 complex film, were different 
from the data obtained for each component alone. This provides support for the argument 
that we obtained a genuine complex, rather than a simple physical mixture of the two 
discrete substances.110  
2.2.2.3 Determination of the complex stoichiometry 
Job’s method of continuous variation was used to investigate the stoichiometry of the β-
CD/1 complex. Two separate 10 mL (0.9 mmol) mother solutions were prepared in water, 
one of β-CD and the other of 1. Specific volumes of each solution were taken and mixed in 
different proportions to prepare eleven sample solutions (each 2 ml) covering the rage of 
mole ratios 0 <  =
[𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝟏]
[𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑 𝟏]+[𝛽−𝐶𝐷]
< 1 
The UV absorbance for each of the eleven sample solutions was recorded at λ = 228 nm, 
and the difference in absorbance (ΔA) between compound 1 alone and in the presence of β-
CD multiplied by the molar fraction () was plotted against molar fraction (), as shown in 
Figure 16. 
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Figure 16: Job’s plot of UV absorbance (λ =228 nm) at different β-CD:1 molar ratios. 
The maximum of the curve at  = 0.5 validates a 1:1 stoichiometry in the complex formed 
upon mixing β-CD with compound 1 in aqueous solution. The rounded shape of the 
curvature also provides an indication that the equilibrium constant of the complexation 
reaction is of low magnitude.58 
2.2.2.4 1D NMR studies of the β-CD/1 complex 
To gain insight into the nature of the interactions between β-CD and compound 1, an NMR 
titration experiment was done. Six different NMR tubes containing a solution of β-CD in 
D2O at 7 mM were prepared. Each tube was prepared with a different equivalence of 
compound 1 to β-CD ranging from 0 equivalents in tube 1, to 2 equivalents in tube 6.  
Figure 17 shows the 1H NMR spectra for each tube. 
Protons H3 and H5 of the β-CD cavity showed a gradual up-field shift with as the amount of 
compound 1 increased with respect to β-CD. At a 1:1 ratio, the change in the chemical shift 
reached 0.15 ppm for H3 and 0.2 ppm for H5. On the contrary, H1, H2, H4 and H6 of β-CD, 
located outside the cavity, did not show any significant shift change throughout the titration. 
These observations can be interpreted as showing that compound 1 is being hosted inside 
the hydrophobic cavity of β-CD. 
The induced shift Δδ, defined as the difference in the chemical shift of a proton belonging 
to one molecule, in the presence and absence of another molecule,64 were calculated by the 
following equation: Δδ = δ(free) - δ(complexed) and are shown in Table 1. In this convention the 
positive sign of Δδ designates an upfield shift. 
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Figure 17: 1H NMR (in D2O solution) of β-CD showing the shift of H3 and H5 with each 
increase in the percentage of compound 1 to β-CD. 
β-CD protons 1 2 3 4 5 6 
Δδ (ppm)  0-100% 0.000 0.000 -0.15 0.000 -0.2 0.000 
Table 1: The change in chemical shift (Δδ) of the β-CD protons between 0% and 100% of 
compound 1. 
On the other hand, all protons of compound 1 show a down-field shift except for Hd and 
HAr2 which show an up field shift with each increase in the percentage of compound 1 to β-
CD. It’s also noteworthy that the multiplicity of Hc changes from a doublet in the free 
compound 1, to a doublet of doublets in the presence of β-CD (see figure 18, and table 2). 
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Figure 18: 1H NMR (in D2O solution) of  N-allyl-N-(4-methoxyphenyl)acrylamide (1) 
(bottom), and at 100% of 1 relative to β-CD (top). 
Compound 1 protons a b c d e e’ f Ar1 Ar2 
Δδ (ppm)  0-100% 0.047 0.031 0.097 -0.009 0.081 0.175 not clear 0.041 -0.040 
Table 2: The change in chemical shift (Δδ) of N-allyl-N-(4-methoxyphenyl)acrylamide (1) 
protons between 0% and 100% of compound 1 relative to β-CD. 
The 1H NMR titration experiment showed that all the protons of compound 1 and only the 
inside protons of the β-CD cavity are affected during the course of the titration, suggesting 
that compound 1 may be bound, totally or partially, inside the hydrophobic cavity of β-CD. 
By identifying the affected protons, one can have a partial idea about the geometry of the 
inclusion complex but a ROESY experiment would be needed to more understand the 
orientation of a guest inside the CD cavity. 
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2.2.2.5 Determination of the binding constant Kb 
The NMR titration experiment data allowed to establish a linear plot of 1/ΔδH3 vs. 1/ [compound 1], 
(see Figure 19). The straight line obtained, has a slope of 1/(Kb × Δδsat) and an intercept at 
1/Δδsat, from which the binding constant Kb for the β-CD/ 1 complex was estimated to be 
14.7.  
 
Figure 19: The linear plot of 1/ΔδH3 vs. 1/ [N-allyl-N-(4-methoxyphenyl)acrylamide] 
2.2.3 The photochemical reactivity of compound 1 
2.2.3.1 Photoreactivity of compound 1 in solution, without β-CD 
Water was the solvent of choice for the photochemical transformation of 1, taking account 
of our intention to perform subsequent reactions in the presence of β-CD. However, when a 
20 mM solution of 1 in water was introduced into a Pyrex tube then irradiated in a Luzchem 
(LCZ-4V) reactor fitted with 14 UV-B (303 nm) lamps, no conversion was observed after 
15 h of irradiation. The same lack of reactivity was observed when ether was used as the 
solvent in place of water.  
When the reaction was carried out in the same conditions using acetone as the solvent, 
complete conversion of 1 was achieved after 9 h irradiation. The solvent was evaporated 
and the crude residue was purified by silica gel column chromatography to give 1-allyl-6-
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methoxy-3,4-dihydroquinolin-2(1H)-one 5 in a 50% yield. The desired 3-(4-
methoxyphenyl)-3-azabicyclo[3.2.0]heptan-2-one 2 was not obtained. (see Scheme 29) 
NMR analyses and a single crystal X-ray diffraction study confirmed the molecular 
structure of 5 (see Figure 20). The formation of compound 5 from substrate 1 is the result of 
a 6π-electron cyclization following photochemical excitation, giving a zwitterionic 
intermediate which undergoes a 1,5-sigmatropic shift to give compound 5, as illustrated in 
Scheme 29. 
 
Scheme 29: The proposed mechanism for the formation of compound 5. 
 
Figure 20: The X ray crystal structure of compound 5. 
In compound 1 the resonance of the nitrogen lone pair gives the C-N bond of the acrylamide 
a partial double bond character which establishes a 6π-electron system with the 
methoxyphenyl ring. Upon irradiation, compound 1 moves into a singlet exited state, at this 
stage there is a competition between a 6π-electron conrotatory ring closure, and an 
evolution of the exited compound 1 into a triplet state. Due to an inefficient inter system 
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crossing only the latter is observed, favoring the formation of compound 5 over the 
anticipated compound 2. 
There are literature precedents for photochemical 6π-photocyclization reactions of N-aryl 
α,β-unsaturated carboxamides. they have been used to make quinolone or isoquinoline 
alkanoids derivatives. Enantiodifferentiating 6π-photocyclization of N-phenylcyclohex-1-
enecarboxamide was mediated by chiral template (see Scheme  30).111 
 
Scheme 30: Chiral template mediated 6π-photocyclization of N-phenylcyclohex-1-
enecarboxamide. 
Analogously, non-aromatic reductive 6π-photocyclization was used as a key step in a the 
total synthesis of (+)-coniceine as its HBr salt (see Scheme  31).112 
 
Scheme 31: The 6π-photocyclization as a key step in the preparation of (+)-coniceine HBr 
salt. 
 Interestingly, the photosensitized photochemical reaction of an N-allyl-N-
benzylacrylamide derivative, which cannot participate in a 6π-photocyclization, proceeds 
smoothly according to a [2+2]-cycloaddition to give a racemic mixture of the photoadduct. 
(see Scheme 32).113 
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Scheme 32:The intramolecular [2+2]-cycloaddition N-allyl-N-benzylcinnamamide. 
 As far as we are aware, the molecular structure of 1 is the first to provide a formal 
test case for the competition between the two different photochemical reactivity types, 
[2+2]-cycloaddition vs. 6π-electrocyclization. In the present case, the latter reaction mode 
prevails. 
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2.3 Conclusion 
Following our goal of developing an enantioselective route to cis-2,3CB-GABA, the 
objective of this chapter was to obtain compound 2 in enantioenriched form, via an 
enantioselective [2+2]-photocycloaddition of N-allyl-N-(4-methoxyphenyl)acrylamide 1 in 
the chiral environment of the β-CD cavity. 
We first adapted a known synthetic procedure to obtain the substrate 1, then determined the 
stoichiometry of its complex with β-CD to be 1:1 β-CD/1. NMR spectroscopic studies 
suggested the formation of a deep-penetration inclusion complex, but with a relatively 
weak binding constant, estimated to have a value of Kb =14.7 M
–1.  
However, when irradiated in water or ether, compound 1 showed no photoreactivity. 
Furthermore, in acetone, a photochemical 6π-electrocyclization reaction took place, leading 
to the formation of compound 5; no photochemical [2+2]-cycloaddition reactivity was in 
evidence.  
At this point, it appeared that appropriate conditions for the proposed enantioselective 
synthesis were unlikely to be secured. The cumulated difficulties of modest host-guest 
binding, solvent incompatibility and competitive photochemical reactivity appeared to be 
insurmountable with our chosen substrate 1. 
It seems likely that a different substrate should be envisaged. The use of a carbamate or 
benzyl group instead of an aryl group on the nitrogen atom might eliminate the unwanted 
electrocyclization reactivity and allow the [2+2]-cycloaddition reactivity to prevail, while at 
the same time bestowing reasonable binding affinity of the substrate in the β-CD cavity (see 
Figure 21). Never the less, we halted our endeavor to access cis-2,3CB-GABA for the time 
being, and turned our attention to study the photochemical reactivity of 1,3-dihydro-2H-
azepin-2-one a pressure of cis-3,4CB-GABA 
 
Figure 21: The benzyl (left), and carbamate (right) analogues of compound 1. 
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Chapter 3: The Photochemical Reactivity of 
1,3-dihydro-2H-azepin-2-one 
3.1 Introduction  
We saw in Section 1.3.3 that the synthesis of cis-3,4CB-GABA starting from azepinone 8 
begins with the photochemical 4π-electrocyclization of the starting compound, during 
which two stereogenic centers are created (see Scheme 33). 
 
Scheme 33: The photocyclization reaction of azepinone 8 leading to the formation of the 
racemic photoadduct 9 
Azepinone 8 has 4 electrons in its π system, which by Woodward–Hoffmann rules would 
undergo a disrotatory photochemical ring closure. Since the diene system of azepinone 8 is 
non symmetrical, and because the rotation of the orbitals can go both clockwise and 
anticlockwise with an equal probability; the photoadduct 9 is formed as a racemic mixture 
of the two enantiomers (See Scheme 34).  
We predict that the presence of β-CD during this 4π electrocyclization could provide a 
chiral environment that would favor one topology of the ring closure over the other, thus 
allowing preferential access to one of the enantiomers (see Scheme 34). 
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Scheme 34: The proposed enantioselective photoelectrocyclization of azepinone 8 induced 
by β-CD 
In this chapter we first planned to synthesize azepinone 8, then to a study its host-guest 
interaction with β-CD, followed by a search for the most productive manner of irradiating 
the complex in terms of chemical yield and ee of the bicyclic adduct 9. Therefrom, 
following the previously described procedure for the racemate, enantioenriched cis-3,4CB-
GABA could be prepared. 
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3.2 Results and discussion 
3.2.1 Synthesis of azepinone 8 
Azepinone 8 was prepared following the previously reported method,102 starting from the 
commercially available caprolactam 6. (see Scheme 35). α-Dibromination of caprolactam 6 
was carried out in the presence of phosphorous pentachloride, zinc chloride and bromine. 
The product 7 was isolated in 73% yield and was pure enough to be used without 
purification. The second step consists of a double elimination of HBr to yield azepinone 8. 
This reaction was carried out in the presence of dry lithium chloride in anhydrous DMF at 
reflux. Azepinone 8 was obtained with 70% yield after chromatography on silica gel. 
 
Scheme 35: Synthesis of azapinone 8 from caprolactam 6. 
Formation of the unconjugated compound 8 instead of compound 8’ might be attributed to 
an excessive ring strain in the latter, due to the sequence of five sp2 hybridized carbons (C2 
→ C6) with the sp2 hybridized nitrogen (See Scheme 36). 
 
Scheme 36: Formation of the more stable azepinone 8. 
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3.2.2 Photoelectrocyclization of azepinone 8 in the absence of β-CD 
The photoelectrocyclization of azepinone 8 in the absence of β-CD was studied both in 
solution as well as in solid state. 
3.2.2.1 Photoelectrocyclization of azepinone 8 in solution 
3.2.2.1.1 Photoelectrocyclization of azepinone 8 in ether 
The photochemical electrocyclization reaction of 8 was first performed in ether, as 
previously reported in the literature (See Scheme 37).102 A solution of azepinone 8 in 
anhydrous diethyl ether was irradiated for 2-3 h with a 400 W mercury vapor lamp, in a 
reactor fitted with a quartz filter and cooled by an external water bath. The choice of a 
quartz filter was made on the basis of a previous analysis of the UV absorbance spectrum of 
8 in acetonitrile (0.11 mM), which showed a maximum absorbance at 269 nm, indicating 
that the molecule has to be in a quartz reactor if we want it to absorb directly. (102)  
 
Scheme 37: The photochemical cyclization of azepinone 8 to give racemic photoadduct 9. 
2-Azabicyclo[3.2.0]hept-6-en-3-one 9 was obtained in 97% yield as a brown solid with a 
very low solubility in ether. As it formed, it stuck on the inner side of the reactor, from 
which it was collected by scraping it out. The very low solubility of the product precluded 
further purification, but the 1H MNR spectrum and HPLC analysis of the crude product 
showed a nearly pure compound. 
3.2.2.1.2 Photoelectrocyclization of azepinone 8 in water 
Since β-CD is not soluble in ether, we tested the photoelectrocyclization of azepinone 8 in 
water. The reaction time was the same as in ether (2 h) when the same concentration (7.33 
mM) was used. With a higher concentration (91 mM) the reaction time was increased to 15 
h. 
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The irradiated reaction mixture was then lyophilized and the crude cyclobutene product (±)-
9 was isolated in a 71% crude yield. Analysis of the crude product by NMR and HPLC 
showed that it was identical to the sample prepared in diethyl ether. The lower yield in case 
of water as a solvent is attributed to the loss of product (±)-9 during the lyophilization 
process. (see Index, section B ) 
3.2.2.2 Photoelectrocyclization of azepinone 8 in solid state 
In the literature, when CDs were used as a chiral hosts, better enatioselectivity was achieved 
when photochemical transformations were performed in the solid state rather than in 
solution.42 For this reason we also tested the photochemical electrocyclization reaction of 
azepinone 8 in the solid state.  
To irradiate azepinone 8 in the solid state, it was first ground into a fine powder then 
introduced in a quartz tube. The tube was closed and set to rotate in a Rayonet (R-200) 
reactor, in which it was irradiated until no starting material could be observed by 1H NMR. 
The 1H NMR spectrum of the photoadduct (±)-9 resulting from the irradiation of azepinone 
8 in solid state was identical to that obtained in solution. 
The reaction time in the solid state, which could range between 6 and 60 h, depended 
greatly on the amount and the homogeneity of the solid being irradiated. The more evenly 
the solid was exposed to the irradiation, the less time it needed for total conversion. 
3.2.3 Analysis of the enantiomeric excess in photoadduct 9 
Before introducing the β-CD to the reaction mixture, a suitable method has to be established 
to determine the ee of the photoadduct (±)-9. We studied the separation of the enantiomers 
of (±)-9 by chiral HPLC. 
The photoadduct (±)-9 was passed through a normal phase chiral Lux Cellulose-1 column 
using a 90/10 hexane/isopropanol eluting mixture at 20 oC and a flow rate of 1.5 ml/min. 
Under these conditions, the two enantiomers of photoadduct (±)-9 could be separated with 
43 sec of difference in retention time. Figure 22 shows an HPLC chromatogram of 
photoadduct (±)-9 prepared by photoelectrocyclization in the absence of β-CD. 
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Figure 22: HPLC chromatogram of racemic (±)-9 on normal phase chiral Lux Cellulose-1. 
3.2.4 The β-CD/azepinone 8 complex 
3.2.4.1 Formation of the β-CD/azepinone 8 complex: 
Both β-CD and azepinone 8 are soluble in water. The β-CD/azepinone 8 complex was 
prepared by mixing an aqueous solution of the latter with an aqueous solution of β-CD. 
Upon stirring at room temperature, a white precipitate started to form gradually, and within 
few minutes, the clear solution turned into a thick “milky suspension” (See Figure 23). It is 
important to point out that a minimum concentration of about 6 mM, with respect to β-CD, 
was needed in order for the precipitate to form; and the lower the concentration of the 
mixture is, the slower the precipitation process became. For this reason, the volume of the 
final solution was always chosen to have a concentration just less than 15 mM, which is the 
maximum solubility of β-CD in water at 25 oC. 
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Figure 23: (a) A clear aqueous solution of azepinone 8 at 0.45 M, (b) a clear aqueous 
solution of β-CD at around 15 mM, (c) the "milky suspension" formed after stirring at room 
temperature for 30 sec, (d) 1.5 min, (e) 5 min. 
3.2.4.2 Evidence of complexation by powder X-Ray diffraction 
To further validate the existence of complexation between the β-CD and azepinone 8, 
powder X-ray diffraction data was obtained for samples of β-CD alone, azepinone 8 alone, 
and for the white precipitate "complex" obtained from mixing both components in solution 
(See Figure 24). 
The powder X-ray diffraction data obtained for the β-CD/azepinone 8 complex were clearly 
different from the data obtained for each component alone. This provides further support for 
the contention that a genuine complex is implicated, rather than a physical mixture of the 
two discrete substances. 
 
Figure 24: The powder XRD spectra of azepinone 8 vs β-CD vs β-CD /8 complex. 
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3.2.4.3 Determination of the complex stoichiometry 
3.2.4.3.1 The azepinone 8 to β-CD ratio in the precipitate  
In order to determine the stoichiometry of the formed β-CD/azepinone 8 complex, the 
“milky suspension” (explained in section 3.2.4.1) was filtered out and the ratio of the 
azepinone 8 to β-CD in the precipitate was found to be around 1:1, even if more than one 
equivalent of β-CD was used in the above mentioned complexation procedure. This ratio 
was calculated by comparing the peak areas in an 1H NMR spectrum of the precipitate with 
a reference equimolar sample of β-CD/azepinone 8 
To further determine the amount of cyclodextrin and lactam in the precipitating solid, the 
“milky suspension” was filtered and the “uncomplexed” azepinone 8 was extracted out from 
the aqueous filtrate using ethyl acetate. The organic layer was then concentrated and the 
aqueous phase was lyophilized to get the uncomplexed β-CD. The masses, summarized in 
table 3, show that about 70% by mass of β-CD and azepinone 8 are precipitating out in a 1:1 
ratio. 
Mass of dry 
β-CD used 
Mass of  dry 
azepinone 8 
used 
Mass of dry 
precipitating 
solid complex 
Mass of remaining 
azepinone 8 extracted 
from the filtrate 
Mass of remaining 
β-CD extracted 
from the filtrate 
1.04 g 100 mg 790 mg 30 mg 321 mg 
Table 3:Distributiuon of  azepinone 8 and β-CD between the precipitate and the filtrate 
after complexation. 
In order to see the effect of adding an excess of β-CD on the complexation equilibrium, the 
starting “milky suspension” described above was charged with two more equivalents of β-
CD. The extra amounts of β-CD added were expected to drive the complexation forward, 
towards the associated β-CD/azepinone 8 form (See Scheme 38). 
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Scheme 38: The proposed equilibrium between the free and the associated form of 1,3-
dihydro-2H-azepin-2-one  8 and β-CD in solution. 
The charged suspension was filtered and the “uncomplexed” azepinone 8 was extracted out 
from the aqueous filtrate using ethyl acetate. The organic layer was then concentrated and 
the aqueous phase was lyophilized. The masses, summarized in table 4, show that about 
90% by mass of the starting azepinone 8 is precipitating with β-CD. 
Mass of dry 
β-CD used 
Mass of dry 
azepinone 8 
used 
Mass of dry 
residue 
 
Mass of remaining 
azepinone 8 extracted 
from the filtrate 
Mass of remaining 
β-CD extracted 
from the filtrate 
3.12 g 100 mg 2.16 g 10 mg 960 mg 
So the equilibrium has certainly been shifted toward the formation of the β-CD/ 8 complex. 
Table 4: Distribution of azepinone 8 and β-CD between the precipitate and the filtrate after 
complexation. 
3.2.4.3.2 The Job’s method of continuous variation: 
Job’s method of continuous variation was used to further investigate the stoichiometry of 
the formed β-CD/azepinone 8 complex. For this, two separate 100 mL (4.10-2 mmol) mother 
aqueous solutions were prepared, one containing β-CD and the other azepinone 8. Volumes 
from each solution were then taken and mixed at different proportions to prepare 11 
samples (2 mL) covering the rage of mole ratios 
0 <  =
[azepinone 𝟖]
[azepinone 𝟖] + [𝛽 − 𝐶𝐷]
< 1 
The UV spectra for each of the 11 samples were recorded at λ = 254 nm, and the difference 
in absorbance, (ΔA), between azepinone 8 alone and in the presence of β-CD multiplied by 
the molar fraction, (), was plotted against molar fraction () (see Figure 25). 
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Figure 25: Job’s plot of UV absorption (λ =254 nm) at different β-CD:azepinone 8 molar 
ratios. 
The position of the maximum of the curve at  = 0.5 further validates that the stoichiometry 
of complex formed upon mixing β-CD with azepinone 8 in aqueous solution is of a 1:1 
stoichiometry. The rounded shape of the curvature also provides an indication that the 
equilibrium constant of the complexation reaction is expected to be of a low magnitude.58 
3.2.4.4 1D NMR studies of the β-CD/azepinone 8 complex 
Trying to understand the nature of the interactions between azepinone 8 and β-CD, an NMR 
titration experiment was done. A 15 mM solution of β-CD in D2O was titrated by adding an 
incremental amount of a D2O solution of azepinone 8 (10 µl at 73 mM / addition), up to 7 
equivalents. The temperature of the experiment was maintained at 40-45 oC to have a clear 
solution throughout the experiment. 
Protons H3 and H5 of the β-CD cavity, showed a gradual up field shift with each addition of 
the lactam (See Figure 26). At a 1:1 ratio of azepinone 8 to β-CD, the change in the 
chemical shift reached 0.03 ppm for H3 and 0.07 ppm for H5. On the contrary H1, H2, H4 
and H6 of β-CD that are pointing outside the cavity did not show any significant shift 
throughout the titration. 
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Figure 26: 1H NMR of β-CD showing the shift of H3 and H5 of the CD with each addition of 
azepinone 8. 
Further addition of azepinone 8 up to 7 equivalents induces a further increase in the Δδ 
values up to 0.064 and 0.012 for H3 and H5 respectively (see table 5). This increase is 
almost linear and no significant inflection point could be detected indicating that the 
complexation of azepinone 8 and β-CD is a dynamic process of fast exchange between the 
complexed and the free form of the two molecules relative to the NMR time scale, and the 
observed chemical shifts at a certain moment are the weighted average of the chemical 
shifts for the free and complexed form coexisting at that moment.69 (69) Correia 2002.  
β-CD proton 1 2 3 4 5 6 
Δδ (ppm)  0-100% 0.000 0.000 0.030 0.000 0.068 0.000 
Δδ (ppm)  0-200% 0.000 0.000 0.043 0.000 0.087 0.000 
Δδ (ppm)  0-700% 0.000 0.000 0.064 0.000 0.120 0.000 
Table 5: The change in chemical shift (Δδ) of the CD protons at 100%, 200%, 700% 
additions of azepinone 8. 
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The protons of the azepinone 8 also showed a gradual up field shift throughout the 
incremental additions. But unlike the inside protons of the CD cavity, the induced shift in 
the azepinone 8 protons were of a lower magnitude. The most affected lactam protons are 
Hb, Hc and Hd (See Figure 27 and table 6). 
 
 
Figure 27: 1H NMR of azepinone 8 with its incremental additions to a solution of β-CD. 
Azepinone 8 proton b c d e f 
Δδ (ppm)  25-100% 0.006 0.009 0.013 0.003 0.003 
Δδ (ppm)  25-200% 0.010 0.014 0.021 0.005 0.006 
Δδ (ppm)  25-700% 0.027 0.034 0.049 0.0186 0.0201 
Table 6: The change in chemical shift (Δδ) of the azepinone 8  protons at 100%, 200%, 
700% of it relative to β-CD. 
1H NMR titration experiments showed that the protons inside the β-CD cavity are the ones 
interacting with azepinone 8, suggesting that the guest may be bound, totally or partially, 
inside the hydrophobic cavity. Nevertheless, the absence of an inflection point in the 
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titration curve with a maximum of variation in the chemical shifts, suggest a fast 
equilibrium between the associated and the free form of the two molecules. 
3.2.4.5    Determination of the binding constant Kb 
Since protons H3 and H5 of the β-CD cavity show a chemical shift difference between the 
free and bound states; one of these protons, H3 whose NMR signal does not overlap with 
other protons, could be monitored throughout a titration experiment in which the 
concentration of the guest azepinone 8 was varied incrementally. The data from such a 
titration experiment allowed to establish a linear plot of 1/ΔδH3 vs. 1/[azepinone 8] (see 
figure 28). The straight line obtained, has a slope of 1/(Kb × Δδsat) and an intercept at 
1/Δδsat, from which Kb was estimated to be 35.4. 
 
Figure 28: The linear plot of 1/ΔδH3 vs. 1/[azepinone 8]. 
The relatively low value of Kb for the β-CD/azepinone 8 complex is in accordance with the 
shape of the Job's plot curve, which shows a gentle rather than a sharp angular curvature 
(see section 3.2.4.3.2). 
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3.2.4.6 2D ROESY NMR studies of the complex 
Complexation of molecules to CDs usually occurs through non-covalent interactions 
between the guest molecule and the CD cavity. This is a dynamic process in which the guest 
molecule continuously associates and dissociates from the host CD. Although in schematic 
representations a host/guest complex is usually shown as a single entity, the complex is 
actually composed of a set of species with the depicted complex representing an average 
structure.114 In fact, CD complexes have high conformational flexibility, which can 
accommodate several modes of complexation.64 This phenomenon is termed multimodal 
complexation.29 
In order to investigate the geometry of the formed complex and propose a mode of 
complexation between the β-CD cavity and azepinone 8, 2D ROESY NMR experiments 
were conducted. 
A ROESY NMR experiment conducted on an equimolar 1:1 β-CD:azepinone 8 mixture in 
solution at 45 °C (15 mM, D2O) showed intermolecular cross peaks only with the inner CD 
protons (H3, H5, H6), (see Figure 29, and 30), which established inclusion of the guest inside 
the cavity without any evidence for outside interactions 
Azepinone 8 can possibly approach the β-CD from the wide secondary face; this mode of 
binding is supported by the correlation of all of its protons with H3 that line up the inner 
cavity of the CD near the secondary face. The penetration from this face inserts the amide 
part of the azepinone 8 deep enough inside the cavity, such that all the azepinone 8 protons, 
except Hd, are in close proximity to correlate with H5 far on the other side of the cavity (see 
Figure 31). Hd, treated as a “probe hydrogen” never sees H5, but still can clearly see H6 
which line up the primary face of the β-CD, suggesting the presence of another mode of 
complexation in which the penetration of the azepinone 8 occurs from the narrow primary 
face; but this time the inclusion is not deep enough to put Hd close contact with H5, but only 
to keep it close to H6.  
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Figure 29: 2D ROESY NMR experiment (600 MHz) of a 1:1 mixture of 8 and β-CD (each 
15 mM, D2O, 45 °C), 
 
Figure 30: 1D slice of the ROESY from Figure 32, at H5, H6 and H3 of the β-CD, aligned 
with the 1H proton spectrum. 
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Figure 31: The proposed mode of complexation between β-CD and azepinone 8. Deep 
penetration of the unsaturated part of azapinone 8 via the two β-CD faces (top left, top 
right) or a shallow penetration of the amid part of the azapinone from the primary face of 
β-CD (bottom left) or a deep penetration from the secondary one (bottom right). 
Several selective ROESY experiments are still needed to establish the exact geometry of the 
azepinone 8 inside the β-CD cavity. Nevertheless, the ROE colorations between the 
azapinone 8 and the inside protons of the β-CD are clear enough to argue that the azapinone 
8 is put in a chiral environment ready for being irradiated. 
 
 
 
3.2.5 Photoelectrocyclization of azepinone 8 in the presence of β-CD 
Irradiation of azepinone 8 in the presence of β-CD was either done in fluid or in solid state. 
Except for one experiment in which the β-CD was manually ground with the lactam without 
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any solvent, all other experiments started by adding a clear solution of azepinone 8 (30-50 
mg in 1 ml of water) to a clear aqueous solution containing the desired equivalents of β-CD. 
The volume of the final solution was chosen to be at 15 mM with respect to the β-CD. Upon 
stirring, a white precipitate started to form almost immediately. The formed "milky" 
suspension was left to stir 2 h at room temperature, and then was treated differently 
according the desired condition of irradiation (in solution, in suspension, in solid state...). 
Our objective was to isolate the resulting bicyclic photoadduct 9 formed by classical 
extraction methods. But it transpired that this was a major problem. 
3.2.5.1 Recovery of the photoadduct 9 
We first attempted to isolate photoadduct 9 from crude irradiated solid by solid-liquid 
extraction (Soxhlet) using organic solvents (chloroform, acetone…). Due to the low 
solubility of 9 in such solvents and probably its interaction with the β-CD molecules, it took 
several days (up to 30 days) to extract the entire amount of 9 out of the irradiated β-
CD/azepinone 8 mixture. The speed of extraction was also dependent on the solvent used. 
Even though the photoadduct 9 was more soluble in chloroform than in acetone, the latter 
was better in the continuous extraction process especially if wet acetone was used due to the 
fact that 9 had a good solubility in water. Due to the prolonged Soxhlet extraction at around 
60 oC, the isolated crude 9 was usually a dark viscous oil rather than a light brown solid as it 
should be. Nevertheless, the 1H NMR spectrum and the chiral HPLC chromatogram were 
identical to the photoadduct 9 prepared by irradiation in ether.  
Since it was difficult to isolate all of the photoadduct 9 from the irradiated complex, chiral 
HPLC analysis was used to determine the ee of samples which were partially extracted. The 
results could not be considered reliable since CDs are known to preferentially hold one 
enantiomer in their cavity, making the extraction of the other easier.115 Thus it is possible 
that the ee observed in a partially extracted sample was due to chiral resolution and was not 
induced during the photochemical reaction. The difficulty in recovering the photoadduct 9 
prompted us to seek a more suitable method to access to the bicyclic cis-3,4CB-GABA 
precursor. 
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3.2.5.2 Reduction of photoadduct 9 
In previous work,102 it was observed that the reduction of the photoadduct 9 gave a product 
which had a better solubility in organic solvents (See Scheme 39). 
 
Scheme 39: Reduction of photoadduct 9 to 2-azabicyclo[3.2.0]heptan-3-one 10. 
Therefore, we reasoned that if we could reduce the photoadduct 9 in the mixture with β-CD, 
it would be easier to extract and isolate the reduced derivative 10. 
The reduction was first attempted on a suspension of photoadduct 9 and β-cyclodextrin in 
ethyl acetate with 10% w/w Pd/C-10% under a dihydrogen atmosphere. The presence of β-
CD slowed down the reaction, and traces of starting photoadduct 9 were still present even 
after 2 weeks of stirring at room temperature with a large excess of the catalyst (See 
Scheme 40). 
 
Scheme 40: Reduction of photoadduct 9 in EtOAc in the presence of β-CD to give 2-
azabicyclo[3.2.0]heptan-3-one 10. 
Since the irradiated the β-CD/photoadduct 9 complex was soluble in water, we supposed 
that when it went into solution the complex would dissociate giving more free photoadduct 
9. This free form of 9 would be more amenable to reduction. 
So the reduction of photoadduct 9 without β-CD was tested in water on an analytical scale. 
The reaction worked well under a dihydrogen atmosphere in the presence of 10% w/w 
Pd/C-10%, and only 2-azabicyclo[3.2.0]heptan-3-one 10 could be observed after stirring 
overnight at room temperature (See Scheme 41). 
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Scheme 41: Reduction of photoadduct 9 in water. 
3.2.5.3 Analysis of the enantiomeric excess compound (±)-10 
To determine the optimal separation conditions of the two enantiomers of (±)-10 on an 
analytical HPLC system, several tests were done and the most satisfying result was 
achieved with a normal phase chiral Lux Cellulose-2 column, using a 90/10 hexane/ethanol 
eluting mixture at 20 oC and a flow rate of 2 ml/min. Under these conditions, the two 
enantiomers of (±)-10 were separated with 42 sec of difference in retention time. Figure 32 
shows a HPLC chromatogram of (±)-10. 
 
Figure 32: HPLC chromatogram of (±)-10 showing separation of the two enantiomers. 
The reduction conditions in water were then applied to a crude irradiated β-CD/azepinone 8 
complex mixture (See Scheme 42). After stirring overnight, the reaction mixture was 
filtered to remove the catalyst, and the 2-azabicyclo[3.2.0]heptan-3-one, (±)-10 was 
completely extracted from the aqueous phase with ethyl acetate. The use of other organic 
solvents like chloroform, dichloromethane or ether, led to the formation of a hard-to-break 
emulsion, with β-CD precipitating out in the extraction funnel. 
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Scheme 42: Reduction, in water, of photoadduct 9 in the presence of β-CD to give 2-
azabicyclo[3.2.0]heptan-3-one,10. 
3.2.6 Photoelectrocyclization/Reduction of azepinone 8 in presence of β-
CD 
All the following reactions were carried out according to the one-pot method: 
photoelectrocyclization/reduction 
3.2.6.1 Irradiation of β-CD/azepinone 8 complex in fluid state 
The "milky suspension” obtained by mixing azepinone 8 and β-CD was treated according to 
the following methods: 
3.2.6.1.1 Experiment A: “1:1 Hot solution” 
The “milky suspension” described above, containing one equivalent of lactam to β-CD, was 
heated up to 45-50 oC; at this temperature it turns into a clear solution. It is worth to note 
that if the solution was cooled back to room temperature the precipitate was observed again. 
The suspension was transferred into a quartz tube fitted with a "heating/cooling finger 
"which is connected to a temperature control system (see Figure 33). The temperature of the 
mixture was maintained at 45-50 oC. The clear hot solution was then irradiated in a Rayonet 
reactor until complete conversion of azepinone 8 (2 h). The resulting yellow solution was 
cooled down to room temperature, and no precipitation was observed. 
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Figure 33: A schematic draw of the Rayonet reactor (left) showing the reaction tube fitted 
with a “heating/cooling” finger connected to the temperature control system (right) 
The photoadduct 9 in the irradiated reaction mixture was reduced under a dihydrogen 
atmosphere in the presence of 10% w/w Pd/C-10%, overnight at room temperature. The 
reduced product, 10 was then extracted out of the aqueous phase with ethyl acetate. The 
organic phase was dried over Na2SO4 and the solvent was evaporated under vacuum to give 
2-azabicyclo[3.2.0]heptan-3-one 10 as a yellow oil. 
The 2-azabicyclo[3.2.0]heptan-3-one 10 from experiment A was obtained in 40% crude 
yield, along with a water soluble solid side product whose 1H NMR spectrum was not clear 
enough to identify it. Analysis of the crude 10 by chiral HPLC showed a pure product but 
no enantiomeric excess (See Figure 34). 
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Figure 34: Chromatogram of 10 obtained from Experiment A 
The lack of enantioselectivity when the irradiation was performed on the hot solution agrees 
with the titration experiment, which showed a weak binding between the host (β-CD) and 
the guest (azepinone 8) at this temperature.  
As mentioned above by Inoue and coworkers,36 when β-CD is used as a chiral host in 
solution, decreasing the temperature could enhance the enantiomeric excess in 
photochemical reactions. So we attempted the irradiation of the “milky suspension” at low 
temperature. 
3.2.6.1.2 Irradiation of 1 β-CD/azepinone 8 in Suspension 
3.2.6.1.2.1 Experiment B: “1:1 β-CD/azepinone 8, Cold suspension” 
The starting “milky suspension” described above, containing one equivalent of azepinone 8 
to β-CD was transferred to a quartz tube and the temperature was maintained at 5-8 oC using 
the temperature control “cold finger”. The cold suspension was then irradiated in a Rayonet 
reactor. Even at this low temperature, as the reaction proceeded, the suspension slowly 
turned into a clear yellowish solution. After complete conversion (2 h) the reaction mixture 
was reduced under a dihydrogen atmosphere, in the presence of 10% w/w Pd/C-10% and 
the 2-azabicyclo[3.2.0]heptan-3-one 10 was extracted out of the aqueous phase with ethyl 
acetate after filtration of the Pd/C catalyst. 
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The 2-azabicyclo[3.2.0]heptan-3-one 10 from experiment B was obtained as a yellow oil in 
79% crude yield over two steps. Chiral HPLC analysis of the crude product showed a 
satisfying degree of purity and an ee of 38% (See Figure 35). 
 
Figure 35: HPLC chromatogram of enantiomerically enriched 2-azabicyclo[3.2.0]heptan-
3-one 10, obtained from experiment  B. 
3.2.6.1.2.2 Experiment C: “3:1 β-CD/azepinone 8 Cold suspension” 
 The starting “milky suspension” described above, was charged with two extra 
equivalents of β-CD. When this 3:1 suspension was cooled to 5-8 oC and irradiated, the time 
needed for a complete reaction was longer than the other fluid state experiments (3.5 h) due 
to the presence of a dense CD suspension which made it harder for the light to reach the 
azepinone. 
 After irradiation the reaction mixture was transferred to a flask and water was added 
to dissolve the excess of β-CD. The resulting clear solution was treated with dihydrogen in 
the presence of 10% w/w Pd/C-10% and 2-azabicyclo[3.2.0]heptan-3-one 10 was then 
extracted out of the aqueous phase with ethyl acetate.  
The 2-azabicyclo[3.2.0]heptan-3-one 10 sample from experiment C was obtained as a 
yellow oil in 75% crude yield over two steps. Chiral HPLC analysis of the crude product 
showed a satisfying degree of purity and an improved ee of 45%, with the same major 
enantiomer (See Figure 36). 
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Figure 36: Chromatogram of enantiomerically enriched 2-azabicyclo[3.2.0]heptan-3-one 
10, obtained from experiment C. 
3.2.6.2 Irradiation of β-CD/azepinone 8 complex in solid state 
 As mentioned in literature, the rigidity of the medium is an important parameter for 
chiral induction during a photochemical reaction;41 and good enatioselectivity was achieved 
when β-CD/pyridone complexes were irradiated in the solid state.42 
3.2.6.2.1 Irradiation of β-CD/azepinone 8 complex in solid state powder form 
3.2.6.2.1.1 Experiment D: Mechanically ground mixture of β-CD and azepinone 8 
One equivalent of azepinone 8 was mechanically ground with β-CD in a mortar. The 
powder mixture was then transferred to a quartz tube which was then closed and set to 
slowly rotate while being irradiate inside a Rayonet reactor (See Figure 47). 
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Figure 37: A photo of the quartz tube containing the solid reactants inside a Rayonet 
reactor. 
The reaction was followed by 1H NMR and when no starting materials could be observed, 
the irradiated solid was dissolved in water then reduced with dihydrogen in the presence of 
10% w/w Pd/C-10%. The 2-azabicyclo[3.2.0]heptan-3-one 10 was extracted from the 
aqueous phase with ethyl acetate, and the organic layer was concentrated to afford 10 as a 
yellow oil. 
Four experiments were done in these conditions and the crude chemical yield was around 
70%, although the ee was not constant, varying from 0 to 40%. The variable 
enantioselectivity suggested that mechanical grinding of azepinone 8 with β-CD does not 
give a sufficiently homogeneous mixture and thus can not be considered as a reproducible 
way to prepare the β-CD/azepinone 8 complex.  
3.2.6.2.1.2 Experiment E: “β-CD/8 complex, filtered then irradiated in powder form” 
The β-CD/azepinone 8 milky suspension was filtered out and the solid residue was left to 
dry in open air, then finely crushed in a mortar.  
The fine solid "complex" was introduced into a rotating quartz tube as illustrated in 
experiment D (see Figure 37 section 3.2.6.2.1.1). The rotation of the tube was intended to 
serve to stir the complex as it was being irradiated, but when performing the experiment, the 
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finely crushed solid always aggregated into small balls that need to be crushed regularly to 
achieve complete conversion (See Figure 38).  
 
Figure 38: Small balls of β-CD/azepinone 8 formed when the complex was irradiated in 
powder form in a rotating quartz tube. 
To avoid the aggregation, the fine powder was spread on a glass plate and irradiated inside 
the Rayonet reactor. Even though the exposed area was larger on the plate, the solid was 
standing still and should be homogenized by agitating it regularly using a spatula, in order 
to achieve complete conversion. The need for manual agitation rendered the experimental 
set-up unpractical, especially on larger scale. 
The time needed for complete conversion of the starting material during the powder solid 
state experiments varied largely, from 6 to 60 h depending on the amount of the irradiated 
solid, its homogeneity and the surface area exposed to the irradiation. 
When no starting materials were observed in the 1H NMR spectrum, the irradiated solid was 
dissolved in water to obtain a clear solution and the photoadduct 9 was then reduced with 
dihydrogen in the presence of 10% w/w Pd/C-10%. The 2-azabicyclo[3.2.0]heptan-3-one 10 
was extracted from the aqueous phase with ethyl acetate. The organic phase was dried over 
Na2SO4 then concentrated under vacuum to give 10 as a yellow oil. 
Crude 10 from experiment E was obtained in 71% yield (for two steps) with respect to the 
amount of azepinone in the irradiated precipitate; the crude product was analyzed by chiral 
HPLC and showed an ee of 36%. The peak at 9.71 min corresponded to caprolactam 6 
formed by the reduction of a small amount of the β-CD/azapinone 8 complex which had not 
been transformed by the electrocyclisation reaction (See Figure 39). No remaining 
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azepinone 8 was detectable by 1H NMR of the reaction mixture. This added further 
drawbacks to performing the irradiation in powder form. 
 
Figure 39: Chromatogram of enantiomerically enriched 2-azabicyclo[3.2.0]heptan-3-one 
10, obtained from experiment E. 
3.2.6.2.2 Irradiation in thin film form 
3.2.6.2.2.1 Experiment F: “1:1 film from 15 mM suspension” 
In order to perform the irradiation in a more homogenous solid state and thus decrease the 
time needed for complete conversion, the starting milky suspension described above was 
spread on a glass plate and left to dry in open air to give a consistent white film. The film 
was irradiated directly in the Rayonet reactor (See Figure 40). The reaction course was 
followed by 1H NMR until complete conversion, which was achieved within 5 h. The solid 
was then dissolved in water to obtain a clear solution and the photoadduct 9 was reduced 
with dihydrogern in the presence of 10% w/w Pd/C-10%. The resulting 2-
azabicyclo[3.2.0]heptan-3-one 10 was then extracted from the aqueous phase with ethyl 
acetate. The organic phase was dried over Na2SO4 then concentrated under vacuum to give 
10 with a crude yield of 77% over two steps. 
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Figure 40: Schematic draw of β-CD/azepinone 8 complex being irradiated as a solid film 
form inside the Rayonet reactor. 
The chiral HPLC analysis of the crude 2-azabicyclo[3.2.0]heptan-3-one 10 showed an ee of 
41%. A small amount of caprolactam 6 (not detectable by 1H NMR) was also observed (see 
Figure 41). 
 
Figure 41: Chromatogram of crude enantiomerically enriched 2-azabicyclo[3.2.0]heptan-3-
one 10, obtained from experiment F. 
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3.2.6.2.2.2 Experiment G: “2:1 film from 15 mM suspension” 
To drive the complexation equilibrium forward, two equivalents of β-CD were used in the 
preparation of the starting milky suspension. The suspension was then spread on a glass 
plate and left to dry in open air to give a consistent white film. The resulting thin film was 
irradiated inside the Rayonet reactor for 4-5 hours. The solid was then collected, dissolved 
in water, and the photoadduct 9 was reduced with dihydrogern in the presence of 10% w/w 
Pd/C-10%. The resulting 2-azabicyclo[3.2.0]heptan-3-one 10 was then extracted from the 
aqueous phase with ethyl acetate. The organic phase was dried over Na2SO4 then 
concentrated under vacuum to give 10 with a yield of 77% over 2 steps. The chiral HPLC 
analysis of the crude product 10 showed an ee of 42%, still accompanied by traces of 
caprolactam 6 (see Figure 42). 
 
Figure 42: Chromatogram of crude enantiomerically enriched 2-azabicyclo[3.2.0]heptan-
3-one 10, obtained from experiment G 
3.2.6.2.2.3 Experiment H: “1:1 film from 5 mM clear solution” 
 A 1:1 mixture of β-CD and azepinone 8 prepared in water at a concentration less 
than 5 mM did not give any precipitate, as we mentioned above. This clear solution was 
spread on a plate and the water allowed to evaporate. The resulting thin film was irradiated 
inside the Rayonet reactor. The solid was then collected, dissolved in water, and the 
photoadduct 9 was reduced with dihydrogern in the presence of 10% w/w Pd/C-10%. The 
resulting azabicyclo[3.2.0]heptan-3-one 10 was then extracted from the aqueous phase with 
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ethyl acetate. The organic phase was dried over Na2SO4 then concentrated vacuum to give 
10 with a yield of 78% over 2 steps. The chiral HPLC analysis of the crude product showed 
an ee of 41%. (see Figure 43) 
 
Figure 43: Chromatogram of the crude enantiomerically enriched 2-
azabicyclo[3.2.0]heptan-3-one 10, obtained from experiment H. 
3.2.7 The β-CD/8 complex film texture 
Although the ee values in all three experiments on film type complexes was similar, a 
change in the texture and consistency of the film was observed when the concentration of β-
CD was changed. A film made from a 1:1 mixture of β-CD and azepinone 8 at 15 mM 
(experiment F) was smooth and could detach itself from the glass plate, whereas at 5 mM 
(experiment H) the film always stuck to the glass and could only be scraped off (see Figure 
44 and 45). 
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Figure 44: Photo showing films of; (a) experiment F, (b) azepinone 8 alone , (c) β-CD 
alone, (d) experiment H. 
 
Figure 45: Photo of 1/1 β-CD/azepinone 8 complex film (experiment F) as it detaches itself 
from the glass plate after 2 days (left), and after 4 days (right). 
Moreover, the presence of two equivalents of β-CD at 15 mM (experiment G) gave a 
ragged, crispier, film with clear crystals all over it. Single crystal X-ray diffraction of the 
crystals showed only β-CD with water inside and outside the cavity (see Figure 49). 
 
Figure 46: Photo showing film of experiment G 
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3.2.7.1   Scanning electron microscopy (SEM) of β-CD/azepinone 8 complex films  
The solid films of all experiments along with one film made from azepinone 8 alone and 
another one from β-CD alone, were subjected to analysis by scanning electron microscopy. 
The pictures showed a well-organized fibrillar morphology in all films, in contrast with 
azepinone 8 alone and β-CD alone, which each showed only amorphous block structures 
(See Figure 47). 
 
Figure 47: SEM images of β-CD alone (top left), azepinone 8 alone (top right), film of 
experiment G: before irradiation (bottom left), and after irradiation (bottom right) 
3.2.8 The absolute configuration of compound 10 
In all the above-described experiments, the same major enantiomer of 10 was in evidence. 
To determine the configuration of this predominant enantiomer, a sample of 10 (from 
experiment G, 42% ee) was transformed into the N-Boc derivative of cis-3,4CB-GABA 12 
following the known procedure.102 The sample of 12 thus obtained had an optical rotation 
value of + 33 (c 0.5, CHCl3, at 25 
oC). The literature value for a sample of (R,R)-12 with 
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97% ee was reported as + 68 (c 0.96, CHCl3, at 27 
oC), indicating that the major enantiomer 
of 10 had an 1R,5R absolute configuration (see scheme 43). 
 
Scheme 43: The chemical transformation of 10 into 12. 
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Figure 48: An overall summary of the different methods tested for the enantioselective photocyclization of azepinone 8 in the presence of CD as 
chiral host. The flowchart shows the corresponding yields over two steps and the measured enantiomeric excess for compound 10.
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3.3 Chiral resolution of ()-cis-3,4CB-GABA by HPLC 
Our efforts to obtain enantiomerically pure cis-3,4CB-GABA through the enantioselective 
photoelectrocyclization of azepinone 8 in the presence of β-CD as a chiral host, followed by 
reduction of the photoadduct, provided samples of 2-azabicyclo[3.2.0]heptan-3-one 10 with 
45% ee at best. 
In order to have a more suitable method to access the target amino acid cis-3,4CB-GABA in 
enantiomerically pure form, we decided to develop a chiral resolution strategy for its N-Boc 
derivative using semi-preparative HPLC. Such a procedure would have several advantages 
when compared to the currently employed resolution methodology, which relies on chiral 
derivatization using an oxazolidinone, as we mentioned before.102  
3.3.1 Preparation of the Boc protected amino acid ()-12 
The multi-step synthesis of the N-Boc derivative of racemic cis-3,4CB-GABA, previously 
described by our collaborated groups, as we mentioned before.102 We decided to reproduce this 
synthesis to obtain ()-12 on gram scale. 
3.3.1.2 Photoelectrocyclization of azepinone 8 in ether 
A solution of azepinone 8 was irradiated for 3 h with a 400 W mercury lamp under argon in a 
reactor fitted with a quartz filter and cooled by an external water/ice bath. The crude product 
was obtained after evaporation of the solvent, with a yield of 97%, as a brown solid (See 
Scheme 44). Since the photoadduct (±)-9 is extremely insoluble in organic solvents, no 
purification was carried out. The 1H NMR spectrum in CDCl3 of the obtained compound (±)-9 
is consistent with the literature.102 
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Scheme 44:  Photocyclization of azepinone 8 in ether 
3.3.1.3 Catalytic hydrogenation of photoadduct (±)-9 
The photoadduct (±)-9 was reduced overnight in ethyl acetate under dihydrogen, in the 
presence of 10% w/w Pd/C-10% (See Scheme 45). The reaction mixture was then filtered 
through Celite, and the filtrate was concentrated under vacuum to obtain the 2-
azabicyclo[3.2.0]heptan-3-one (±)-10 as a yellow solid with a yield of 92%, sufficiently pure to 
be used in the next step without purification. 
 
Scheme 45: Catalytic hydrogenation of photoadduct (±)-9. 
3.3.1.4 Activation of the 2-azabicyclo[3.2.0]heptan-3-one (±)-10 
tert-Butyl 3-oxo-2-azabicyclo[3.2.0]heptane-2-carboxylate (±)-11 was obtained by reacting 2-
azabicyclo[3.2.0]heptan-3-one (±)-10 with an excess of Boc2O in the presence of a catalytic 
amount of DMAP in acetonitrile at room temperature overnight (See Scheme 46). The reaction 
mixture was concentrated, and the crude product was purified by flash chromatography on 
silica. Compound (±)-11 was obtained as a white solid with a yield of 77%. 
 
 
Scheme 46: Protection of 2-azabicyclo[3.2.0]heptan-3-one (±)-10 with a carbamate group. 
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3.3.1.5 Basic hydrolysis of (±)-11 
A solution of (±)-11 in a 50/50 mixture of THF-H2O was stirred in the presence of an excess of 
LiOH at room temperature overnight (See Scheme 47). THF was then evaporated and the 
remaining aqueous solution was acidified with 0.5 M HCl. The crude product (±)-12 was 
extracted with ethyl acetate and purified by flash chromatography on silica. The N-Boc 
protected amino acid (±)-12 was obtained as a white solid with a yield of 71%. 
 
Scheme 47: Basic hydrolysis of (±)-11. 
3.3.2 Chiral HPLC resolution of N-Boc amino acid (±)-12 
We first tried to resolve the N-Boc amino acid (±)-12 on an analytic chiral HPLC column. A 
solution of (±)-12 in acetonitrile was passed through a reversed phase chiral Lux Cellulose-3 
column with a 15/85 acetonitrile/water (0.1% TFA) eluting mixture, at 30 oC and a flow rate of 
1 ml/min. Under these conditions, the two enantiomers of (±)-12 were separated with a 
retention time difference of 1.5 min. Figure 49 shows a chromatogram of racemic (±)-12 eluted 
on an analytical HPLC. 
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Figure 49: HPLC chromatogram of racemic 12 showing separation of the two enantiomers on 
an analytical column. 
These conditions were then applied on a semi-preparative scale, a saturated solution of (±)-12 
in acetonitrile was introduced at a rate of 50 μl each 15 min (50 μl/injection). The eluted 
products were collected over three fractions; one that contained the first enantiomer, one that 
contained the second enantiomer, and a small middle fraction containing both (See Figure 50). 
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Figure 50:HPLC chromatogram of racemic 12,  separation of the two enantiomers on an a 
semi-preparative column. 
There were two main drawbacks in the separation of (±)-12 under these conditions. The first 
one was that the relatively low solubility of amino acid 12 in acetonitrile, limits the separable 
amount of product to around 2.5 mg of each enantiomer per hour. The second one was the use 
of a large amount of water in the eluent which takes several hours to eliminate by 
lyophylization to obtain the dried products (˗)-12 and (+)-12. 
3.3.3 Switching to the N-Boc benzylic ester (±)-13 
In order to circumvent these problems, we considered HPLC chiral resolution of the benzyl 
ester of (±)-12. The ester (±)-13, (see Scheme 48) was expected to be more soluble in organic 
solvents, which should improve the rate of the separation. Furthermore, it was proposed that 
ester (±)-13 could be resolved using a normal phase column, thus avoiding the use of water as 
an eluant.  
3.3.3.1 Preparation of N-Boc benzyl ester (±)-13 
To obtain ester (±)-13, compound (±)-12 was reacted with one equivalent of benzyl alcohol in 
the presence of DMAP and DCC in dichloromethane, overnight. The reaction mixture was then 
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filtered and the filtrate was concentrated under vacuum. The crude product was purified over 
silica to obtain (±)-13 as a white solid in 90% yield (see Scheme 50). 
 
Scheme 48: Synthesis of benzyl ester (±)-13 from (±)-12. 
3.3.3.2 Chiral HPLC resolution of N-Boc benzylic ester (±)-13 
The N-Boc protected benzyl ester (±)-13 was passed through a normal phase chiral Lux 
Cellulose-2 column using a 97/3 hexane/isopropanol eluting mixture, at 30 oC and a flow rate 
of 1 ml/min. Under these conditions, the two enantiomers of 13 were separated with a retention 
time difference of 2.4 min. Figure 51 shows a chromatogram of racemic 13 eluted on an 
analytical HPLC. 
 
Figure 51: HPLC Chromatogram of racemic 13,  separation of the two enantiomers on an 
analytical HPLC. 
These conditions were then applied on semi-preparative scale. A 166 mg/ml solution of (±)-13 
in isopropanol was introduced at a rate of 120 μl each 17 min (120 μl/ injection). The eluted 
products were collected over three fractions: one that contained the first enantiomer, one that 
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contained the second enantiomer and a small middle fraction containing the second enantiomer 
along with traces of the first (See Figure 52). 
 
Figure 52: HPLC chromatogram of racemic amino acid (±)-13,  separation of the two 
enantiomers on a semi-preparative column. 
At this rate, around 70 mg of (±)-13 was processed per hour, to give 35 mg of the first 
enantiomer, 24 mg of the second one (see Figure 53), and 11 mg of a middle fraction 
containing more than 90% of the second enantiomer. 
 
Figure 53: Chromatogram of the pure enantiomers (+)-13 (top) and (-)-13 (bottom) 
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The absolute configuration of the first enantiomer was determined by x-ray analysis and was 
found to have a (3R,4R) configuration. The second enantiomer was thus deduced to be the 
(3S,4S) enantiomer (see Figure 54). 
 
Figure 54: X-ray diffraction structure of the (3R,4R) enantiomer of the protected (+)-cis-3,4CB-
GABA. 
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3.4 Conclusion 
The 2+2 photoelectrocyclization of 1,3-dihydro-2H-azepin-2-one (8) was studied in the 
presence of β-CD as a chiral host. The formation of a precipitate upon mixing 8 with β-CD in 
aqueous solution suggested an interaction between the two components. 1H NMR titration 
experiments were conducted to explore this interaction and showed that the protons inside the 
β-CD cavity interacted with azepinone 8, suggesting that the guest was bound, totally or 
partially, inside the hydrophobic cavity. Nevertheless, the absence of an inflection point in the 
titration curve with a maximum of variation in the chemical shifts, and a low Kb value of 35 
suggested a fast equilibrium between the associated and the free form of the two molecules.  
The photoelectrocyclization reaction of the formed β-CD/azepinone 8 precipitate was 
performed at different ratios of both components, in hot solution, in cold suspension, in solid 
powder form, as well as in a solid thin film form. The isolation of the photoadduct 9 from β-CD 
after the irradiation was not practical so it was reduced into 2-azabicyclo[3.2.0]heptan-3-one 10 
in water in the presence of β-CD then extracted in an average chemical yield of 75% over two 
steps. While no enantiomeric excess was observed in hot solution, up to 45% enantiomeric 
excess of the (R,R) enantiomer could be reached in cold (5-8 oC) suspension and up to 42% in 
solid form.  
The presence of β-CD provided a chiral environment for the photoelectrocyclization of 
azepinone 8 into photoadduct 9, and its reaction into 2-azabicyclo[3.2.0]heptan-3-one 10 could 
be performed on a preparative scale, with a reasonable yield of 75% over two steps, but at best 
a 45% enantiomerically enriched mixture was obtained.  
We established a more suitable method to access both enantiomers of cis-3,4CB-GABA via a 
semi-preparative HPLC fitted with a chiral column. The N-Boc benzyl ester derivative (±)-13 
was most amenable to this procedure. The use of semi-preparative HPLC circumvented the 
long procedure of chiral resolution using an oxazolidinone and provided both enantiomers of 
cis-3,4CB-GABA in a conveniently diprotected form. 
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Chapter 4: Synthesis and Folding Pattern of γ/α-
Hybrid Peptides  
4.1 Introduction 
The diversity of protein structures depends on the amino acid polypeptide backbone which can 
be induced to adopt a very large range of compact conformation. Privileged conformations are 
often stabilized by short- or long-range non-covalent interactions, leading to well-defined 
molecular architectures. Substantial progress has been made in establishing peptidomimic 
architectures, called foldamers, displaying helices, sheets and ribbon shapes.  
The folding pattern of homogeneous oligomers of α, β, or γ amino acids have been more 
extensively studies than folding pattern of mixed hybrid α/β, α/γ and β/γ-oligomers of amino 
acids. The most common regularly-folded architectures are helical: they include the 14-helix 
and the 9-helix for γ-peptides, the 13-helix and the 11/13-helix for β,γ-peptides, the 12-helix 
and the 12/10-helix for α,γ-peptides.  
Many of these secondary structures along with other helical manifolds have been anticipated 
and simulated by theoretical calculations of systematic conformational analysis.116, 117 Mixed 
α/γ-peptides manifolds merit further experimental investigations, to explore if indeed their 
folded architecture are as suggested by the Hoffman’s group theoretically studies.  
The Hoffman group117 suggested through theoretical studied that in a hybrid α/γ peptide a θ 
dihedral angle around 33o, for the γ-amino acid component, is ideal for the formation a 12/10 
helix. The X ray crystal structure of the cis3,4CB-GABA, which was synthesized in chapter 
three, showed that this molecule has an angle θ around 27o which makes it a suitable building 
block for a hybrid α/γ-peptide that could fold into a 12/10 helical secondary structure.  
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In this chapter we aim to synthesize, characterize, and study the three dimensional folding 
behavior of mixed α/γ-peptides composed of alternating, enantiomerically pure cis3,4CB-GABA 
as the constrained γ-amino acid component and D-Alanine (D-Ala) as the α-amino acid 
component. Two series of mixed α/γ-peptides were studied one that has the (R,R)-cis3,4CB-
GABA enantiomer as the γ-amino acid component and one that has the (S,S)-cis3,4CB-GABA 
enantiomer as the γ-amino acid component.  
 
4.1.1 The Three dimensional conformation of polypeptides 
In order to understand the three dimensional structure of a given polymer, two essential types 
of information should be known. The first one is the configuration of the monomer unit itself, 
and the second, is the relative orientation of the units at each linkage.  
4.1.1.1 The conformation of the peptide link  
In the case of polypeptides, the dimensions of the peptide unit itself has been determined by 
Pauling and Corey,119, 120 although slight variations are observed in certain structures, it is 
established that the peptide link or amid unit form a considerably rigid plane. The origin of this 
planer organization of the amid unit, is the resonance of the double bond between the carbon-
oxygen and carbon-nitrogen positions which leads to a partial double bond character between 
the O-C-N atoms (see Figure 55).119 As a consequence, the set of atoms Cαn-C'O-NH-Cαn+1, 
starting from one α-carbon and going to the next α-carbon atom, forms a planer group. 
  
Figure 55: The resonant structures of the peptide unit. 
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4.1.1.2 The conformation around the peptide bond 
When two peptide groups are linked together, it is possible to have a rotation of the planer amid 
units around the bonds N-Cαn and CαC', and thus the relative configuration of the two groups 
about the Cα atom can be indicated by two parameters φ and ψ.118 
To properly visualize the two rotations around Cα, the two planer amid units are first kept in 
the same plane, fully stretched with the carbonyls pointing roughly in opposite directions (see 
Figure 56). Now, the O-C''-N0 residue (blue) is held in plane, and the other unit (red) as a whole 
is given a rotation of an angle φ about the N0-Cα bond, in an anticlockwise sense looking from 
N0 towards Cα. This bond, N0-Cα, is then tightened and the O-C''-N0 residue (blue) is then 
rotated through the angle ψ about the Cα-C' bond, in a clockwise sense, looking from C' 
towards Cα. The resulting dipeptide has now a conformation which can be described by the 
dihedral angles (φ, ψ) . 
 
Figure 56:The dihedral angles (φ, ψ, ω, and χ) that describe the conformation of two peptide 
units. 
This procedure could be further applied for describing the conformation of a complete 
polypeptide chain containing “n” amino acid residues by first keeping them all stretched in the 
same plane, and then applying, the series of rotations (φ1, ψ1), (φ2, ψ2). . . up to (φn, ψn) at each 
successive α-carbon. The obtained set of n pairs of dihedral angles contains the most important 
information needed for describing the conformation of the backbone for the entire polypeptide 
chain.121 
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The φ and, ψ parameters would be enough to fully describe the conformation of a polypeptide 
chain only when each peptide unit is considered as an ideal plane with the same dimensions at 
every α-carbon. In reality this is never the case, and the dimensions at each peptide unit can 
vary. In order to compensate for these variations, it is necessary to have further parameters to 
completely describe the conformation of a polypeptide chain. 
To describe the deviation of a peptide unit from being an ideal plane, we need to define the 
dihedral angle ω. It represents a rotation around the peptide bond C'-N1 and may be defined as 
the angle between the planes Cα-C'-N1 and C'-N1-Cα (See Figure 59). Another parameter that 
affects the overall conformation of a poly peptide chain is denoted by χ, which describes the 
conformation of the atoms in the side chain, and is denoted by a series of dihedral angles χ1, χ2, 
etc., that describe the rotations about the bonds (Cα-Cβ), (Cβ-Cγ), etc. 
 Nevertheless, it is important to realize that, although these φ, ψ, ω, and χ parameters are all 
needed to describe the exact conformation of a polypeptide chain. The most important 
parameters are the φ and ψ angles.A good knowledge about the conformation of the 
polypeptide chain may be obtained from a set of these two dihedral angles. 
4.1.2 The folding pattern in natural peptides 
4.1.2.1 The Ramachandran diagram 
The dihedral angles φ and ψ are both defined over a range of [−180°, 180°]. The φ, ψ values for 
each amino acid residue can be plotted, with φ along the horizontal axis, and ψ along the 
vertical one, to produce what is referred as Ramachandran diagram or a [φ, ψ] plot. (See Figure 
57)  
  
Page | 94  
 
 
Figure 57: The Ramachandran plot for all residues, except glycine, with the permitted 
combinations of  torsional angles shown as colored regions. 
The Ramachandran diagram gives a graphical representation of all the possible combinations of 
dihedral angles φ and ψ. In fact, many of these angle combinations are not allowed due to steric 
hindrance between atoms.  
By looking at a Ramachandran diagram, one can determine the allowed and disfavored 
torsional angles thereby obtaining an insight into the structural conformation of a given peptide.  
For instance, the Ramachandran diagram of Figure 57 indicates the different pairs of dihedral 
angles allowing the formation of -helices and -sheets conformationally accessible in natural 
proteins. 
4.1.2.2 Conformation of natural peptides 
Proteins can have four different structural levels. The most basic one is the linear arrangement 
of amino acid residues in a polypeptide, which defines its primary structure. Due to stabilizing 
hydrogen bonds between certain residues, parts of this linear amino acid sequence can assume 
local structural conformations. These different spatial arrangements define the protein’s 
secondary structure. Peptides secondary structure includes: helices, strands and loops. The 
folding of a polypeptide into its secondary structure puts some specific amino acids in a close 
proximity. This can lead to a further folding of the protein into its tertiary structure, which is 
defined as the overall three-dimensional shape of the entire protein molecule. Some proteins 
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can show an additional level of organization, when they interact with other proteins and arrange 
themselves to form an aggregate protein complex called the protein quaternary structure. The 
final structure of the protein is stabilized by different interaction between its constituents (see 
Figure 58).122 
 
Figure 58: The Primary, secondary, tertiary, and quaternary structures of protein122 
4.1.2.2.1 The α-helix “natural helix” 
Helices are the most abundant secondary structures found in globular proteins.123 They are 
named p(n)-helix according to the number of atoms (n), and the number of residues (p) for each 
turn. For example, a 3(10)-helix has 10 atoms and 3 residues per turn. 
 As mentioned in section 4.1.1.2 above, the secondary structure i.e. the three dimensional 
folding pattern of a polypeptide is governed by the repeated display of a particular set of 
backbone dihedral angles φ and ψ. Table 7 shows the (φ, ψ) values that define the three types of 
natural protein helices. 
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Helix type Φ Ψ 
α  -58o -47o 
310 -49
o -26o 
π -57o -70o 
Table 7: The (φ, ψ) values that define the three types of natural protein helices. 
The three types of helix whose φ and ψ are presented Table 7, are populated differently in 
natural proteins.123, 124 The 3.6(13)-helix also known as the right handed α-helix was discovered 
by L. Pauling and is the most abundant helix in natural proteins.119, 125 About 32-38% of 
residues are involved in α-helices. The 3.0(10)-helix also known as the 310-helix is a rare 
secondary structure of natural proteins. It accounts for only 3.4% of all residues. The 310-
helices are typically very short structures, found at the beginning or the end of some α-helices. 
The π-helix, or 4.4(16)-helix, has been recently discovered and is an extremely rare protein 
secondary structure that is found at the end of certain α-helix.126 The left-handed 3.6(13)-helix 
and the  2.2(7), 4.3(14) or 4.4(16)-helices, have been predicted but never yet found in natural 
proteins.127 
4.1.3 The folding pattern in unnatural peptides 
During the past few decades, chemists have been inspired by the ability of natural peptides to 
fold into a well-defined helical secondary structure. These self-organized systems have gained 
an increasing attention, and have found various applications, like molecular recognition, 
peptidomimetics, and therapeutics.128, 129 (128) (129) The term “foldamers” was first coined by 
Gellman130 and defines “oligomers with a strong tendency to adopt a specific conformationally 
ordered structure in solution, stabilized by a set of noncovalent interactions between 
nonadjacent monomer units”.131 These noncovalent interactions include steric repulsions, 
hydrogen-bonding, electrostatic and π-π interactions, coordination to metal ions, as well as 
solvophobic effects. Out of these interactions, hydrogen-bonding are the most versatile in 
creating intra-strand connections that could stabilize a well-defined three dimensional structure 
adopted by an oligomeric peptide chain.129  
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The early studies of Gellman130, 132 and Seebach133, 134 and the later contributions of 
Hofmann116, 117, 135 have certainly initiated the rapidly evolving field of foldamers. In this 
context, several homo and hybrid peptides of α, β, and γ-amino acids have been studied for 
their preferential three dimensional folding pattern. 
4.1.3.1 Folding pattern in homo-peptides 
4.1.3.1.1 β-Peptides  
β-amino acids are homologated analogous of α-amino acids. The additional backbone carbon 
inserted between the carboxylic acid and the amino group gives to β-peptides an additional 
dihedral angle θ, and thus a higher conformational flexibility than α-peptides (see Figure 59). 
This additional torsional freedom does not prevent the formation of ordered secondary 
structures in -peptides.132, 136 
 
Figure 59: The dihedral angels in a β-peptide. 
The Hofmann group135, 136 predicted via ab initio calculations the different types of helices that 
could be adopted by β-peptide. So far, seven different helices have been experimentally 
observed (see Figure 60, solid arrows); the 8-,137 10-,138 10/12-,139 12-,140 12/10-,141 14-,133 and 
18/20-helices.142 
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Figure 60: The different types of helices that could be adopted by a β-peptide, as predicted by 
the Hofmann group. Solid arows indicate the so far experimentally observed ones. 
4.1.3.1.1.1  Example and application of the β-Peptides  
The 12- and 14-helical structures adopted by β-peptides are the most important ones. The 
helicity in these two structures is comparable to the one of a native α-helix (13-helix). This has 
led researchers to study β-peptides as scaffolds to mimic certain native α-helices in terms of 
structure and biological activity.129  
One example is the 17-residue β-peptide prepared by the Gellman group.143 Their peptide was 
composed of (R,R)-trans-2-aminocyclopentanecarboxylic acid (trans-ACPC) and trans-4-
aminopyrrolidine-caboxilic acid (trans-ACP) (see Figure 61). The trans-ACP served as a 
cationic residue giving an amphiphilic property to the formed 12-helix, which was essential to 
mimic the biological activity of amphiphilic cationic antimicrobial peptides found in nature. 
  
Page | 99  
 
 
Figure 61: The Gellman’s group 12-helix antimicrobial β-peptide. 
4.1.3.1.2 γ-peptides 
γ-amino acids are doubly homologated α-amino acids, the two extra carbons inserted between 
the carboxylic acid and the amino group gives them two additional dihedral angle θ, and ζ 
which makes γ-peptides more flexible than their α- and β-counterparts (see Figure 62). 
 
Figure 62: The dihedral angels in a γ-peptide. 
The Hofmann group predicted via ab initio calculations that a hexamer γ-peptide has the ability 
to fold into eight different helical secondary structures.144 So far only the 7-,145 9-,146 and 14-
helices147 have been experimentally observed (see Figure 63, solid arrows). One should note 
that the folding pattern with a 7-membered pseudocycle arising from intraresidual H-bond 
formation is viewed as a 7- ribbon rather than a helix due to its small pitch and flattened 
structure. 
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Figure 63: The different types of helices that could be adopted by a γ-peptide, as predicted by 
the Hofmann group. Solid arows indicate the so far experimentally observed ones. 
4.1.3.1.2.1 Examples and application of the γ-peptides 
Unlike β-peptides, γ-peptides did not receive any attention in the field of biological 
applications. The prepared γ-peptides were only a subject of structural and conformational 
behavior studies. Hanessian147 and Seebach148,149, 150 groups independently studied one example 
of substituted γ-peptides that fold into a stable 14-helix (see Figure 64). The research groups 
also pointed out the effect of having a substituent at the C-4 position in promoting the 
formation of a helical structure in γ-peptides. For instance, γ4-, γ2,4-, γ2,3,4-peptides all adopted a 
14-helical structure, whereas γ2-, γ3-peptides folded into a flexible, hard to determine structure.  
 
Figure 64: One example of the γ4-peptides that fold into a stable 14-helix, from Seebach’s 
group. 
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4.1.3.2 Folding pattern in hybrid peptides 
Hybrid peptides include α/β, α/γ, and β/γ-peptides. They have drawn much attention due to 
their ability to further expand the scope of foldamers in terms of variations in the backbone 
pattern compared to their homo-peptides counterparts. Furthermore, incorporating unnatural 
amino acids such as β or γ-amino acids into an α-peptide sequence with a proteinogenic side 
chain needed for biological activity, could enhance its in vivo proteolytic stability, due to the 
absence of suitable enzymes. This heterogeneous structure could so allow the peptide to keep 
its biological function without being easily hydrolyzed by the protease enzymes.151, 152 
In hybrid peptides, the formed hydrogen-bonding interactions between the non-neighboring 
amino acids that define their helical structures, could be categorized into three types: hydrogen 
bonds formed in a backward direction along the sequence, hydrogen bonds formed in a forward 
direction of the sequence, and hydrogen bonds formed alternately in backward and forward 
direction (see Figure 65).116 
 
Figure 65: The three possible directions of hydrogen bonding in an α/β-hybrid peptide.  
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4.1.3.2.1 Mixed α/β-peptides 
The Hofmann group studied the possible helical secondary structures that could be adopted by 
a, free of strain, α/β-octapeptide composed of alternating glycine and β-alanine.116 The authors 
found via ab initio calculations that such a peptide could fold into seven distinct stable helices 
which are: 9/11-, 11/9-, 11-, 12/13-, 14/15, 16/18- and 18/16-helices.  
So far, only the 11/9-,153 11-,154 12/13-,155 and 15/14-helices156 have been experimentally 
observed. 
4.1.3.2.1.1 Examples of α/β-peptides and applications 
One example of α/β-hybrid peptide, was studied by the Gellman group.157 The authors were 
able to design a chimeric peptide composed of an N-terminal α/β-fragment and a C-terminal α-
fragment. The α/β-fragment which was made of trans-ACP and trans-ACPC folded into a 
15/14-helical structure whereas the α-fragment composed of proteinogenic amino acids adopted 
a native α-helix structure (see Figure 66). This α/β+α-peptide had the ability to bind, with an 
inhibitory effect, to its target transmembrane protein (Bcl-xL). This demonstrates the potential 
use of specially designed peptide foldamers to inhibit certain protein-protein interactions.  
 
Figure 66: The Gellman’s group chimeric α/β+α-peptide. 
  
Page | 103  
 
4.1.3.2.2 Mixed β/γ-peptides 
The β/γ-peptides form another class of hybrid peptides, which consist of alternating β- and γ-
amino acids. β/γ-peptides are interesting due to their ability to adopt helical secondary 
structures that mimic those of the native α-peptides, such as the 13- or α-helix.  
The Hofmann group studied via ab initio calculations the different possible helical structures 
which could be adopted by a β/γ- octapeptide composed of alternating β-Glycine and GABA.117 
The authors found ten distinct stable helical forms: 11-, 11/13-, 13/11-, 13‐,15/16-, 18/17-, 20-, 
20/22-, 22/20- and 22-helices. Out of the ten stable helical structures predicted by the Hofmann 
group, the 11/13-helix has been experimentally observed in solution and the 13-helix has been 
observed both in solution and in solid state. 
Recently the Aitken group were the first to established the ability of β/γ-peptide composed of 
(1R,2R)-2-aminocyclobutane carboxylic acid (trans-ACBC) and GABA, to fold into a 9/8-
ribbon, with  alternating 9-, 8-hydrogen bonding pseudocycles.158 
4.1.3.2.2.1 Examples of β/γ and applications 
As mentioned above the β/γ-hybrid peptides are important because they are able to fold into a 
13-helix similar to the natural α-helix. The Gellman group,96 based on the Hoffman group 
calculations,117 have designed a β/γ-hybrid peptide composed of (R,R)-trans-ACPC and ethyl-
cis-2(aminocyclohexane)acetic acid ((R,R,R)-EtACHA). The hybrid hexapeptide adopted a 
regular 13-helix in solution as well as in solid state (see Figure 67). 
 
Figure 67 : The Gellman’s group β/γ-hybrid peptide that folds into a 13-helix. 
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More recently the Aitken group designed an α/β/γ-hybrid peptide using the trans-ACBC as the 
key β-amino acid component and γ4-amino acids as the γ-amino acid components.159 The α/β/γ-
hybrid peptide folded into a 12,13-helix in solution, (see Figure 68) which resembles the native 
α-helix, and was able to act as functional and selective α-helix-mimetic inhibitor of the 
p53/hDM2 interaction, validating the importance of designed peptide foldamers for 
applications in the field of protein-protein interactions. 
 
Figure 68: The Aitken’s group α/β/γ-hybrid peptide that folds into a 13-helix. 
 
4.1.3.2.3 Mixed α/γ-peptides 
Another class of hybrid peptides, α/γ-peptides, are composed of alternating α- and γ-amino 
acids. α/γ-peptides dimer units, with their proteinogenic α-amino acid component, may 
properly replace a dipeptide unit in the nonproteinogenic β-peptides.117 This could open the 
door to a pool of foldamers having a secondary structure that resembles the folding pattern of 
β-peptides but with proteinogenic component needed for biological activity. 
The Hofmann group studied via ab initio calculations the different possible helical structures 
which could be adopted by an α/γ-octapeptide composed of alternating glycine and GABA.117 
The authors found eleven distinct stable helical forms: 10-, 10/12-, 12/10-, 12-, 15/17-, 18-, 
18/20-, 20/18‐, 20-, 21/23‐ and 26-helices. They also suggested that α/γ-hybrid peptides have 
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helix conformers, which locks like the overall structure of β-peptide helices. Both the most 
stable 12- and 12/10-helices formed by an α/γ-hybrid peptide showed a very good 
correspondence with the experimentally found 12- and 12/10-helices of β-peptides with a Root 
Mean Square Deviation (RMSD) of 0.6 Å, and 0.7 Å respectively (see Figure 69). 
 
Figure 69: The resemblance between a theoretically predicted 12/10-helix for a α/γ-hybrid 
octapeptide (bottom), and that of the experimentally found for a beta peptide (top), with a three 
dimensional superimposition of both helical structures (right).  
4.1.3.2.3.1 Examples and applications 
Out of the eleven stable helical structures predicted by the Hofmann group, the 12-, the 12/10- 
and most recently the 9- and the 9/12-helix have been experimentally observed in solution and 
in solid state as illustrated below. 
The Balaram group studied α/γ-hybrid peptides composed of alternating α-aminoisobutyric acid 
(Aib) and gabapentin (Gpn).160 The conformational restrictions, imposed by the constrained 
Aib and Gpn residues on the dihedral angles, allowed the α/γ-nonapeptide to adopte a 12-
helical structure in solution but, more interestingly the authors were able to characterize C9, 
C7, C12, and C17 hydrogen-bonded turns in the crystalline form, in the shorter tetrapeptide; 
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which emphasizes the fragility of structuration in short oligomers compared to longer ones (See 
Figure 70). 
 
Figure 70: The folding pattern in the Balaram’s group α/γ-hybrid nonapeptide (top), and 
tetrapeptides (bottom) 
A 12-helix structuration in solution, as well as in crystalline form, was also observed by the 
Gopi group.161 An α/γ-peptides composed of alternating α-aminoisobutyric acid (Aib) and γ4-
phenyl alanine showed a 12-helical structure which was favored by gauche conformation 
adopted by the dihedral angels θ, and ζ of the γ4-phenyl alanine component. Moreover, the 
obtained 12-helical structure presented a good correlation between its backbone, with its side 
chain projections, and a native α-helix (RMSD = 0.8 Å); signifying the possibility of 
employing specially designed α/γ-peptides for natural peptides mimicry (see Figure 71). 
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Figure 71 : The Gopi’s group α/γ-hybrid peptide that folds into a 12-helix (left), and a three 
dimensional superimposition of it with a native α-helix (right).  
On the other hand the 12/10 secondary helical structure in solution was first reported by the 
Kunwar’s group,162 the authors prepared a α/γ-hybrid tetrapeptide ,composed of alternating L-
alanine and C-linked carbo-γ-amino acid of D-mannose, whose tetra and hexamers folded into 
a 12/10-helix in solution (see Figure 72).  
 
Figure 72: The Kunwar’s group α/γ-hybrid tetrapeptide that folds into a 12/10-helix. 
Similarly, the Gellman’s group studied the conformational behavior of a α/γ-hybrid 
hexapeptide composed of alternating L-alanine and (1R,2R,3S)-2-(1-aminopropyl)-
cyclohexanecarboxylic acid (APCH).163 The conformationally restricted backbone of the 
(APCH) residue, strongly enforced the formation of a 12/10-helical structure with an 
alternating direction of the hydrogen bond pattern in solution as well as in crystalline state (see 
Figure 73). 
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Figure 73: : The Gellman’s group α/γ-hybrid peptide that folds into a 12/10-helix. 
Most recently the Gopi’s group reported a 12/10 folding pattern in α/γ-hybrid peptides 
composed of alternating alanine (Ala), or leucine (Leu), and 4-aminoisocaproic acid (Aic).164 
The authors were able to flip from a 12/10- into a 12-helical structure when the α-amino acid 
component was changed into the achiral 1-aminocyclohexane-1-carboxylic acid (Ac6c), thus 
presenting the influence of small structural variations in the α-amino acid structure on the 
overall helicity of an α/γ-hybrid peptide. (See Figure 74). 
 
Figure 74:  The Gopi’s group α/γ-hybrid peptide that changes its folding pattern from 12/10 
(top) into 12 (bottom), with a change in the α-amino acid side chain substituent. 
Aside from the 12 and the 12/10- helical structuration, The Maillard’s group,165 prepared α/γ-
hybrid peptide containing enantiomeric pure 4-amino(methyl)-1,3-thiazole-5-carboxylic acids 
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(ATCs) as the restricted γ-amino acid component. The authors found that ATCs induced a 
highly stable 9 pseudocycle (see Figure 75). 
 
Figure 75: The Maillard’s group peptide that show a 9-membered hydrogen bonding 
pseudocycle. 
4.1.3.3 Stereochemistry effect on the peptide secondary structure  
The stereochemistry of each building block of a peptide sequence has an important effect on the 
nature and the conformation of the formed secondary structure.166 For instance, an oligomer 
composed of alternating homochiral cis-1R,2S-aminocyclopentanecarboxylic acid (cis-ACPC) 
is found to adopt a strand secondary conformation,167 whereas an alternation of heterochiral 
1R,2S- and 1S,2R-cis-ACPC oligomer folds into a stable 10/12-helix.139 The change in the 
relative stereochemistry of amino acid residues changed the secondary structure from a strand 
to a helix, revealing a profound correlation between the stereochemistry of the amino acid 
residues and the conformation of the adopted secondary structure (See Figure 76). 
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Figure 76: The effect of changing the chirality of an amino acid componant on the over all 
structuration in an ACPC ologomer. 
Aside from the more popular 12- and the 12/10- helical folding, the Maillard’s group165,168 
prepared an α/γ-hybrid peptide, containing enantiomeric pure 4-amino(methyl)-1,3-thiazole-5-
carboxylic acids (ATCs) as the restricted γ-amino acid component, (see Figure 77), which 
showed unique conformational properties resulting from its aromatic ring. These ATC γ-amino 
acids, having a ζ torsion angle locked around 0o, are structurally similar to Z-vinylogous γ-
amino acids. The ATC acted as a strong turn inducer for folding. The folding pattern depended 
as well of the absolute configuration of the γ-amino acid. The alternating homochiral (S)-α/(S)-
ATC dipeptide exhibited a C-9 foldwhile the heterochiral (S)-α/(R)-ATC dipeptide displayed 
ribbon structure stabilized by unusual C-9/12 bifurcated hydrogen bonds 
 
Figure 77: The 9,12-bifurcated hydrogen bonding pattern  recently found by the Maillard’s 
group in γ/α-hybrid peptides. 
  
Page | 111  
 
4.1.4 Objectives of this work 
Studies on α/β-, β/γ-, and α/γ-hybrid peptides provided a rich pool of foldamers having helical 
secondary structures. These foldamers have attractive features, which give them applications in 
various fields of molecular recognition, peptidomimetics, and therapeutics.128, 129  
Over the last few years, the Aitken research team has become specialized in the synthesis of 
unnatural amino acids, especially those incorporating small constrained rings and the 
development of oligomers based on these building blocks. Oligomers of these constrained 
amino acids present specific dihedral angles that confer to them the ability to promote stable 
three dimensional secondary conformations. Even though, there is a lot of theoretical 
knowledge that correlates between structure of amino acids and peptides folding pattern, a lot 
remains to be explored experimentally before one can intentionally manipulate the design of a 
peptide sequence to promote a specific desirable folding pattern in a bottom-up approach.92, 158 
 
The ab initio theoretical studies done by the Hoffman group suggested that in an α/γ-hybrid 
peptide a θ dihedral angle around 33o, for the γ-amino acid component, is ideal for the 
formation a 12/10-helix.117 The crystal structure of the cis3,4cyclobutane -aminobutyric acid 
(cis-3,4CB-GABA), which was synthesized in chapter three, showed that this molecule has an θ 
angle around 27o (see Figure 78) which makes it a suitable building block for a α/γ-hybrid 
peptide that could fold into a 12/10-helical secondary structure.  
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Figure 78: The crystal structure of the cis-3,4cyclobutane -aminobutyric acid (cis-3,4CB-GABA) 
(left), the torsional angel needed to obtain a 12/10 helical folding pattern in mixed α/γ-
peptides, as predicted by the Hoffman group (right) 
In this chapter, we aimed to validate the cis-3,4CB-GABA as a γ-amino acid component 
capability to induce a 12/10-helical folding pattern in mixed γ/α-peptides. We also studied the 
effect of reversing the stereochemistry of the cis-3,4CB-GABA, on the three dimensional 
folding pattern of these γ/α-peptides. Thus we synthesized and characterized, γ/α-hybrid 
peptides composed of alternating, enantiomerically pure either (S,S)- or (R,R)-cis-3,4CB-GABA 
as the constrained γ-amino acid component and D-Alanine (D-Ala) as the α-amino acid 
component. The three dimensional folding behavior of these peptides was subsequently studied 
(see Figure 79). 
 
Figure 79: The target γ/α-hybrid peptide, the (S,S/R)-series (left), and the (R,R/R)-series right. 
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4.2. Results and discussion 
4.2.1 The starting amino acids: Enantiomerically pure protected γ- and α-
amino acids 
The synthesis of mixed γ/α-peptides requires access to enantiomerically pure γ- and α- amino 
acid monomers.  
4.2.1.1 The enantiomerically pure Boc-cis-3,4CB-GABA-OBn 
The diprotected Boc-cis-3,4CB-GABA-OBn was prepared in its racemic form following by the 
semi-preparative Chiral-HPLC separation method as described in chapter three, to obtain both 
enantiomers in pure form (see Scheme 49). 
 
Scheme 49: The synthesis of Boc-cis-3,4CB-GABA-OBn in its racemic form (top); separation of 
the two enantiomers via the semi-preparative Chiral-HPLC resolution method (bottom). 
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4.2.1.2 The Enatiomerically pure D-Alanine  
The 12/10 helical structure of a α/γ-peptides, generated by the theoretical calculations of the 
Hofmann group,117 suggested that, if we used the (S,S)-cis3,4CB-GABA as the γ-amino acid 
component and a R configuration around the Cα of the α-amino acid component,  the α-amino 
acid side chain and the cyclobutane ring would be in a plane perpendicular  to the helix axis 
and would not disturb the helical structure formation. On these bases D-Alanine was chosen to 
be the α-amino acid component in our studied α/γ-peptides. 
The enantiomerically pure Boc-D-Ala-OBn 14 and Boc-D-Ala-NHBn 15 were prepared from 
commercial D-Ala amino acid, by reacting it with Boc2O in the presence of NaOHaq, in 
dioxane. The resulting “clean” crude Boc-D-Ala was then, either reacted with benzyl alcohol in 
the presence of DCC and DMAP, to get the benzyl ester Boc-D-Ala-OBn 14 with a 75% yield, 
or coupled with benzyl amine in the presence of HATU to easily obtain the benzyl amide Boc-
D-Ala-NHBn 15 in 80% yield (see Scheme 50).  
  
Scheme 50. The synthesis of compounds 15 and 16 from commercial D-Alanine. 
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4.2.2 The general Synthetic method 
4.2.2.1 The activation/ coupling strategy 
Peptide synthesis via amino acids coupling involves two steps (see Scheme 51). The first step is 
the activation of the carboxylic acid group of one amino acid residue using a coupling agent. 
The second step involves the nucleophilic addition of the amino group of the other amino acid 
derivative at the activated carboxylic acid. 
 
Scheme 51: The steps of peptide synthesis via amino acid coupling. 
A suitable coupling method has to form peptide bonds in high yields and to maintain the 
configurational integrity of the carboxylic component.169,170 Racemization at the α-carbon 
usually occurs during the activation of the carboxylic acid function if the amine part is bearing 
an electron withdrawing group (see Scheme 52). 
   
Scheme 52: The two possible explanations for the racemization at the α-carbon during peptide 
coupling. 
  
Page | 116  
 
It is important to note that even though our convergent strategy in building up the mixed γ/α-
peptides involved an activation of a carboxylic acid group and an amine protected with an 
electron withdrawing group, no racemization of the D-alanine was observed in any of the 
synthesized peptides. 
4.2.2.2 Choice of the coupling agent 
The carboxylic acid activation, first step in peptide coupling, is crucial and one should 
experiment in order to find the best coupling agent and reaction conditions for a given peptide 
synthesis. Several coupling reagents are available. For instance, carbodiimide reagents, like 
DCC, have been used as peptide coupling agents for a long time.  
In the recent years, two classes of coupling reagents became popular, the phosphonium type 
reagents such as BOP, and PyBOP, and the aminium-(uronium) type reagents such as TBTU, 
HBTU, and HATU (see Figure 80).  
 
Figure 80: Examples of the phosphonium (top), and  aminium-uronium (bottom) type coupling 
reagents. 
These compounds achieve high coupling rates accompanied by few undesired side reactions. In 
contrast with carbodiimide based reagents, activation by these coupling agents require the 
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presence of a base like diisopropylethylamine (DIPEA) for the activation reaction to proceed 
(see Scheme 53).170 
 
Scheme 53: The general mechanism of peptide coupling using HATU. 
In our coupling reactions we followed the reaction conditions established previously in our 
group for β/γ-hybrid peptides preparation.158 Thus we used HATU, as the coupling agent, 
which was easy to handle and provided high coupling yields, without any unwanted 
racemization. 
The dipeptide coupling reactions were performed by first cleaving the Boc protecting group of 
the amine partner using TFA in DCM. Then the activation of the carboxylic acid residue of the 
acid partner, using HATU in the presence of DIPEA, generates the activated carboxylate in a 
mixture of DCM and DMF. (Scheme 5 below) The DCM/DMF mixture allowed a better 
dissolution of the HATU, as well as higher order peptides, which have low solubility. The 
activation of the carboxylic acid residue could be confirmed by the darkening of the reaction 
mixture (from light brown to dark brown) due to the 1-hydroxy-azaenzine-triazole anion 
(HOAt) released by HATU (see Scheme 55). Once the activation was complete, within 10 min, 
a solution of the amine partner, in DCM, with a sufficient amount of DIPEA to neutralize the 
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excess of TFA, was added to the HATU activated reaction mixture, the resulting reaction 
mixture was then left to stir at room temperature, under argon, for 24 hours, after which it was 
purified to give the desired dipeptide. 
4.2.2.3 Convergent peptide synthesis 
The general synthetic strategy we followed in building up the mixed γ/α-peptides was a 
convergent one. This strategy seems to us more adequate than the linear synthesis of peptides, 
where the monomers are successively coupled one after the other until the target molecule is 
reached, with the yield dropping quickly as the number of steps increases. A convergent 
synthesis is a strategic approach in which fragments of the peptide are first prepared and then 
combined together to complete the target molecule (see Figure 81). In a convergent strategy, 
fewer steps than in the linear one are needed to reach the same molecule, thus enhancing the 
yield and saving time.   
 
Figure 81: The linear (top) v.s. the convergent (bottom) startegie for γ/α-hybrid peptide 
synthesis. 
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4.2.3 Synthesis of Boc-(S,S)-cis-3,4CB-GABA/(R)-Ala-OBn peptides  
The synthesis of Boc-[(S,S)-cis-3,4CB-GABA-(R)-Ala]n-OBn peptides p1 and p2 was carried 
out following a convergent strategy, starting from the Boc-(S,S)-cis-3,4CB-GABA-OBn 
enantiomer (-)-13 as the γ-amino acid partner, and the Boc-D-Ala-OBn (+)-15 as the α-amino 
acid partner (see Scheme 54). 
 
Scheme 54: The convergent synthesis of Boc-[(S,S)-cis-3,4CB-GABA-(R)-Ala]n-OBn peptides p1 
and p2. 
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4.2.3.1 Synthesis of the Boc-[(S,S)-cis-3,4CB-GABA/(R)-Ala]-OBn peptide p1 
The C-terminal benzyl protecting group, of Boc-(S,S)-cis-3,4CB-GABA-OBn was first removed 
in a quantitative yield by catalytic hydrogenolysis under dihydrogen atmosphere in the presence 
of 10% Pd-C (10% w/w) for 4 hours to obtain the free acid intermediate (see Scheme 54). The 
N-terminal Boc protecting group of Boc-D-Ala-OBn was cleaved by treatment with a large 
excess of TFA for 1 hour to give the corresponding amine partner as a TFA salt.  
The obtained free acid was then activated with HATU and reacted with the amine partner in the 
presence of DIPEA for 24 hours at room temperature, under argon. to afford dipeptide p1 in an 
85% yield after purification. 
4.2.3.2 Synthesis of the Boc-[(S,S)-cis-3,4CB-GABA/(R)-Ala]2-OBn peptide p2 
One equivalent of dipeptide p1 was selectively deprotected at the N-terminal with large excess 
of TFA for 1 hour. Another equivalent of dipeptide p1 was selectively deprotected at the C-
terminal by catalytic hydrogenolysis under dihydrogen atmosphere in the presence of 10% Pd-
C (10% w/w) for 4 hours. The two monoprotected dipeptides were then mixed together in the 
presence of excess of DIPEA before HATU was added. The coupling reaction was left to stir 
for 24 hours, at room temperature, under argon to afford tetrapeptide p2 in a 66% yield. 
  In is coupling reaction, the free acid and the free amine partners were mixed together 
along with enough DIPEA to make the reaction mixture basic before adding the HATU to 
avoid the risk of racemization of the activated dipeptide (see section 4.2.2.1), by minimizing 
the time of it being activated without the presence of the nucleophilic amine partner.  
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4.2.4 Synthesis of Boc-(R,R)-cis-3,4CB-GABA/(R)-Ala-OBn peptides 
 In order to investigate the effect of reversing the stereochemistry of the cis-3,4CB-GABA 
component on the three dimensional folding pattern of our α/γ-hybrid peptide, we prepared a di 
and a terrapeptide composed of alternating (R,R)-cis-3,4CB-GABA and D-Alanine. 
 The synthesis of Boc-[(R,R)-cis-3,4CB-GABA-(R)-Ala]n-OBn peptides p3 and p4 was carried 
out following a convergent strategy, starting from the Boc-(R,R)-cis-3,4CB-GABA-OBn 
enantiomer (+)-13 as the γ-amino acid partner, and the Boc-D-Ala-OBn (+)-15 as the α-amino 
acid partner (see Scheme 55). 
 
Scheme 55: The convergent synthesis of Boc-[(R,R)-3,4CB-GABA-(R)-Ala]n-OBn peptides p3 
and p4. 
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4.2.4.1 Synthesis of the Boc-(R,R)-cis-3,4CB-GABA-(R)-Ala-OBn peptide p3 
The C-terminal benzyl protecting group, of Boc-(R,R)-cis-3,4CB-GABA-OBn was first removed 
in a quantitative yield by catalytic hydrogenolysis under dihydrogen atmosphere in the presence 
of 10% Pd-C (10% w/w) for 4 hours to obtain the free acid intermediate (see Scheme 55). The 
N-terminal Boc protecting group of Boc-D-Ala-OBn was cleaved by reaction with a large 
excess of TFA for 1 hour to give the corresponding amine partner as a TFA salt. 
The obtained free acid was activated with HATU and reacted with the amine partner in the 
presence of DIPEA for 24 hours at room temperature, under argon to afford dipeptide p3 in a 
92% yield.  The dipeptide p3 was selectively deprotected at the C-terminal by catalytic 
hydrogenolysis under dihydrogen atmosphere in the presence of 10% Pd-C10% (w/w) for 4 
hours to give its free acid from, p3-OH. The analysis of a single crystal of dipeptide p3-OH by 
X-ray diffraction shows no intra residual hydrogen bonding in solid state, but rather an infinite 
array of intermolecular hydrogen bond interactions implicating three hydrogen bond donors and 
two acceptors that stack the dipeptide p3-OH molecules in an anti-parallel fashion (see Figure 
82).  
 
Figure 82: The X ray crystal structure of peptide p3-OH (top), and its intermolecular hydrogen 
bonding interactions viewed from the side (left), front (middle), and top (right).  
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4.2.4.2 Synthesis of the Boc-[(R,R)-cis-3,4CB-GABA-(R)-Ala]2-OBn peptide p4 
One equivalent of dipeptide p3 was selectively deprotected at the N-terminal with large excess 
of TFA for 1 hour. Another equivalent of dipeptide p3 was selectively deprotected at the C-
terminal by catalytic hydrogenolysis under dihydrogen atmosphere in the presence of 10% Pd-
C (10% w/w) for 4 hours. The two monoprotected dipeptides were then mixed together in the 
presence of excess of DIPEA before HATU was added. The coupling reaction was left to stir 
for 24 hours, at room temperature, under argon to afford tetrapeptide p4 in a 40% yield 
The tetrapeptide p4 exhibited low solubility in organic solvents such as chloroform, and 
displayed a tendency to form a gel, which made its purification problematic. The preparation of 
the higher order hexapeptide was subsequently inaccessible. Thus the conformational analysis 
was performed on the tetrapeptide.   
4.2.5 Structural and Conformational analysis in solution 
4.2.5.1 General methods for structural and conformational analysis 
The linear structure and the three dimensional conformation of the synthesized peptides were 
studied, in solution, using different experimental and theoretical techniques. 
4.2.5.1.1 Structural analysis 
The linear structure of the synthesized di- and tetrapeptides was confirmed by a combination of 
a series of 1D and 2D NMR experiments (1H, 13C, TOXY, COSEY, HSQC, and HMBC). 
These spectroscopic techniques allowed the unambiguous assignment of all the protons and 
carbons of the studied peptides, except for some ones, which appeared overlapped with each 
other.  
4.2.5.1.2 DMSO-d6 NMR titration experiments  
DMSO-d6 NMR titration experiments were done to assign the free and bonded N-H in peptides. 
Incremental amounts of DMSO-d6 were successively added to an NMR tube containing a 
peptide in CDCl3 (6-7 mM), and the 
1H spectra were recorded after each addition. Addition of 
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the DMSO-d6 into the tube increases the polarity of the environment around the peptide. This 
change in polarity induced a significant change in the chemical shift on the free N-H while it 
had less effect on the bonded ones.  
4.2.5.1.3 Conformational analysis 
2D ROESY NMR experiments were used to understand the three dimensional molecular 
conformation of the synthesized peptides, in solution, by detecting through-space dipolar 
magnetic interactions known as the Nuclear Overhauser Effect (NOE). By looking at the 
intramolecular NOE correlations within a peptide molecule, one could gain insight into the 
overall folding pattern of this peptide. 
Here again ROESY was chosen over NOESY due to its better sensitivity in detecting NOE 
colorations in molecules of molecular masses above 1 KDa (see Section 1.2.3). 
4.2.5.1.4 Molecular modeling  
Molecular modeling studies for both tetrapeptides (p2 and p4) were performed using a hybrid 
Monte Carlo Multiple Minima (MCMM). The three dimensional conformational examination 
was carried out in a chloroform medium using Macromodel 04 from Schrödinger software and 
the Merck Molecular Force Field (MMFF). Out of the 10 000 conformers that were generated 
by MCMM, the 100 lowest energy conformers (E=10KJ/mol) were retained and classified 
into different conformational families. 
The performed molecular modeling was done without any constraints from the experimental 
data. Thus, the modeling data could be considered as a theoretical tool that is completely 
independent from experimental one. 
4.2.5.2 Determining the linear structure of the peptides p2 and p4 
The linear structure of the tetrapeptides p2 and p4 was confirmed by a combination of a series 
of 1D and 2D NMR experiments. The chemical shift of the carbamate N-H always relatively 
more shielded than the other N-Hs was easily attributed. An analysis combination of COSY, 
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HSQC and HMBC experiments allowed the unambiguous assignment of all the protons and 
carbons of the studied peptides. A TOXY experiment allowed us to distinguish between the γ-
and α- amino acid protons especially when they appeared to overlap with each other. 
4.2.5.2.1 DMSO-d6 titration experiment 
The DMSO-d6 NMR titration experiment was performed on  CDCl3 solutions of the 
tetrapeptides p2 (1.3 mg/ 0.3 ml, 7.5 mM) and p4 (1.5 mg/ 0.4 ml, 6.5 mM) at 300 K. The 
difference in chemical shifts Δδ of the N-Hs between 0% and 50 or 10% of added DMSO-d6 
were determined (see Table 8) 
 50%  
DMSO-d6 
10% 
DMSO-d6 
Tetrapeptide p2 
Δδ(NH4) 1.25 0.73 
 
Δδ(NH11) 1.25 0.73 
Δδ(NH15) 0.008 -0.02 
Δδ(NH22) 0.75 0.17 
 
 
Tetrapeptide p4 
Δδ(NH4) 1.42 0.81 
 
Δδ(NH11) 1.40 0.84 
Δδ(NH15) 0.39 0.27 
Δδ(NH22) 1.38 0.82 
Table 8: The results of the DMSO-d6 NMR titration experiment for tetrapeptides p2, and p4. 
The tetrapeptide p2 showed two N-H (4 and 11) with relatively high DMSO-d6 titration 
coefficient (red color) and two N-H with relatively low coefficients (15 and 22) (blue color). 
The low mobility of N-H 15 and 22 is most likely an indication of their involvement in 
intramolecular hydrogen bonding. 
 On the other hand, tetrapeptide p4 showed three N-H (4, 11, and 22) with relatively high 
DMSO-d6 titration coefficient (red color) and only one N-H with relatively low coefficients (N-
H 15) (blue color). This preliminary observation hints a difference in the preferential folding 
pattern of the two diastereomeric tetrapeptides in solution, which will be further investigated 
via two dimensional NMR experiments and molecular modeling. 
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4.2.5.3 Conformational analysis of the peptides p2 and p4 
4.2.5.3.1 2D ROESY NMR experiment 
2D ROESY NMR experiments were done on a CDCl3 solution (5 mg/ 0.5 ml) for each of the 
tetrapeptides p2 and p4. Best ROE colorations were detected when the spinlock parameter 
during the experiment was set to 400 ms. The most significant ROE correlations and the 
deduced hydrogen bonding patterns are presented in Figure 83 for tetrapeptide p2 and in Figure 
84 for tetrapeptide p4. 
The tetrapeptide p2 generated ROE correlations, which suggest the presence of an alternating 
12 and 10-membered pseudocyles, indicating the tendency of this peptide to have a 12/10 
helical secondary structure (see Figure 84), which is in accordance with the Hofmann group 
predictions.117 
 
Figure 83: Tetrapeptide p2 showing ROE correlations characteristic of a 10-membered (blue) 
and 12-membered (green) hydrogen-bond rings (above) and the overall deduced hydrogen bond 
pattern (below). The fade colored arrow corresponds to a weak ROE correlation. 
Unlike the tetrapeptide p2, ROEs correlations observed for the tetrapeptide p4 do not suggest 
the presence of a 12/10 folding pattern. They rather indicate the occurrence of an alternating 7- 
and 9-membered pseudocycles (see Figure 84).  This kind of experimentally uncharted, 
secondary structure results from interactions between adjacent peptide bonds rather than non-
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nearest neighbour ones, which is a competitive possibility as suggested by the Hofmann 
group.117 
 
Figure 84: Tetrapeptide p4 showing ROE correlations characteristic of a 9-membered 
(orange) and 7-membered (pink) hydrogen-bond rings (above) and the deduced overall 
hydrogen bond pattern (below). The fade colored arrow corresponds to a weak ROE 
correlation. 
4.2.5.3.2 Molecular modeling 
An MCMM (Monte Carlo Multiple Minima) calculation was performed on the tetrapeptides p2 
and p4 to investigate their conformational landscape in chloroform. The lowest energy 
conformations, were arranged according to the hydrogen-bonded ring systems they form. 
Table 9 shows the list of predicted conformations by the MCMM calculations for tetrapeptide 
p2 along with their percentage abundance. The discreet, successive hydrogen bonded rings 
formed between a carbonyl oxygen and an amide hydrogen are separated by a hyphen ‘-’, while 
the ones implicating a carbonyl oxygen that is bifurcated between two amide hydrogens are 
separated by a coma ‘,’. 
 
 
 
  
Page | 128  
 
Conformations Relative abundance of each conformation 
[10-12-10] 9.3% 
[12-10] 3.5% 
[7,7-9] 6.4% 
[7,12-10] 25% 
[7,7-13-9] 44.4% 
[7,7-10] 5% 
[7-10] 5.8% 
[12-13] 0.6% 
Table 9: The list of conformations for tetrapeptide p2 as predicted by the MCMM calculations 
Even though the most abundant conformation is found to be the [7,7-13-9] (44.4%), the lowest 
energy conformer corresponds to the experimentally found [10-12-10]. The Figure 85 below 
shows the hydrogen bonding pattern in the most abundant [7,7-13-9] and the lowest energy [10-
12-10] conformers as calculated by MCMM. 
 
Figure 85: The hydrogen bonding pattern in the most abundant (left), and the lowest energy, 
also experimentally found (right), conformer of peptide p2, as predicted by the MCMM 
calculations. 
On the other hand, for the tetrapeptide p4 the most abundant conformation is found to be the 
[9-7,12] (27%), and the lowest energy conformer is the [9,12-9], this conformer is similar to the 
one recently reported by the Maillard group  for α/γ-hybrid peptides containing enantiomeric 
pure ATCs (See Figure 75, and 77). 165, 167 Such short range H-bonds are reminiscent of the 
Aitken group for homologous γ-peptides of cis-2,3CB-GABA, which showed short range 
consecutive intramolecular 7-membered hydrogen bonds topology in dilute solution;94 and for 
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β/γ-peptide composed of (1R,2R)-2-aminocyclobutane carboxylic acid (trans-ACBC) and 
GABA, that fold with an alternating 9-, 8-hydrogen bonding pseudocycles.158 
 Table 10 shows the list of predicted conformations by the MCMM calculations of tetrapeptide 
p4 along with their percentage abundance. 
Conformations Relative abundance of each conformation 
[9,12-9] 7% 
[9-7,12] 27% 
[15-13-7]a 9% 
[9-7-9] 15% 
[9,12-12] 20% 
[7-13-7] 2% 
[7,12-10] 3% 
[9-12-10] 9% 
[10-12-10] 5% 
[7-10,7] 2% 
Table 10: The list of conformations for tetrapeptide p4 as predicted by the MCMM 
calculations. a15 and 7 rings are from the same carbonyl 
The experimentally found [9-7-9] conformer is the third most abundant (15%) and has the third 
lowest energy. Figure 89 shows the hydrogen bonding pattern in the most abundant [9-7,12] 
and the lowest energy [9,12-9] conformers as calculated by MCMM, and the experimentally 
found [9-7-9] conformer. 
 
Figure 86: The hydrogen bonding pattern in the most abundant (left), the lowest energy 
(middle), and the experimentally found (right), conformers of peptide p4, as predicted by the 
MCMM calculations. 
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4.2.6 Boc-(S,S)-cis-3,4CB-GABA/(R)-Ala-NHBn peptides  
Having a terminal amide group in a peptide should provide an extra hydrogen bond acceptor, 
thus increasing the chance of a relatively short tetrapeptide to adopt a well-defied secondary 
structure. For this, we opted to prepare an analog of the tetrapeptide p4 with a benzyl amide 
terminal rather than a benzyl ester.  
The synthesis of Boc-[(S,S)-cis-3,4CB-GABA-(R)-Ala]n-NHBn peptides p5 and p6 was carried 
out following a convergent strategy, starting from the Boc-(S,S)-cis-3,4CB-GABA-OBn 
enantiomer (-)-13 as the γ-amino acid partner, and the Boc-D-Ala-NHBn (+)-16 as the α-amino 
acid partner (see Scheme 58). 
 
Scheme 56: The convergent synthesis of Boc-[(S,S)-3,4CB-GABA-(R)-Ala]n-NHBn peptides p5 
and p6. 
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4.2.6.1 Synthesis of the Boc-(S,S)-cis-3,4CB-GABA-(R)-Ala-NHBn peptide p5 
The C-terminal benzyl protecting group of Boc-(S,S)-cis-3,4CB-GABA-OBn was first removed 
in a quantitative yield by catalytic hydrogenolysis under dihydrogen atmosphere in the presence 
of 10% Pd-C (10% w/w) for 4 hours to obtain the free acid intermediate. The N-terminal Boc 
protecting group of Boc-D-Ala-NHBn, was cleaved by treating it with a large excess of TFA 
for 1 hour to give the corresponding amine partner as a TFA salt. 
The obtained free acid was then activated with HATU and reacted with the amine partner in the 
presence of DIPEA for 24 hours, at room temperature, under argon, to afford dipeptide p5 in 
85% yield. The analysis of a single crystal of dipeptide p5 by X-ray diffraction shows no intra 
residual hydrogen bonding in solid state, but rather an infinite array of intermolecular hydrogen 
bond interactions implicating three hydrogen bond donors and three acceptors that stack the 
dipeptide p5 molecules in a parallel fashion (see Figure 87). 
 
Figure 87:The X ray crystal structure of peptide p5 (top), and its intermolecular hydrogen 
bonding interactions viewed from the side (left), front  (middle), and top (right). 
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4.3 Conclusion 
In conclusion two diastereoisomeric γ/α-hybrid tetrapeptides composed of alternating cis-3,4CB-
GABA and D-Alanine were synthesized and fully characterized and their three dimensional 
folding pattern in solution was investigated. Even though, more conformational analysis 
including infrared spectroscopy and DFT calculations are still needed to further validate the 
folding behavior of the two diastereoisomeric γ/α-hybrid tetrapeptides, 2D ROESY NMR 
experiments and molecular modeling data revealed the tendency of these peptides to fold into a 
12/10 helix in solution when the (S,S)-cis-3,4CB-GABA was used as the γ-amino acid 
component. These experimental results are in correlation with the Hofmann group theoretical 
calculations.117 On the other hand when the chirality of the γ-amino acid component was 
switched to (R,R)-cis-3,4CB-GABA, the peptide showed a tendency to adopt an unprecedented 
9/7 folding pattern interpreted by observing the intra residual ROEs colorations displayed by 
tetrapeptide p4. 
Despite the fact that the 9/7 folding pattern was only the third abundant one as calculated by the 
preliminary molecular modeling of p4 in CDCl3, the switching from a 12/10 structuration 
observed for its diasteriomeric analog p2 emphasizes the importance of the side chain 
configuration as a tool to design peptides in a deliberate secondary structure. 
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Perspective and Overall Conclusion 
Our goal in this work was to prepare two cyclobutane- constained -amino acids, cis-2,3CB-
GABA and cis-3,4CB-GABA, in an enantioselective manner, and use these building blocks for 
the synthesis of -hybrid peptides that are likely to adopt helical structuration. We focused 
our interest on a supramolecular photochirogenesis method, adopting -CD as the chiral guest, 
since it appeared easily adaptable to our proposed photochemical reactions. 
We synthesized N-allyl-N-(4-methoxyphenyl)acrylamide 1 and assumed its photocycloaddition 
reaction would lead to the cycloadduct 2, a precursor of cis-2,3CB-GABA. The complexation of 
compound 1 with -CD was studied by 1D and 2D 1H NMR experiments which showed 
diagnostic interactions between protons of both host and guest. The complex was identified as 
having a 1:1 (-CD/1) ratio and had a low binding constant (Kb =14.7). 
A photocyclization reaction test performed with compound 1 (without -CD) did not lead to the 
expected photochemical [2+2]-cycloaddition product but gave instead 1-allyl-6-methoxy-3,4-
dihydriquinolin-2(1H)-one 5, resulting from a photochemical 6-electrocyclization followed by 
a 1,5-sigmatropic shift. 
Then we turned our attention to the photoelectrocyclization of 1,3-dihydro-2H-azepin-2-one 8 
in the presence of β-CD which was expected lead to an enantiomerically enriched photoadduct 
9, a precursor of cis-3,4CB-GABA. The complexation of compound 8 with -CD was studied by 
1D and 2D 1H NMR experiments which showed diagnostic interactions between protons of 
both host and guest. The complex was identified as having a 1:1 (-CD/8) ratio and had a 
moderate binding constant (Kb = 35.4).  
Irradiation of the -CD/8 complex in aqueous solutions, suspensions, or in the solid state, 
resulted in the electrocyclization of azepinone 8 to give the photoadduct 9. This later compound 
had a very low solubility in organic solvent and was immediately reduced in a one-pot reaction 
into the 2-azabicyclo[3.2.0]heptan-3-one 10 with an yield up to 79% from azepinone 8. The 
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highest ee of 45% was obtained when the irradiation of the -CD/8 complex was performed in 
suspension form. 
Continuing our efforts to have access to (R,R) and (S,S)-cis-3,4CB-GABA, we then established a 
resolution method for the N-Boc benzyl ester derivative on a semi-preparative HPLC 
instrument fitted with a chiral column, which furnished both enantiomers in pure form and on a 
gram scale.  
Enantiomerically pure (-) and (+)-cis-3,4CB-GABA derivatives were used thereafter to 
synthesize two diastereoisomeric -peptides. These hybrid peptides were composed of 
alternating either (-)-cis-3,4CB-GABA or (+)-cis-3,4CB-GABA with D-Alanine. Two -
dipeptides, Boc-S,S-GABA-R-AlaOBn and Boc-R,R-GABA-R-AlaOBn, as well as two -
tetrapeptides, Boc-(S,S-GABA-R-Ala)2OBn and Boc-(R,R-GABA-R-Ala)2OBn, were prepared 
by a convergent synthesis and fully characterized. 
The conformational analysis of both diastereoisomeric dipeptides by single crystal X-ray 
diffraction showed no intramolecular interactions but a network of intermolecular hydrogen 
bonding. 1D and 2D NMR experiments showed that the tetrapeptide, Boc-S,S-GABA-R-
Ala)2OBn, adopted a 12/10 helical conformation, whereas its diastereomeric analog, Boc-(R,R-
GABA-R-Ala)2OBn, displayed evidence of an unprecedented 7/9 folding pattern in solution. 
As a perspective of this work, the [2+2] photocycloaddition of N-allyl acrylamide could be 
favored by the use of a benzyl group on the nitrogen atom in place of an aryl group, thereby 
suppressing the conjugated 6π system responsible of the 6π-electrocyclization. 
Photochirogenesis using β-CD in the electrocyclization of azepinone 8 could be improved by 
use of a benzyl or tert-butyloxycarbonyl group attached on the nitrogen, to strengthen the -
CD/azepinone complexation. 
-tetrapeptides, Boc-(S,S-GABA-R-Ala)nNHBn, could be prepared and their conformational 
preferences studied, since the amide on the C-terminal is able to provide additional H-bond 
interactions to enhance folding propensity. 
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Experimental Part 
3-(phenylsulfonyl)propanoic acid [2] 
 
To a stirring solution of sodium benzenesulfinate (4.00 g, 24.39 mmol) in 25 ml distilled water, 
acrylic acid (1.67 ml, 1 eq.) was added, and the reaction mixture was left to stir overnight. The 
aqueous solution was then acidified with 2 M HCl and the desired product was extracted with 
diethyl ether (4 x 25 ml). The organic layer was concentrated under vacuum to obtain the 
desired product as white solid (3.90 g, 18.29 mmol). The crude product was pure enough to be 
used in the next step after drying under high vacuum.  
Yield: 75% 
TLC Rf (EtOAc): 0.6 
1H NMR (300 MHz, CDCl3): δ = 2.80 (t, 2H, H-2), 3.42 (t, 2H, H-1), 3.76 (s, 3H, H-13), 7.56-
7.62 (m, 2H, H-8), 7.66-7.71 (m, 1H, H-9), 7.90-7.94 (m, 2H, H-7) 
13C NMR (75 MHz, CDCl3): δ = 27.6 (C-2), 51.3 (C-1), 128.9 (C-6), 129.6 (C-7), 134.3 (C-8), 
138.5 (C-5), 175.2 (C-3) 
MP: 115-116 ºC. 
HR-MS: m/z calcd for [C9H10O4S+Na]
+ 237.0192 ; found 237.0194  
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N-(4-methoxyphenyl)-3-(phenylsulfonyl)propanamide [4] 
 
To a solution of 3 (4.00 g, 18.69 mmol) in dry dichloromethane 25 ml, thionyl chloride was 
added (14 ml, 10 eq.). the reaction mixture was left to reflux overnight. The solvent along with 
excess thionyl chloride were distilled out under vacuum. The solid residue was left to dry under 
high vacuum then dissolved in 150 ml dry dichloromethane. The solution was cooled to 0 OC 
and p-anisidine (2.30 g, 1 eq.) was added followed by trimethylamine (2.5 ml 1.2 eq.). The 
reaction mixture was left to stir for 3 hours at 0 oC then washed with 1 molar HCl (2 x 20 ml), 
followed by brine (2 x 20 ml). The organic layer was dried over MgSO4 and concentrated to 
half under reduced pressure. To the resulting solution petroleum ether 300 ml was added to 
precipitate the desired product 4, which was filtered off over a sintered glass funnel, porosity 3. 
The crude product was pure enough to be used in the next step. It could also be recrystallized 
from dichloromethane/ hexane to get clear crystals (5.06 g, 15.88 mmol). 
Yield: 85% 
TLC Rf (Hex/EtOAc 2/1): 0.25 
1H NMR (500MHz, CDCl3): δ = 2.87 (t, 2H, H-2), 3.55 (t, 2H, H-1), 3.76 (s, 3H, H-13), 6.81 
(d, 2H, H-11), 6.32 (d, 2H, H-10), 7.55-7.58 (m, 2H, H-7), 7.65-7.66 (m, 1H, H-8), 7.80 (s, 1H, 
H-4), 7.93 (d, 2H, H-6). 
13C NMR (125 MHz, CDCl3): δ = 29.8 (C-2), 42.1 (C-1), 55.5 (C-13), 114.2 (C-11), 121.9 (C-
10), 128.1 (C-6), 129.6 (C-7), 130.6 (C-8), 134.2 (C-9), 138.7 (C-5), 156.6 (C-12), 166.9 (C-3). 
MP: 118-119 ºC. 
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HR-MS: m/z calcd for [C16H17NO4S+Na]
+ 342.0770 ; found 342.0761  
N-allyl-N-(4-methoxyphenyl)acrylamide [1] 
 
To a solution of 4 (3.00 g, 9.4 mmol) in 100 ml dry THF, at 0 oC, potassium tertiary butoxide 
(1.04 g 1 eq.) was added. The reaction mixture was left to stir for 1 hour at 0 oC after which 
another equivalent of potassium tertiary butoxide was added followed by allyl bromide (0.8 ml, 
1eq.) the reaction mixture was left to stir at 0 oC for 3-4 h. The THF was removed under 
vacuum and ethyl acetate (100 ml) was added. The organic layer was washed with brine (5 x 30 
ml). then dried over MgSO4 and reduced under vacuum. The crude was purified by 
chromatography on silica (80/20 hexane/EtOAc) to obtain compound 1 as a clear oil. Diethyl 
ether was added to co-evaporate ethyl acetate and obtain a white solid (1.22 g, 5.6 mmol). Note 
that the product could polymerize if heated and left as an oil under high cavum.    
Yield 60% 
TLC Rf (PE/EtOAc 7/3): 0.54 
1H NMR (300 MHz, CDCl3): δ = 3.82 (s, 3H, H-11), 4.34 (dt, J = 6.3 Hz, J = 1.3 Hz, 2H, H-
4), 5.06-5.15 (m, 2H, H-6), 5.51 (dd, J = 10.3 Hz, J = 2.1 Hz, 1H, H-1), 5.88 (ddt, J = 16.7 Hz, 
10.3 Hz, 6.2 Hz, 1H, H-5), 6.03 (dd, J = 16.8 Hz, 10.3 Hz, 1H, H-2), 6.36 (dd, J = 16.8 Hz, 2.1 
Hz, 1H, H-1’), 6.88-6.91 (m, 2H, H-9), 7.05-7.07 (m, 2H, H-8). 
1H NMR (300 MHz, D2O): δ = 3.83 (s, 3H, H-11), 4.34 (d, J = 5.6 Hz, J = 2H, H-4), 5.1-5.18 
(m, 2H, H-6), 5.61 (dd, J = 9.6 Hz, J = 2.4 Hz, 1H, H-1), 5.84 (ddt, J = 16.5 Hz, J = 11.0 Hz, J 
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= 5.6 Hz, 1H, H-5), 6.10 (dd, J = 17.0 Hz, J = 9.5 Hz, 1H, H-2), 6.2 (dd, J = 17.0 Hz, J = 2.5 
Hz, 1H, H-1’), 7.02 (d, J = 8.8 Hz, 2H, H-9), 7.22 (d, J = 8.9 Hz, 2H, H-9). 
13C NMR (75 MHz, CDCl3): δ = 52.6 (C-4), 55.6 (C-11), 114.7 (C-9), 118.1 (C-6), 127.7 (C-
1), 128.7 (C-2), 129.5 (C-8), 133.1 (C-5), 134.7 (C-10), 159.0 (C-7), 165.7 (C-3) 
MP: 62-63 ºC. 
HR-MS: m/z calcd for [C13H15NO2+Na]
+ 240.0995; found 240.0995 
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1-allyl-6-methoxy-3,4-dihydroquinolin-2(1H)-one [5] 
 
A solution of 1 (44 mg, 0.20 mmol) in 10 ml degassed acetone in a Pyrex tube was irradiated 
for 9 h inside a Luzchem (LCZ-4V) reactor fitted with 14 UV-B lamps. The solvent was then 
evaporated under reduced pressure and the crude was purified by chromatography on silica 
(gradient from 90/10 to 70/30 hexane/EtOAc) to obtain compound 5 as a white solid (22 mg, 
0.1 mmol). 
Yield: 50%  
TLC Rf (PE/EtOAc 7/3): 0.38 
1H NMR (300 MHz, CDCl3): δ = 2.67 (dd, J = 8.7 Hz, J = 5.8 Hz, 2H, H-2), 2.89 (dd, J = 8.8 
Hz, J = 5.9 Hz, J = 2H, H-3), 3.78 (s, 3H, H-13), 4.63-4.41 (m, 2H, H-10), 5.37-5.02 (m, 2H, 
H12), 5.88 (ddt, J = 17.2 Hz, J = 10.0 Hz, 4.7 Hz, 1H, H-11), 6.79-6.67 (m, 1H, H-9, 1H, H-7), 
7.12-6.84 (m, 1H, H-6). 
13C NMR (75 MHz, CDCl3): δ = δ 25.9 (C-3), 31.9 (C-2), 45.3 (C-10), 55.6 (C-13), 111.9 (C-
9 or C-7), 113.9 (C-7 or C-9), 116.41 (C-12), 16.45 (C-6), 128.0 (C-5 or C-4), 132.9 (C-11), 
133.5 (C-4 or C-5), 155.4 (C-8), 169.8 (C-1). 
MP: 59-60 ºC. 
HR-MS: m/z calcd for [C13H15NO2+Na]
+ 240.0995 ; found 240.0994. 
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β-cyclodextrin (β-CD) 
 
 
 
RMN 1H (600 MHz, D2O) : δ = 3.65 (t, J= 9 Hz, 7H, H-4), 3.73, (dd, J = 3.6 Hz, J = 9.9Hz, 
7H, H-2), 3.92-3.96 (m, 7H, H-5, 14H, H-6), 5.14 (d, J = 3.6, 6H, H-1) 
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3,3-Dibromoazepan-2-one [7] 
 
A solution of caprolactam 6 (5.00 g, 44.25 mmol) in chloroform (125 mL) was cooled to 4 °C 
in an ice bath. Phosphorus pentachloride (18.39 g, 89.01 mmol, 2 eq.) was then added followed 
by dry zinc iodide (0.56 g, 1.75 mmol). Bromine (4.5 mL, 88.5 mmol) was then added slowly 
over 15 min. The reaction mixture was allowed to warm to room temperature and left to stir 
overnight. The reaction was quenched with an ice-water mixture (200 mL). The organic layer 
was separated and washed with water (3 × 100 mL) and with a 0.5 M solution of sodium 
bisulfite (3 × 100 mL), dried over sodium sulfate, and concentrated under reduced pressure. 
The crude yellow solid was washed with water to obtain compound 7 as white solid (8.30 g, 
30.86 mmol). 
Yield: 70%. 
TLC Rf (PE/EtOAc 50/50): 0.60. 
1H NMR (400 MHz, CDCl3): δ = 1.67-1.75 (m, 2H, H-6), 1.97 (ddd, J = 8.4, 7.2, 4.7 Hz , 2H, 
H-5), 2.72-2.75 (m, 2H, H-4), 3.35-3.44 (m, 2H, H-7), 6.59 (bs, 1H, H-3). 
13C NMR (75 MHz, CDCl3): δ =28.3 (C-6), 28.4 (C-5), 42.5 (C-4), 46.0 (C-7), 69.3 (C-1), 
168.3 (C-2). 
MP: 162 ºC. 
IR (solid): (C-Br) 769, (C-C) 1326, (C=O) 1665, (C-H) 2940, (NH) 3090, (NH) 3207 cm-1 
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HR-MS: m/z calcd for [C6H9Br2NO+Na]
+ 291.8943; found 293.8918 (2.5 ppm). 
2,3-Dihydro-1H-azepin-2-one [8] 
 
To a solution of compound 7 (5.80 g, 21.56 mmol) in dry DMF (130 mL), dried anhydrous 
LiCl (2.71 g, 63.93 mmol) was added. The reaction mixture was heated to reflux under argon 
atmosphere for 5 h, then left to stir at room temperature overnight. The solvent was then 
distilled out under reduced pressure. Water 50 ml was added, and the aqueous layer was 
extracted with CH2Cl2 (5 X 50ml). The organic layer was dried over NaS2O4, filtered and 
concentrated to obtain crude 8 as dark brown oil that was purified by flash chromatography on 
silica (gradient eluent from 80/20 to 50/50 PE/EtOAc). Compound 8 was obtained as yellow 
solid which was recrystallized from pentane to give white crystals (1.63 g, 14.65 mmol). 
Yield: 69%. 
TLC Rf (PE/EtOAc 50/50): 0.53. 
1H NMR (360 MHz, CDCl3): δ= 2.91 (d, J = 6.8 Hz, 2H, H-7), 5.61 (dt, J = 9.3 Hz, J = 6.8 
Hz, 1H, H-6), 5.84 (dd, J = 5.1 Hz, J = 8.9 Hz, 1H, H-4), 6.17-6.23 (m, 1H, H-5, 1H. H-3), 8.17 
(bs, 1H, H-2). 
1H NMR (300 MHz, D2O): δ= 2.79 (d, J = 6.8 Hz, 2H, H-7), 5.55 (dt, J = 9.3 Hz, J = 6.8 Hz, 
1H, H-6), 5.94 (dd, J = 5.3Hz, J = 8.9 Hz, 1H, H-4), 6.19 (dd, J = 5.3 Hz, J = 9.3, 1H, H-5), 
6.25 (d, J = 9.0 Hz, 1H, H-3). 
UV/Vis (CH3CN): λmax = 259 (ε= 104 M-1.cm-1). 
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13C NMR (75 MHz, CDCl3): δ = 37.2 (C-6), 114.2 (C-3), 121.1 (C-1), 125.4 (C-2), 127.6 (C-
4), 168.7 (C-7). 
MP: 45 ºC. 
IR (solid): (C-C) 1334, (C=O) 1592, (C=C, C=O) 1635 and 1650, (C-H) 2943, (NH) 3083, 
(NH) 3193 cm-1. 
HR-MS: m/z calcd for [C6H7NO+H]
+ 110.0600 ; found 110.0604 (-3.3 ppm). 
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Photoelectrocyclization of azepinone 8 in ether without β-CD: 
(±)-Cis-2-azabicyclo[3.2.0]hept-6-en-3-one [(±)-9] 
 
A solution of 8 (200 mg 1.834 mmol) in diethyl ether (250 mL) was degassed with an argon 
stream in a cylindrical water-cooled reactor during 15 min, and then irradiated for 2 h with a 
400 W medium-pressure mercury lamp fitted with a Quartz filter, while the reactor was cooled 
with an external ice bath. The solvent was evaporated under reduced pressure to obtain crude 
(±)-9 (195 mg 1.788 mmol). The crude product was pure enough and was not further purified 
Crude yield: 97%. 
TLC Rf (Et2O): 0.11. 
1H NMR (300 MHz, CDCl3): δ = 2.27 (dd, J = 17.9 Hz, J = 3.4 Hz, 1H, H-6), 2.46 (dd, J = 
17.9 Hz, J = 10.2 Hz, 1H, H-6), 3.56 (dt, J = 10.2 Hz, J = 3.4 Hz, 1H, H-1), 4.43-4.44 (m, 1H, 
H-2), 6.30-6.33 (m, 1H, H-3, 1H, H-4), 7.05 (bs, 1H, H-5). 
13C NMR (75 MHz, CDCl3): δ =33.7 (C-1), 41.4 (C-2), 57.9 (C-6), 142.3, 142.5 (C-3, C-4), 
178.7 (C-7). 
MP: 75 ºC. 
IR (solid): (C-C) 1250, (C-N) 1302, (C=C) 1645, (C=O) 1676, (C-H), 2961, (NH) 3266 cm-1. 
HR-MS: m/z calcd for [C6H7NO+H]
+ 110.600 ; found 110.0599 (1.2 ppm). 
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Photocyclization of azepinone 8 in water without β-CD: 
 
A solution of azepinone 8 (500 mg, 4.58 mmol) in 50 ml of ultra-pure water was introduced in 
a quartz tube and irradiated inside a Rayonet for 15 h at 10°C. The reaction mixture was then 
lyophilized to obtain crude (±)-9 (356 mg, 3.26 mmol). The crude product was pure enough and 
was not further purified. The spectral data were identical to those previously reported on page 
145. 
Crude yield: 71%. 
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Preparation of (±)-2-azabicyclo[3.2.0]heptan-3-one (±)-10 by 
photoelectrocyclisation/reduction. 
 
 
A solution of azepinone 8 (50.00 mg, 0.458 mmol) in 30 ml of ultra-pure water, was irradiated 
in a quartz tube, inside a Rayonet for 2 h at 10 °C. The reaction mixture was then transferred 
into a round bottom flask and 10% w/w Pd/C-10% were added. The reaction mixture was 
stirred, without degassing, overnight, at room temperature, under dihydrogen atmosphere. The 
catalyst was then filtered out and the product (±)-10 was extracted with ethyl acetate (13 x 40 
ml). The organic layer was dried over Na2SO4 then concentrated under reduced pressure to 
obtain crude (±)-10 (41.70 mg, 0.375 mmol) as a yellow oil. The crude product was of enough 
purity and no further purification was done. 
Crude yield over 2 steps: 82%. 
TLC Rf (PE/EtOAc 1/1): 0.25. 
1H NMR (360 MHz, CDCl3): δ = 1.83-2.00 (m, 1H, H3, 1H, H4), 2.17 (d, J = 17.8 Hz, 1H, 
H6), 2.23-2.33 (m, 1H, H3, 1H, H4), 2.57 (dd, J = 9.1 Hz, J = 17.8 Hz, 1H, H6), 3.05-3.09 (m, 
1H, H1), 4.04-4.07 (m, 1H, H2), 7.20 (bs, 1H, H5). 
1H NMR (300 MHz, D2O): δ =1.75-1.85 (m, 1H, H-3, 1H, H-4), 2.2 (d, J = 17.7 Hz, 1H, H-6), 
2.18-2.35 (m, 1H, H-3, 1H, H-4), 2.51 (dd, J = 8.7 Hz, J = 17.7 Hz, 1H, H-6), 3.03-3.12 (m, 
1H, H-1), 4.03-4.12 (m, 1H, H-2). 
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13C NMR (75 MHz, CDCl3): δ=25.2 (C-4), 26.3 (C-3), 33.1 (C-1), 37.1 (C-6), 54.2 (C-2), 
179.3 (C-7). 
IR (solid): (C-C) 1287, (C-N) 1310, (C=O) 1677, (C-H), 2939, (NH) 3237 cm-1. 
HR-MS: m/z Calcd for [C6H9NO+H]
+ 112.0757; found 112.0761 (-3.5ppm).  
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Photoelectrocyclization of azepinone 8 in solid state without β-CD: 
 
Azepinone 8 (30.00 mg, 0.275 mmol) was mechanically ground in mortar and introduced in a 
quartz tube. The tube was closed and set to rotate in a Rayonet in which it was irradiated for 7 
h. The crude product was then completely dissolved in ultra-pure water and stirred overnight, 
without degassing, at room temperature, under dihydrogen atmosphere with 10% w/w Pd/C-
10%. The catalyst was then filtered out and the product (±)-10 was extracted with ethyl acetate 
(12 x 25 ml). The organic layer was dried over Na2SO4 then concentrated under reduced 
pressure to obtain crude (±)-10 (12.22 mg, 0.110 mmol). The crude product was of enough 
purity and no further purification was done. Spectral data were identical to those previously 
reported. 
Crude yield over 2 steps: 40%. 
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Photoelectrocyclisation in the presence of β-CD: 
Photoelectrocylisation in fluid state: 
General procedure "I" for irradiation in fluid state: 
All experiments in fluid state started by adding a clear aqueous solution of azepinone 8 to a 
clear aqueous solution containing the desired equivalents dried β-CD. The volume of the final 
solution was chosen to be just below 15 mM with respect to the hostβ-CD. Upon stirring, a 
white precipitate starts to form almost immediately. The suspension was left to stir 2 h at room 
temperature, and then transferred into a quartz tube fitted with a stirring bar, and a temperature 
control system (heating cooling finger). The tube was then irradiated inside a in Rayonet RPR-
200 equipped with a carousel of 16 lamps [λ = 254 nm]. The course of the reaction was 
followed by 1H NMR. When no more starting material azepinone 8 could be detected, the 
reaction was considered complete. The irradiated solution was then transferred into a round 
bottom flask and 10% w/w Pd/C-10% were added. The reaction mixture was stirred overnight, 
at room temperature, under a dihydrogen atmosphere. The catalyst was then filtered out and the 
aqueous phase was extracted with ethyl acetate until no more 10 could be detected in the 
aqueous phase by 1H NMR. 
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Photoelectrocyclisation of β-CD/azepinone 8 complex in hot water / reduction 
Experiment A 
 
According to general procedure "I" azepinone 8 (50.00 mg, 0.458 mmol) was complexed with 
1 equivalent of β-CD (0.52 g, 0.458 mmol) in 31 ml of water. The suspension was transferred 
to a quartz tube, and then heated up to 45 °C using a temperature control system (heating 
cooling finger). The hot solution was then irradiated in the Rayonet for 2 hours at 45 °C. The 
resulting yellowish clear solution was transferred to a flask. The cycloadduct 4 was reduced and 
extracted from the aqueous phase with ethyl acetate (13 x 40ml). The organic phase was dried 
over Na2SO4 then concentrated under vacuum to obtain crude 10 (12.22 mg, 0.110 mmol). The 
product was of enough purity and no further purification was done. Spectral data were identical 
to those previously reported. 
Crude yield: 40%. 
ee 0%. 
 
 
 
 
 
  
Page | 153  
 
Photoelectrocyclisation of β-CD/azepinone 8 complex in cold water / Reduction 
Experiment B 
 
According to general procedure "I" azepinone 8 (30.00 mg, 0.275 mmol) was complexed with 
1 equivalent of β-CD (0.32 g, 0.282 mmol) in 19 ml of water. The suspension was cooled to 5 
°C, and the cold suspension was irradiated for 2 h at 5°C. The resulting clear solution was 
subjected to reduction extracted with ethyl acetate (12 x 25 ml). The organic phase was dried 
over Na2SO4 then concentrated vacuum to obtain crude 10 (24.01 mg, 0.216 mmol). The crude 
product was of enough purity and no further purification was done. Spectral data were identical 
to those previously reported. 
Crude yield: 79%. 
ee 38%. 
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Photoelectrocyclisation of β-CD/azepinone 8 "3/1 complex" in cold water / Reduction 
Experiment C 
 
According to general procedure "I" azepinone 8 (30 mg, 0.275 mmol) was complexed with 1 
equivalent of β-CD (0.32 g, 0.282 mmol) in 19 ml of water the suspension was charged with 
extra 2 equivalents β-CD during the stirring time. The suspension was cooled to 5 °C, and the 
cold suspension was irradiated for 3.5 hours at 5 °C. The resulting clear aqueous solution was 
subjected to reduction and extracted with ethyl acetate (12 x 25 ml). The organic phase was 
dried over Na2SO4 then concentrated under vacuum to obtain crude 10 (23.02 mg, 0.207 
mmol). The crude product was of enough purity and no further purification was done. Spectral 
data were identical to those previously reported. 
Crude yield: 75%. 
ee 45%. 
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Photoelectrocyclisation of β-CD/azepinone 8 "3/1 complex" in solid 
state / Reduction 
Experiment D 
Mechanically ground: 
 
One equivalent of azepinone 8 (30.00 mg, 0.275 mmol) was mechanically ground with β-CD 
(0.32g, 0.282mmol) in a mortar. The solid was transferred to a quartz tube which was set to 
slowly rotate while being irradiate inside a Rayonet. When no starting material can be observed 
by 1H NMR (7 hours), the irradiated solid was dissolved in ultra-pure water (10 ml) and 
subjected to reduction. The aqueous phase was extracted with ethyl acetate (12 x 25ml). The 
organic phase was dried over Na2SO4and concentrated under vacuum to obtain crude 10 (21.30 
mg, 0.191 mmol). The crude product was of enough purity and no further purification was 
done. Spectral data were identical to those previously reported. 
Crude yield: 70%. 
ee 0-40%. 
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General procedure "II" for photoelectrocyclisation in solid state / Reduction: 
All of the next experiments in solid state started by adding a clear aqueous solution of 
azepinone 8 to a clear aqueous solution containing the desired equivalents dried β-CD. The 
volume of the final solution was always chosen to be just below 15 mM with respect to the 
hostβ-CD. Upon stirring, a white precipitate starts to form almost immediately. The suspension 
was left to stir for 2 hours at room temperature, and then treated accordingly to obtain a white 
solid (powder or film). The resulting solid was irradiated in Rayonet RPR-200 equipped with 
16 lamps [λ = 250 nm (RPR-3000 Å, Rayonet)]. The course of the reaction was followed by 1H 
NMR. When no more azepinone 8 starting material could be detected, the reaction was 
considered complete and the irradiated solid was transferred into a round bottom flask, 
dissolved in ultra-pure water then reduced overnight, at room temp, under dihydrogen 
atmosphere with 10% w/w of Pd/C-10%. The catalyst was then filtered out and the crude 10 
was extracted with ethyl acetate until no more of it could be detected in the aqueous phase by 
1H NMR. 
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Photoelectrocyclisation of β-CD/azepinone 8 in powder form / Reduction: 
Experiment E 
 
According to general procedure "II" azepinone 8 (50.00 mg, 0.458 mmol) was complexed with 
1 equivalent of β-CD (0.52 g, 0.458 mmol) in 31 ml ultra-pure water. The suspension was then 
filtered on a sintered glass funnel (porosity 3) and washed with 10 ml of ultra-pure water. The 
uncomplexed azepinone 8 was extracted with ethyl acetate from the filtrate, and 20 mg of it 
could be recovered. The white complex was dried in air, finely crushed in a mortar and 
transferred into a quartz tube. The tube was closed and set to rotate inside a Rayonet in which it 
was irradiated for 20 hours. The irradiated solid was dissolved in ultra-pure water, reduced, and 
then extracted with ethyl acetate (13 x 40 ml). The organic phase was dried over Na2SO4 and 
concentrated under vacuum to obtain crude 10 (21.30 mg, 0.191 mmol). The product was of 
enough purity and no further purification was done. Spectral data were identical to those 
previously reported. 
 
Crude yield: 71% (with respect to the remaining 30 mg in the complex). 
ee 36%. 
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Potoelectrocyclisation of β-CD/azepinone in a 1:1 film, made from a 15 mM suspension 
/Reduction 
Experiment F 
 
According to general procedure "II" azepinone 8 (50.00 mg, 0.458 mmol) was complexed with 
1 equivalent of β-CD (0.52 g, 0.458 mmol) in 31 ml of water the suspension was then spread on 
a glass sheet and left to dry in open air for 3 days. The film that forms was irradiated in a 
Rayonet for 5 hours. The irradiated solid was dissolved in ultra-pure water, reduced, and then 
extracted with ethyl acetate (13 x 40 ml). The organic phase was dried over Na2SO4 then 
concentrated under vacuum to obtain crude 10 (39.20 mg, 0.323 mmol). The product was of 
enough purity and no further purification was done. Spectral data were identical to those 
previously reported. 
Crude yield: 77%. 
ee 41%. 
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Potoelectrocyclisation of β-CD/azepinone 8 in a 2:1 film, made from a 15 mM suspension / 
Reduction 
Experiment G 
 
According to general procedure "II" azepinone 8 (33.60 mg, 0.308 mmol) was complexed with 
2 equivalents of β-CD (0.702 g, 0.619 mmol) in 41 ml of ultra-pure water. The suspension was 
then spread on a glass sheet and left to evaporate in open air for 3 days. The film that forms was 
irradiated in a Rayonet for 5 h. The irradiated solid was put in solution, reduced, and then 
extracted with ethyl acetate (12 x 30 ml). The organic phase was concentrated under vacuum to 
obtain crude 10 (26.34 mg, 0.237 mmol). The crude product was of enough purity and no 
further purification was done. Spectral data were identical to those previously reported. 
Crude yield: 77%. 
ee 42%. 
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Potoelectrocyclisationof β-CD/azepinone 8 in a 1:1 film, made from a 5 mM solution 
/Reduction: 
Experiment H 
 
According to general procedure "II" azepinone 8 (30.00 mg, 0.275 mmol) was complexed with 
1 equivalent of β-CD (0.32 g, 0.282 mmol) in 55 ml ultra-pure water 5 mM. The clear solution 
was then spread on glass sheet and left to dry in open air for 3 days. The film that forms was 
irradiated in a Rayonet for 5 hours. The irradiated solid was solved in ultra-pure water, reduced 
and then extracted with ethyl acetate (12 x 25 ml). The organic phase was dried over Na2SO4 
then concentrated under vacuum to obtain crude 10 (23.79 mg, 0.214 mmol). The crude product 
was of enough purity and no further purification was done. Spectral data were identical to those 
previously reported. 
Crude yield: 78%. 
e.e 41%. 
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(±)-cis-tert-butyl-3-oxo-2-azabicyclo[3.2.0]heptane-2-carboxylate [(±)-11] 
 
DMAP (52.22 mg, 0.528 mmol, 0.1 eq.) and Boc2O (2.41g 11.05 mmol, 2 eq.) were added to a 
solution of compound (±)-10 (0.614 mg, 5.528 mmol) in acetonitrile (57 mL) at 0 ° C, under 
argon. The solution was stirred at 0 °C for 5 min and then left to stir over night, at room 
temperature. The solvent was then evaporated under reduced pressure and the crude product 
obtained was purified by flash chromatography on silica (gradient from 10/90 to 0/100 
PE/Et2O). The product (±)-11 was obtained in the form of a white solid (0.853 g 4.042 mmol). 
Yield: 77%. 
TLC Rf (EtOAc/EP 1/1): 0.72. 
1H NMR (250 MHz, CDCl3): δ = 1.51 (s, 9H, H-8), 1.82-1.92 (m, 1H, H-4), 1.98-2.05 (m, 1H, 
H-3), 2.25-2.35 (m, 1H, H-4), 2.43 (dd, J = 1.8 Hz, J = 18.2 Hz, 1H, H-9), 2.43-2.53 (m, 1H, 
H-3), 2.68 (dd, J = 9.1 Hz, J = 17.7 Hz, 1H, H-9), 2.93-3.01 (m, 1H, H-1), 4.41-4.45 (m, 1H, 
H-2). 
13C NMR (60 MHz, CDCl3): δ = 25.1 (C-4), 27.8 (C-3), 28.0 (C-8), 28.4 (C-1), 39.5 (C-9), 
58.0 (C-2), 82.5 (C-7), 149.7 (C-6), 175.1 (C-10). 
MP: 51 ºC. 
HR-MS: m/z calcd for [C11H17NO3+Na]+ 234.1101; found 234.1096 (2.2 ppm). 
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(±)-cis-2-(2-((tert-butoxycarbonyl)amino)cyclobutyl)acetic acid  [(±)-12)] 
 
LiOH (4.08g, 9.71 mmol, 10 eq.) was added to a solution of the compound (±)-11 (2.052 g, 
9.72 mmol), in a 1/1 THF / H2O mixture (30 mL). The reaction mixture was left to stir 
overnight at room temperature. The THF was evaporated under reduced pressure. The residual 
aqueous phase was acidified with a solution of HCl (0.5 M) to pH = 1 and then saturated with 
solid NaCl. It was then extracted with AcOEt (5 x 30 mL). The combined organic phases were 
dried over MgSO4, filtered and concentrated under reduced pressure. The crude product was 
then purified by flash chromatography on silica (gradient from 50/50 to 0/100 PE/EtOAc). The 
N-Boc protected amino acid (±)-12 was obtained in the form of a white solid (1.58 g, 6.89 
mmol). 
Yield: 71%. 
TLC Rf (EP/EtOAc 1/1): 0.28 
1H NMR (250 MHz, CDCl3): δ = 1.42 (s, 9H, H-8), 1.45-1.62 (m, 1H, H-4), 1.80-2.10 (m, 1H, 
H-3, 1H, H-4), 2.20-2.50 (m, 1H, H-3), 2.41 (dd, J = 15.8 Hz, J = 9.0 Hz, 1H, H-9), 2.55 
(dd, J = 15.8 Hz, J = 6.8 Hz, 1H, H-9), 2.78-3.01 (m, 1H, H-1), 4.04-4.30 (m, 1H, H-2), 4.82 
(bs, 0.6H, H-5), 6.07 (bs, 0.4H, H-5), 9.71 (bs, 1H, H-11). 
13C NMR (90 MHz, CDCl3): δ = 21.2 (C-4), 27.2 (C-3), 28.3 (C-8), 34.2 (C-9), 36.7 (C-1), 
46.8 (C-2), 79.4 (C-7), 155.2 (C-6), 177.7 (C-10). 
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MP:117 ºC. 
HR-MS: m/z calcd for [C11H19NO4+Na]+ 252.1206 ; found 252.1212 (- 2.4 ppm). 
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(±)-BenzylCis-2-(2-{[(tert-butoxy)carbonyl]amino}cyclobutyl)acetate [(±)-13)] 
  
To a stirring solution of amino acid (±)-7(400 mg, 17.46 mmol), and benzyl alcohol (0.185 ml, 
1.02 eq.) in dichloromethane (26ml) was added DMAP (21.2 mg, 0.1 eq.). The reaction mixture 
was then cooled to 0 oC and DCC (400 mg, 1.1 eq.) was added. The reaction mixture was 
stirred for 10 min at 0 oC overnight at room temperature. The formed precipitate side product 
was removed by filtration, and the filtrate was concentrated under vacuum. The crude product 
was then purified by flash chromatography on silica (gradient from 90/10 to70/30 PE/EtOAc) 
to obtain (±)-8 (490 mg, 1.53 mmol) as a white solid. 
Yield: 90%. 
TLC Rf (PE/EtOAc 70/30): 0.85. 
1H NMR (360 MHz, CDCl3): δ = 1.42 (s, 9H, H-8), 1.49-1. 57 (m, 1H, H-4), 1.81-1.91 (m, 
1H, H-3), 1.95-2.03 (m, 1H, H4), 2.24-2.37 (m, 1H, H-3), 2.45 (dd, J = 15.3 Hz, J = 9.4 Hz, 
1H, H-9), 2.55 (dd, J = 15.3 Hz, J = 6.4 Hz, 1H, H-9), 2.85-3.02 (m, 1H, H-1), 4.28-4.33 (m, 
1H, H-2), 4.82 (d, J = 6.3 Hz, 0.75H, H-5), 5.11 (s, 2H, H-11), 7,32-7,31 (m, 5H, H-Ar) 
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13C NMR (90 MHz, CDCl3): δ = 21.2 (C-4), 27.5 (C-3), 28.4 (C-8), 34.5 (C-9), 37 (C-1), 46.8 
(C-2), 66.4 (C-11), 79.4 (C-7), 128.3, 128.7 (C-13, C-14, C-15), 136 (C-12), 155.2 (C-3), 172.8 
(C-10). 
HR-MS: m/z calcd for [C18H25NO4+Na]+ 342.1683 ; found 342.1676 (2.2 ppm). 
(R,R) enantiomer: [𝜶]𝑫
𝟐𝟐(C = 0.5; CHCl3): 0.342 
 (S,S) enantiomer: [𝜶]𝑫
𝟐𝟐(C = 0.5; CHCl3): -0.356 
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(R)-2-((tert-butoxycarbonyl)amino)propanoic acid [(+)-14)] 
 
 To a solution of D-alanine (1.00 g, 11.2 mmol, 1 eq.) in ultrapure water (25 ml), at 0 oC, 
were added dropwise NaOH 1 M (22.5 ml) (24.5 mmol, 2 eq.) and a solution of Boc2O (3.60 g, 
16.5 mmol, 1.5 eq.) in dioxane (25 ml). After the addition, the reaction mixture was left to stir 
overnight at room temperature. The dioxane was then evaporated under vacuum and the 
aqueous solution was cooled to 0 oC, and acidified with 1 M HCl to pH = 1. The aqueous layer 
was then extracted with ethyl acetate (4 x 50 ml) and the combined organic layers were washed 
with brine, dried over MgSO4 and concentrated under vacuum to afford crude Boc-(R)-Ala-OH 
(+)-14 (1.90 g, 10.1 mmol) as white solid. The crude product was pure enough to be used in the 
next step without any purification. 
Crude yield: 90% 
TLC Rf (EtOAc): 0.44 
1H NMR (360 MHz, DMSO): δ = 1.21 (d, J = 7.3 Hz, 3H, H-6), 1.37 (s, 9H, H-1), 3.91 (p, J = 
7.4 Hz, 1H, H-5), 7.10 (d, J = 7.6 Hz, 1H, H-4). 
13C NMR (75 MHz, DMSO): δ = 17.07 (C-6), 28.24 (C-1), 48.84 (C-5), 77.95 (C-2), 155.30 
(C-3), 174.74 (C-7).  
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(R)-benzyl 2-((tert-butoxycarbonyl)amino)propanoate [ (+)-15] 
 
 To a solution of (+)-14 (600 mg, 3.17 mmol, 1eq.), benzyl alcohol (0.33 ml, 1.02 eq.) 
and DMAP (0.038 mg, 0.1 eq.) in DCM (15 ml) at 0 oC, was added DCC (0.719 g, 1.1eq.). The 
reaction mixture was warmed to room temperature and left to stir overnight. The solvent was 
then evaporated to dryness and the crude product was then purified by flash chromatography on 
silica (8/2 PE/EtOAc) to obtain Boc-(R)-Ala-OBn (+)-15 (663 mg, 2.37 mmol) as a colorless 
solid. 
Crude yield: 75%  
TLC Rf (PE/EtOAc 8/2): 0.44  
1H NMR (300 MHz, CDCl3): δ = 1.40 (d, J = 7.2 Hz, 3H, H-6), 1.44 (s, 9H, H-1), 4.32-4.42 
(m, 1H, H-5), 5.07 (d, 1H, H-4), 5.15 (d, J = 12.3 Hz, 1H, H-6), 5.21 (d, J = 12.4 Hz, 1H, H-6), 
7.32-7.46 (m, 5H, H-Ar). 
13C NMR (75 MHz, CDCl3): δ = 18.60 (C-6), 28.27 (C-1), 49.25 (C-5), 66.95 (C-8), 79.81 (C-
2), 128.11(C-9), 128.34, 128.56, 135.41(C-9, C-11, C-12), 155.06 (C-3), 173.19 (C-7). 
MP: 24-25 ºC. 
HR-MS: m/z calcd for [C15H21NO4+Na]
+ 302.1363 ; found 302.1356. 
[𝜶]𝑫
𝟐𝟎= +13 (c. 0.5 in CHCl3)  
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(R)-tert-butyl (1-(benzylamino)-1-oxopropan-2-yl)carbamate [(+)-16] 
 
To a solution of (+)-14 (100 mg, 0.52 mmol, 1eq.), benzyl amine (14 µl, 1.02 eq.) and DIPEA 
(275 µl, 1.58 mmol, 3 eq.) in DCM (15 ml) was added HATU (0.72 g, mmol 1.05 eq.). The 
reaction mixture was stirred for 48 h and the solvent was then evaporated to dryness. Ethyl 
acetate was added to solubilized the solid products, and the organic layer was then successively 
washed with a saturated solution of bicarbonate (10 ml), brine, HCl 1M (10 ml), and then brine 
(10 ml). The organic layer was dried over MgSO4 then concentrated under vacuum. The crude 
product was purified by chromatography on flash silica (PE/EtOAc 8/2) to obtain Boc-(R)-Ala-
NHBn (+)-16 (117 mg, 0.42 mmol) as a white solid.  
Yield: 80% 
TLC Rf (PE/EtOAc 1/3): 0.75 
1H NMR (360 MHz, CDCl3) δ= 1.39 (d, J = 7.1 Hz, 3H, H-6), 1.41 (s, 9H, H-1), 4.16-4.32 (m, 
1H, H-5), 4.44 (s, 2H, H-9), 5.16 (bs, 1H, H-4), 6.76 (bs, 1H, H-8), 7.42 – 7.19 (m, 5H, H-Ar). 
13C NMR (90 MHz, CDCl3): δ= 18.371 (C-6), 28.27 (C-1), 43.35 (C-9), 50.13 (C-5), 80.13 
(C-2), 127.43, 127.56, 128.66, (C-11, C-12, C-13), 138.10 (C-10), 155.59 (C-3), 172.63 (C-7).  
MP: 104-106 ºC. 
HR-MS: m/z calcd for [C15H22N2O3+Na]
+ 301.1523 ; found 301.1520. 
[𝜶]𝑫
𝟏𝟖 = + 24 (c. 0.5 in CHCl3) 
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2-((1R,2R)-2-((tert-butoxycarbonyl)amino)cyclobutyl)acetic acid [(+)-17] 
 
To a solution of Boc-(R,R)-cis-34GABA-OBn (+)-13 (154 mg, 0.48 mmol) in 40 ml of 20/5 
DCM/ethyl acetate was added 10% Pd-C (10% w/w) and the black suspension was stirred 
under dihydrogen atmosphere. When no starting material could be detected by TLC the 
reaction mixture was filtered (through a PVDF 0.45 μm filter) and concentrated under reduced 
pressure to afford Boc-(R,R)-cic-34GABA-OH (+)-17 in quantitative yields. The acid (+)-17 
was pure enough to be used in the coupling reactions without any purification.  
The analysis is identical to that reported in literature102 
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2-((1S,2S)-2-((tert-butoxycarbonyl)amino)cyclobutyl)acetic acid [(-)-17] 
 
Same procedure than for compound (+)-17 
The analysis is identical to that reported in literature102 
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General procedure “III” for the synthesis of the dipeptides (p1, p3, p5) 
Step one 
In flask A, Boc-(R)-Ala-OBn, or (Boc-(R)-Ala-NHBn for peptide p5) (1eq.), was dissolved in 
dry DCM (4 ml), TFA (30 eq.) was then added, and the reaction mixture was stirred at room 
temperature. When no Boc-(R)-Ala-OBn starting material could be detected by TLC, the 
reaction was considered complete and the DCM was evaporated under reduced pressure. The 
excess TFA was co-evaporated with DCM several times, and then left under high vacuum for 2 
h. the resulting crude TFA salt was then dissolved in dry DCM, and DIPEA (6 eq., sufficient 
quantity to reach PH 9) was added and the mixture was left to stir at room temperature. 
Step two 
In flask B, Boc-cis-34GABA-OH (1eq.) was dissolved in a mixture of DCM/DMF (4/1), DIPEA 
(2 eq.) was then added followed by HATU (1.05 eq.)  and the resulting mixture was stirred for 
10 min at room temperature during which the color changes from light to dark brown. 
Step three 
The content of flask A was then transferred to flask B and the resulting reaction mixture was 
stirred at room temperature for 24 h. The reaction mixture was concentrated under reduced 
pressure and toluene was added to co-evapourate DMF. The crude solid was dissolved in Ethyl 
acetate, or DCM (for p5), (50 ml) and successively washed by a saturated bicarbonate solution 
(20 ml), brine (20 ml), a 1 M HCl solution (20 ml), then brine (20 ml). The organic layer was 
dried over MgSO4, filtered, and concentrated under reduced pressure, and the resulting crude 
was purified accordingly. 
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General procedure “IV” for the hydrogenolysis of the benzyl ester prodecting group 
To a solution of Boc-peptide-OBn in 25 ml DCM/Ethyl acetate (20/5), 10% Pd-C (10% w/w) 
(125 ml/mmol) was added and the black suspension was stirred under dihydrogen atmosphere; 
when no Boc-peptide-OBn starting material was detected by TLC the reaction was considered 
complete. The reaction mixture was filtered through a (PVDF 0.45 μm filter), concentrated 
under reduced pressure to afford Boc-peptide-OH which was of sufficient purity to be used in 
the coupling reactions.  
General procedure “V” for the synthesis of the tetrapeptides (p2, p4, p6) 
Step one 
In flask A, Boc-peptide-O(or NH)Bn (1 eq.) was dissolved in dry DCM (2 ml), TFA (30 eq.) 
was then added, and the reaction mixture was stirred at room temperature. When no Boc-
peptide-O(or NH)Bn starting material could be detected by TLC, the reaction was considered 
complete and the DCM was evaporated under reduced pressure. The excess TFA was co-
evaporated with DCM several times, and then left under high vacuum for 2 h. the resulting 
crude TFA salt was then dissolved in dry DCM, and DIPEA (6 eq., sufficient quantity to reach 
PH 9) was added and the mixture was left to stir at room temperature. 
Step two 
In flask B, Boc-peptide-OH (1eq.) and DIPEA (2 eq.) was dissolved in a dry mixture of 
DCM/DMF (3/1). The content of flask A was then transferred into flask B, then HATU (1.05 
eq.) was introduced to the reaction mixture, which was left to stir at room temperature for 24 h 
during which a precipitate forms. The solvent was removed under reduced pressure and the 
remaining DMF was co-evaporated with toluene. And the resulting crude was purified 
accordingly.  
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Boc-(S,S)-GABA-(R)-Ala-OBn [p1] 
 
Following the general procedure “III” dipeptide p1 was prepared from Boc-(S,S)-cis-3,4GABA-
OH (200 mg, 0.87 mmol), DIPEA (152 µl, 2 eq.), HATU (348 mg, 1.05 eq.) in a mixture of 
DCM/DMF (4/1) (4 ml) and the corresponding TFA salt of Boc-(R)-Ala-OBn (243 mg, 0.87 
mmol), DIPEA (0.91 ml, 6 eq.) in dry DCM (4 ml), overnight. After workup the resulting crude 
was purified by flash chromatography on silica (6/4 PE/EtOAc) to afford Boc-(S,S)-GABA-
(R)-Ala-OBn p1  as white solid (289 mg, 0.74 mmol). 
Yield: 85% 
TLC Rf (PE/EtOAc 3/2): 0.22 
1H NMR (360 MHz, CDCl3): δ= 1.41 (d, J = 7.3 Hz, 3H, H-13, overlapped with H-1) , 1.43 (s, 
9H, H-1), 1.55-1.67 (m, 1H, H-7), 1.80-1.93 (m, 1H, H-6), 1.93-2.07 (m, 1H, H-7), 2.29 (dd, J 
= 8.0, 14.5 Hz, 1H, H-9), 2.33-2.40 (m, 1H, H-6, overlapped with H-9), 2.46 (dd, J = 6.8, 14.5 
Hz, 1H, H-9), 2.80-2.91 (m, 1H, H-8), 4.20-4.35 (m, 1H, H-5), 4.63 (p, J = 7.2 Hz, 1H, H-12), 
5.15 (d, J = 12.3 Hz, 1H, H-15), 5.21 (d, J = 12.3 Hz, 1H, H-15), 5.32 (bs, 1H, H-4), 6.29 (bs, 
1H, H-11), 7.30-7.41 (m, 1H, H-Ar),  
13C NMR (90 MHz, CDCl3): δ= 18.3 (C-13), 21.4 (C-7), 27.5 (C-6), 28.3 (C-1), 36.4 (C-9), 
37.4 (C-8), 47.3 (C-5), 48.1 (C-12), 67.1 (C-15), 79.3 (C-2), 128.1, 128.4, 128.6, (C-17, C-18, 
C-19), 135.2 (C-16), 155.4 (C-3), 171.9 (C-10), 172.9 (C-14). 
  
Page | 174  
 
 MP: 155-157 ºC. 
HR-MS: m/z calcd for [C21H30N2O5+Na]
+ 413.2047 ; found 413.2032 
[𝜶]𝑫
𝟐𝟓 = +49.6 (c. 0.23 in MeOH)   
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Boc-[(S,S)-GABA-(R)-Ala]2-OBn [p2] 
 
Following the general procedure “IV” the benzyl ester of dipeptide p1 (86 mg, 0.22 mmol) was 
hydrolysex in 4 h to afford Boc-(S,S)-GABA-(R)-Ala-OH (65 mg, 0.21 mmol) (crude yield 
95%) 
Following the general procedure “V” peptide p2 was prepared from Boc-(S,S)-GABA-(R)-Ala-
OH (44.60 mg, 0.15 mmol, 1eq.), DIPEA (50 µl, 2 eq.), HATU (60 mg, 1.05 eq.) in a mixture 
of DCM/DMF (3/1) (2 ml) and the corresponding TFA salt of Boc-(S,S)-GABA-(R)-Ala-OBn 
(58.0 mg, 0.15 mmol), DIPEA (0.155 ml, 6 eq.) in dry DCM (2 ml), over 24 h. The resulting 
yellowish crude solid dissolved in DCM (25 ml) and successively washed with a saturated 
bicarbonate solution (10 ml), brine (10 ml), a 1 M HCl solution (10 ml), then brine (10 ml). The 
organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The 
resulting crude was purified by flash chromatography over silica (gradient eluent of 100/1 to 
100/4 DCM/MeOH) to afford Boc-[(S,S)-GABA-(R)-Ala]2-OBn p2 as white solid (57.20 mg, 
0.1 mmol). 
Yield: 66% 
TLC Rf: (DCM/MeOH / 100/ 4): 0.7 
1H NMR (400 MHz, CDCl3): δ= 1.37 (d, J = 7.1 Hz, 3H, H-13), 1.43 (s, 9H, H-1), 1.45 (d, J = 
7.5 Hz, 1H, H-24), 1.68 – 1.57 (m, 1H, H-7), 1.91 – 1.80 (m, 1H, H-6), 2.07 – 1.92 (m, 3H, 1H, 
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H-7; 1H, H-17; 1H, H-18), 2.41 – 2.12 (m, 6H, 1 H, H-18; 2H, H-20, 1H, H-9; 1H, H-17; 1H, 
H-6), 2.48 (dd, J = 7.6, 14.3 Hz, 1H, H-9), 2.94 – 2.78 (m, 2H, 1H, H-19; 1H, H-8), 4.33 – 4.18 
(m, 2H, 1H, H-5; 1H, H-12), 4.53 (p, J = 8.5 Hz, 1H, H-16), 4.65 (p, J = 7.4 Hz, 1H, H-23), 
5.18 (d, J = 12.3 Hz, 1H, H-26), 5.24 (d, J = 12.4 Hz, 1H, H-26), 5.57 (d, J = 4.5 Hz, 1H, H-4), 
6.59 (d, J = 6.9 Hz, 1H, H-11), 7.42 – 7.31 (m, 2H, H-Ar), 7.80 (d, J = 7.4 Hz, 1H, H-15), 7.91 
(d, J = 7.1 Hz, 1H, H-22). 
13C NMR (100 MHz, CDCl3): δ= 16.95 (C-24), 17.53 (C-13), 19.81 (C-17 or 18), 21.33 (C-7), 
26.68 (C-18 or 17), 27.43 (C-6), 28.41 (C-1), 35.27 (C-20), 36.40 (C-9), 37.65 (C-8 or 19), 
37.82 (C- 19 or 8), 46.75 (C-16), 47.38 (C-5), 48.15 (C-23), 49.49 (C-12), 67.34 (C-26), 79.33 
(C-2), 128.03, 128.41, 128.61 (C-28, 29, 30), 135.25 (C-27), 155.52 (C-3), 172.38 (C-14), 
173.07 (C-21), 173.22 (C-10), 175.31 (C-25). 
MP: 195-197 ºC. 
HR-MS: m/z calcd for [C30H44N4O7+Na]
+ 595.3102 ; found 595.3095 
[𝜶]𝑫
𝟐𝟓.𝟑= - 72.76 (c. 0.5 in CHCl3)   
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Boc-(R,R)-GABA-(R)-Ala-OBn [p3] 
 
 Following the general procedure “III” dipeptide p3 was prepared from Boc-(R,R)-cis-
3,4GABA-OH (97.0 mg, 0.42 mmol), DIPEA (150 µl, 2 eq.), HATU (169 mg, 1.05 eq.) in a 
mixture of DCM/DMF (4/1) (2 ml) and the corresponding TFA salt of Boc-(R)-Ala-OBn (118 
mg, 0.42 mmol), DIPEA (0.45 ml, 6 eq.) in dry DCM (24 ml), overnight. After workup the 
resulting crude product was purified by flash chromatography on silica (6/4 PE/EtoAc) to 
afford Boc-(R,R)-GABA-(R)-Ala-OBn p3 as a white solid (152 mg, 0.39 mmol). 
Yield: 92% 
TLC Rf (PE/EtOAc 3/2): 0.22 
1H NMR (360 MHz, CDCl3): δ = 1.42 (d, J = 7.4 Hz, 3H, H-13), 1.44 (s, 9H, H-1), 1.54-1.66 
(m, 1H, H-7), 1.79-1.91 (m, 1H, H-6), 1.92-2.05 (m, 1H, H-7), 2.27 (dd, J = 14.6, 7.6 Hz, 1H, 
H-9), 2.27-2.38 (m, 1H, H-6,) 2.47 (dd, J = 14.6, 7.1 Hz, 1H, H-9), 2.77-2.90 (m, 1H, H-8), 
4.18-4.33 (m, 1H, H-5), 4.62 (p, J = 7.3 Hz, 1H, H-12), 5.15 (d, J = 12.3 Hz, 1H, H-15), 5.21 
(d, J = 12.2 Hz, 1H, H-15), 5.22 (m, 1H, H-4), 6.36 (bs, 1H, H-11), 7.31-7.42 (m, 5H, H-Ar ). 
13C NMR (90 MHz, CDCl3): δ= 18.1 (C-13), 21.7 (C-7), 27.4 (C-6), 28.3 (C-1), 36.4 (C-9), 
37.3 (C-8), 47.4 (C-5), 48.1 (C-12), 67.0 (C-15), 79.3 (C-2), 128.1, 128.4, 128.5, (C-17, C-18, 
C-19), 135.3 (C-16), 155.5 (C-3), 171.9 (C-10), 172.8 (C-14). 
 MP: 145-146 ºC. 
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HR-MS: m/z calcd for [C21H30N2O5+Na]
+ 413.2047 ; found 413.2039 
[𝜶]𝑫
𝟐𝟓 = + 51 (c. 0.5 in CHCl3) 
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Boc-[(R,R)-GABA-(R)-Ala]2-OBn [p4] 
 
Following the general procedure “IV” the benzyl ester of dipeptide p3 (80 mg, 0.20 mmol) was 
hydrolysex in 4 h to afford Boc-(R,R)-GABA-(R)-Ala-OH (60 mg, 0.20 mmol) (crude yield 
100%) 
Following the general procedure “V” peptide p4 was prepared from Boc-(R,R)-GABA-(R)-Ala-
OH (34.0 mg, 0.11 mmol, 1eq.), DIPEA (40 µl, 2 eq.), HATU (45 mg, 1.05 eq.) in a mixture of 
DCM/DMF (3/1) (2 ml) and the corresponding TFA salt of Boc-(R,R)-GABA-(R)-Ala-OBn 
(44.1 mg, 0.11 mmol), DIPEA (0.118 ml, 6 eq.) in dry DCM (2 ml), over 24 h. The resulting 
yellowish crude solid was washed with water and filtered on a sintered glass funnel (size 4), the 
residue was washed with ether, dried under vacuum then purified by flash chromatography over 
silica (gradient eluent of 100/1 to 100/4 DCM/MeOH) to afford Boc-[(R,R)-GABA-(R)-Ala]2-
OBn as white solid (25.2 mg, 0.044 mmol). 
Yield: 40% 
TLC Rf (DCM/MeOH 100/4): 0.7 
1H NMR (400 MHz, CDCl3): δ= 1.36 (d, J = 6.7 Hz, 3H, H-13) ,1.42 (d, J = 7.1 Hz, 3H, H-24 
covered by H-1), 1.43 (s, 9H, H-1), 1.53-1.70 (m, 2H, 1H, H-7; 1H, H-18), 1.78-1.94 (m, 1H, 
H-6), 1.94-2.12 (m, 3H, 1H, H-7; 1H, H-17; 1-H, H-18 ), 2.21-2.41 (m, 4H, 1H, H-9; 1H, H-6; 
1H, H-17; 1H, H-20), 2.41-2.57 (m, 2H, 1H, H-20; 1H, H-9), 2.82-3.01 (m, 2H, 1H, H-8; 1H, 
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H-19) 4.15-4.34 (m, 1H, H-5), 4.34-4.52 (m, 2H, 1H, H-12; 1H, H-16), 4.55-4.69 (m, 1H, H-
23), 5.15 (d, J = 12.4 Hz, 1H, H-26), 5.21 (d, J = 12.4 Hz, 1H, H-26), 5.29 (d, J = 5.6 Hz, 1H, 
H-4), 6.37 (d, J = 12.0 Hz, 1H, H-211), 6.81 (d, J = 12.4 Hz, 1H, H-22), 7.30-7.42 (m, 5H, H-
Ar), 7.65 (d, J = 11.2 Hz, 1H, H-15). 
13C NMR (100 MHz, CDCl3): δ= 17.8 (C-24), 18.48 (C-13), 22.1 (C-7 and 18), 27.0 (C-17), 
27.3 (C-6), 28.3 (C-1), 36.6 (C-9, or 20), 36.8 (C-9, or 20), 37.1 (C-8, or 19), 37.3 (C-19 or 8), 
46.8 (C-16), 47.7 (C-5), 48.2 (C-23), 49.3 (C-12), 67.1 (C-26), 79.4 (C-2), 128.15, 128.4, 128.6 
(C-28, C-29, C-30), 135.3 (C-27), 155.6 (C-3), 172.0 (C-14), 172.3 (C-10 or 21), 172.4 (C-21, 
or 10), 173.1 (C-25). 
MP: 204-207 ºC. 
HR-MS: m/z calcd for [C30H44N4O7+Na]
+ 595.3102 ; found 595.3079 
[𝜶]𝑫
𝟐𝟓 = - 35 (c. 0.5 in CHCl3)   
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Boc-(S,S)-GABA-(R)-Ala-NHBn [p5] 
 
Following the general procedure “III” dipeptide p5 was prepared from Boc-(S,S)-cis-3,4GABA-
OH (50.0 mg, 0.22 mmol), DIPEA (75 µl, 2 eq.), HATU (87 mg, 1.05 eq.) in a mixture of 
DCM/DMF (4/1) (2 ml), and the corresponding TFA salt of Boc-(R)-Ala-NHBn (60.7 mg, 0.22 
mmol), DIPEA (0.23 ml, 6 eq.) in dry DCM (24 ml), overnight. After workup the resulting 
crude was purified by flash chromatography over silica (1/3 PE/EtOAc) to obtain Boc-(S,S)-
GABA-(R)-Ala-NHBn p5 as white solid (72.2 mg, 0.18 mmol). 
Yield: 82% 
TLC Rf (PE/EtOAc 1/3): 0.53  
1H NMR (400 MHz, CDCl3): δ= 1.40 (d, J = 7.0 Hz, 1H, H-13), 1.43 (s, 2H, H-1), 1.51-1.62 
(m, 1H, H-7) 1.78-1.90 (m, 1H, H-6), 1.90-2.03 (m, 1H, H-7), 2.24 (dd, J = 7.7, 14.5Hz, 1H, H-
9), 2.28 -2.39 (m, 1H, H-6, overlapped with H-9), 2.45 (dd, J = 7.1, 14.5Hz, 1H, H-9), 2.76-
2.87 (m, 1H, H-8), 4.18-4.30 (m, 1H, H-5), 4.41 (d, J = 6.8 Hz, 1H, H-16), 4.44 (d, J = 7.0 Hz, 
1H, H-16), 4.50 (p, J = 7.1 Hz, 1H, H-12), 5.19 (s, 1H, H-4), 6.44 (d, J = 6.4 Hz, 1H, H-11), 
6.71 (s, 1H, H-15), 7.22-7.35 (m, 1H, H-Ar). 
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13C NMR (63 MHz, CDCl3): δ= 18.06 (C-13), 21.72 (C-7), 27.37 (C-6), 28.37 (C-1), 36.48 
(C-9), 37.41 (C-8), 43.49 (C-16), 47.55 (C-5), 48.87 (C-12), 127.46, 127.58, 128.67 (C-18, 19, 
20), 137.99 (C-17), 155.55 (C-3), 172.13 (C-10 or 14), 172.35 (C-14, or 10). 
MP: 196-197 ºC. 
HR-MS: m/z calcd for [C21H31N3O4+Na]
+ 412.2207 ; found 412.2201 
[𝜶]𝑫
𝟐𝟔= - 7.7 (c. 0.5 in CHCl3)   
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Index 
A- Determination of the binding constant Kb for a 1:1 complex 
The equilibrium constant, K, for a complex formation between a host (H) and a guest (G) can 
be formulated from the general equilibrium reaction: 
 
when the stoichiometry of the formed β-cycldextrin/ guest complex is 1:1, the desired 
equilibrium or binding constant Kb is given by: 
        𝐾𝑏 =
[𝐻𝐺]
[𝐻][𝐺]
                      (1) 
Where [G] is the concentration of free guest, [H] is the concentration of free host, i.e. (β-CD), 
and [HG] the concentration of the formed host/guest complex.  
Because the complexation process is a dynamic equilibrium, the individual concentration of 
each species is not readily measurable. Instead of measuring separate concentrations, a well-
known approach to determine the molecular binding constant, is to generate the binding curve 
and then to extract K via a regression analysis.65 
To apply this approach, we need to define the total guest concentration [H]t, which is always 
equal to the concentration of the host in the free form added to the concentration of the Host in 
the bound form, equation (2): 
     [𝐻]𝑡 =  [H]  + [HG]            (2) 
In addition, we have the expression that indicates the fraction of the host that is bound Xb, 
which is the concentration of the bound host at a given time divided by the total concentration 
of the host at that time: 
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          𝑋𝑏 =  
[𝐻𝐺]
[𝐻]𝑡
                   (3) 
Substituting equations (2) and (3) in equation (1) and rearranging for Xb, we obtain equation (4) 
which is known as the binding isotherm:66 
 
           𝑋𝑏 =
𝐾[𝐺]
1+𝐾[𝐺]
             (4) 
In order for equation (4) to be useful, Xb needs to be described in terms of a measurable 
property whose magnitude varies as a function of the amount of Host bound, i.e. complex 
formation.65 
One of the most common properties whose variation could be studied as a function complex 
formation is the NMR shift of specific protons located on the host or the guest molecules. 
So we first need to relate Xb to the chemical shift variation of a specific proton on the host or 
the guest. To be able to establish such a relation one should be aware that the rates of complex 
formation and dissociation are usually faster than the NMR time scale, and the observed signals 
are actually an average between the chemical shifts in the free and the bound form of the host 
and the guest molecules.29 
 Thus if δH is the chemical shift of the monitored proton in the free state, and δHG is the 
chemical shift of the same proton in the bound state, then the observed chemical shift, δobs, is 
given by:66 
    δobs =  XfδH + XbδHG               (5) 
In equation (5) Xf and Xb represent the fraction of the host in the free and bound form 
respectively. Now since Xf + Xb = 1 equation (5) could be written as 
   δobs =  Xb(δHG − δH) + δH       (6) 
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Rearranging equation 6 for Xb we obtain equation (6') 
              Xb =
δobs−δH
δHG−δH
                   (6’) 
The expression δobs - δH represents the variation in the chemical shift of the monitored proton 
Δδ, and the δHG − δH represents the maximum change in chemical shift which is attained at 
saturation Δδsat. using this notation equation 6' becomes: 
                Xb =
Δδ
Δδsat
                   (6”) 
Substituting equation 6'' into equation 4 we get: 
            Δδ =  
Δδsat K [G]
1+K[G]
                   (7) 
The reciprocal of equation 7 gives: 
    
1
Δδ
=
1
Δδsat K [G]
+  
1
Δδsat
               (8) 
A plot of 1/Δδ vs [G] establishes a straight line whose slop is directly related to the value of K 
(see Figure 88). 
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Figure 88:  A plot of 1/Δδ vs [G]. 
 
B- In a subsequent control reaction, we observed that up to half the amount of cyclobutene 
product (±)-9 was lost when an equimolar solution of this compound and β-CD in water was 
lyophilized for 3 days. 
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Introduction 
La majorité des molécules naturelles et biologiquement actives ont une configuration bien 
définie en lien avec leur fonction moléculaire. Il est étonnant de voir comment les organismes 
vivants ont la capacité de choisir ou de biosynthétiser de manière sélective un seul énantiomère 
d’une molécule donnée. Les chimistes cherchent depuis toujours à imiter les systèmes 
biologiques; ainsi, la synthèse asymétrique de composés organiques est devenue un terrain de 
prédilection pour la recherche. La préparation énantiosélective de molécules revêt également 
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une importance industrielle, en raison du besoin de molécules stéréochimiquement pures dans 
le domaine de la médecine et de la science des matériaux. 
Au cours des dernières décennies, la synthèse asymétrique de composés organiques a été 
traditionnellement réalisée par des transformations catalytiques ou enzymatiques, et un large 
éventail de méthodes a été développé pour obtenir un contrôle stéréochimique sur diverses 
transformations chimiques. La photochimie s’est révélée être un outil polyvalent en synthèse 
organique et fait l’objet d’une attention encore plus grande aujourd’hui, car elle est considérée 
comme une méthode de préparation de nouveaux matériaux dans un contexte «respectueux de 
l’environnement», appelé chimie verte. Néanmoins, les transformations photochimiques 
asymétriques ne sont pas très largement étudiées. Le terme «photochirogenèse» est assez 
récent. Elle a été inventée en 1996 et est conceptuellement synonyme de «photochimie 
asymétrique» ou «photochimie chirale», l'accent étant mis sur la création d'une chiralité 
moléculaire via l'utilisation d'un photon. 
La recherche en matière de photochirogénèse a fait de grands progrès quantitatifs et qualitatifs 
grâce aux nouvelles méthodologies développées pour contrôler les processus impliqués. Il est 
essentiel pour obtenir un contrôle stéréochimique d'une réaction photochimique, de s'assurer 
que la molécule « substrat » réside déjà dans un environnement chiral pendant l'étape 
d'excitation. À cet égard, la photochirogenèse peut être facilement divisée en deux catégories 
principales. Le premier comprend les réactions dans lesquelles la chiralité est transférée à une 
molécule réactive par la présence d'un substituant chiral, lié de manière covalente ou ionique au 
réactif. Avec une telle approche, la chiralité peut être induite par l'interaction intramoléculaire 
entre le centre chiral, agissant comme un «auxiliaire chiral», et le fragment réactif. La 
deuxième catégorie, la photochirogenèse supramoléculaire, peut être décrite comme une 
interaction hôte-invité entre le réactif, en tant qu'invité, et une molécule hôte qui fournit un 
environnement chiral pour que la réaction photochimique se déroule de manière asymétrique. 
Ici, la chiralité est transférée d'une molécule à une autre par le biais d'interactions 
intermoléculaires entre le substrat et une molécule voisine possédant certaines propriétés 
chirales. 
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L'objectif de ce travail 
Dans ce travail, nous avons cherché à explorer la possibilité d'utiliser la photochimie 
supramoléculaire asymétrique comme stratégie de synthèse alternative pouvant fournir un accès 
plus rapide et / ou plus efficace au cis-2,3CB-GABA et au cis-3,4CB-GABA sous une forme 
énantiomériquement pure. Nous envisagions ensuite d’utiliser ces molécules comme éléments 
de base pour la préparation de nouvelles séquences de peptides mixtes et d’étudier  le 
comportement de repliement en trois dimensions de ces peptides. 
Nous avons envisagé la synthèse énantiosélective des dérivés du cis-2,3CB-GABA et de cis-
3,4CB-GABA. L'avantage évident de cette approche énantiosélective étant d’éviter l’utilisation 
d’un auxiliaire chiral pour effectuer la résolution des composés racémiques. Pour atteindre cet 
objectif, afin de contribuer à la croissance de la photochirogenèse, nous avons décidé d'étudier 
l'utilisation de la β-cyclidextrine (β-D) en tant qu'hôte supramoléculaire chiral, facilement 
disponible pour les transformations photochimiques énantiosélectives (Schéma a). La 
cycloaddition intramoléculaire [2 + 2] photochimique du N-allyl-N-arylacrylamide 1 en 
présence de β-CD pourrait donner accès à un adduit bicyclique 2 sous forme énantio-enrichie 
précurseur du cis-2,3CB-GABA. D’autre part, La 4π-électrocyclisation photochimique de 
l'azépinone 8 en présence de β-CD pourrait donner accès au produit bicyclique 9 sous forme 
énantio-enrichie, pouvant conduire au cis-3,4CB-GABA. 
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Scheme a: Réactions photochirogéniques proposées en présence de β-CD, pouvant conduire au 
cis-2,3CB-GABA (en haut) et au cis-3,4CB-GABA (en bas) énantioenrichis 
La réactivité photochimique du N-Allyl-N-(4-
méthoxyphényl)acrylamide. 
Nous avons commencé ce projet en étudiant la réactivité photochimique du N-allyl-N-(4-
méthoxyphényl) acrylamide 1. Les chimistes organiciens sont constamment à la recherche de 
nouvelles méthodologies pour la synthèse de composés d'importance biologique tels que les 
dérivés du N-allylacrylamide. Ces dérivés ont déjà été préparés pour la construction de 
composés hétérocycliques à stéréocentres multiples, présentant un intérêt en tant que 
médicaments ou réactifs bioactifs, par réactions de métathèse à cycle fermé régiosélectives 
(RCM) ou par réactions de cyclisation tandem catalysées par le palladium. Les réactions de 
cycloaddition photochimiques énantiosélectives de dérivés de N-allylacrylamide n’ont pas 
encore été étudiées, mais pourraient constituer une méthode de synthèse «verte» pour la 
préparation de composés hétérocycliques. Les lactames bicycliques, tels que l’intermédiaire 
particulier 2 que nous ciblons ci-dessous, présentent un intérêt synthétique considérable à cet 
égard  
Nous avons donc entrepris d'établir un nouvel accès synthétique au dérivé cis-2,3CB-GABA, sur 
la base de la cycloaddition photochimique intramoléculaire énantiosélective [2 + 2] d'un dérivé 
de N-allylacrylamide inclu dans la cavité chirale d’une β-CD. Le dérivé de N-allylacrylamide 
sélectionné était le N-allyl-N-(4-méthoxyphényl) acrylamide 1 (schéma b). Le groupe 
méthoxyphényle a été choisi afin de favoriser l'inclusion du composé 1 dans la cavité 
hydrophobe et asymétrique de la β-CD. 
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Schéma b: Photocycloaddition [2+2] intramoléculaire énantiosélective du composé 1 en 
présence de β-CD. 
 
La synthèse du N-allyl-N-(4-méthoxyphényl)acrylamide 1 
La synthèse du composé 1 a tout d'abord consisté en une addition de Michael du 
benzènesulfonate de sodium sur l'acide acrylique, conduisant au composé 3 avec un rendement 
de 75% (Schéma 3). L'acide carboxylique 3 a ensuite été converti en chlorure d'acyle avant de 
le faire réagir avec la p-anisidine pour donner le N-(4-méthoxyphényl)-3-
(phénylsulfonyl)propanamide 4 avec un rendement de 85% sur les deux étapes. L’élimination 
du groupe phénylsulfonyle du composé 4 a été effectuée dans un processus « one pot » avec 
l’allylation de l’azote amidique pour donner le N-allyl-N-(4-méthoxyphényl)acrylamide 1 
(Schéma c). 
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Scheme c: Synthèse du N-allyl-N-(4-méthoxyphényl)acrylamide 1, à partir du benzenesulfonate 
de sodium et de l’ acide acrylique 
La réactivité photochimique du composé 1 
Avec le composé 1 en main, nous avons étudié sa photoréactivité. L'eau était le solvant de 
choix pour la transformation photochimique de 1, en tenant compte de notre intention 
d'effectuer des réactions ultérieures en présence de β-CD. Cependant, L’exposition aux rayons 
UV du composé 1 n’a donné lieu à aucune réaction. D'autre part, lorsque la réaction a été 
effectuée dans l'acétone, une conversion complète de 1 a été observée, mais le 3-(4-
méthoxyphényl)-3-azabicyclo [3.2.0] heptan-2-one désiré 2 n'a jamais été obtenu. Au lieu de 
cela, une électrocyclisation-6π suivi d’un réarrangement 1,5-sigmatropique s’est produite, pour 
conduire au composé 5 dont la structure a été validée par analyse par diffraction aux rayons X. 
(Schéma d, figure a). 
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Schema d: Mécanisme proposé pour la formation du composé 5.
 
Figure a: Structure par diffraction aux rayons X du composé 5. 
Dans le composé 1, le doublet non-liant de l’azote associé avec la partie acryloyle et le cycle 
aromatique donne lieu à un système à 6 électrons π délocalisables. Lors de l'irradiation, le 
composé 1 entre dans un état exité singulet. À ce stade, il existe une compétition entre une 
fermeture de cycle conrotatoire à 6 électrons π et une évolution du composé 1 vers un état 
triplet. En raison d’un échange intersystème inefficace, on n’observe que le premier de ces 
deux phénomènes, conduisant à la formation du composé 5 vis à vis composé 2. À ce stade, il 
est apparu que les conditions appropriées pour la synthèse énantiosélective proposée n’était 
probablement pas réunies. Les difficultés cumulées de l’interaction faible hôte-invité, de 
l’incompatibilité des solvants et de la réactivité photochimique compétitive semblaient 
insurmontables avec le substrat 1 que nous avions choisi. Il semble évident qu'un substrat 
différent devrait être envisagé. L'utilisation d'un groupe carbamate ou benzyle au lieu d'un 
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groupe aryle sur l'atome d'azote pourrait éliminer la réactivité indésirable à l'électrocyclisation 
et permettre à la cycloaddition [2 + 2] de prévaloir, tout en conférant une affinité de liaison 
raisonnable du substrat dans la cavité β-CD (Figure b). Néanmoins, nous avons suspendu nos 
efforts pour accéder au cis-2,3CB-GABA pour le moment et avons concentré notre attention sur 
la réactivité photochimique de la 1,3-dihydro-2H-azépine-2-one 8 précurseur du cis-3,4CB-
GABA. 
 
Figure b: Analogues benzyl (left), and carbamate (right) analogues of compound 1. 
 
La réactivité photochimique de la 1,3-dihydro-2H-azépine-2-one 8 
Dans cette partie du projet de recherche, nous avons cherché à établir un accès synthétique aux 
dérivés du cis-3,4CB-GABA, sur la base de l’électrocyclisation photochimique intramoléculaire 
énantiosélective du composé 8 en présence de β-CD. 
Nous supposions que la présence de β-CD au cours de cette électrocyclisation 4π pourrait 
fournir un environnement chiral qui favoriserait une topologie de fermeture du cycle par 
rapport à l'autre, permettant ainsi un accès préférentiel à l'un des énantiomères (schéma e). 
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Schéma e: Photoélectrocyclisation énantiosélective de l'azépinone 8 induite par la β-CD 
Dans ce chapitre, nous avons d’abord planifié la synthèse de l’azépinone 8, l’étude de 
l’interaction hôte-invité 8/β-CD, les meilleurs conditions d’irradiation du complexe en termes 
de rendement chimique et d’excès énantiomérique en produit 9. Par la suite, le cis-3,4CB-GABA 
énantioériquement enrichi pourraient être préparés en suivant le mode opératoire décrit pour la 
forme racémique. 
 
La synthèse de l'azépinone 8 
L'azépinone 8 a été préparée selon un procédé précédemment décrit. Elle est ainsi obtenue par 
la dibromation du caprolactame 6 commercial conduisant au composé 7 avec un rendement de 
73%, qui par double élimination de HBr produit l'azépinone 8 avec 70% de rendement (schéma 
f). 
 
Schema f: Synthèse de l’azapinone 8 à artir du caprolactame 6 
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Préparation et caractérisation du complexe β-CD / 8 
La β-CD et l'azépinone 8 sont solubles dans l'eau. Le complexe β-CD / azépinone 8 a été 
préparé en mélangeant une solution aqueuse de cette dernière avec une solution aqueuse de β-
CD. Sous agitation à la température ambiante, un précipité blanc se forme pour conduire à une 
«suspension laiteuse» épaisse. Il est important de souligner qu'une concentration minimale 
d'environ 6 mM par rapport à la concentration de β- CD, est nécessaire pour que le précipité se 
forme; et plus la concentration du mélange est faible, plus le processus de précipitation est lent. 
Pour cette raison, le volume de la solution finale a toujours été choisi pour avoir une 
concentration juste inférieure à 15 mM, ce qui correspond à la solubilité maximale de la β-CD 
dans l'eau à 25 °C. 
L’apparition d'un précipité lors du mélange du lactame 8 avec la β-CD suggère la présence 
d’une interaction entre ces deux composés. Cela a été validé par l'analyse du précipité par 
diffraction aux rayons X sur poudre (PXRD). Les données obtenues pour le complexe β-CD / 8 
étaient effectivement différentes de celles du lactame 8 et de la β-CD seules. Nous avons ainsi 
eu une indication supplémentaire de l'implication d'un véritable complexe, plutôt que d'un 
mélange physique de deux substances distinctes (Figure c). 
 
 
Figure c: Spectre PXRD de l’azépinone 8 vs β-CD vs complexe  
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La microscopie électronique à balayage (MEB) a également été utilisée pour valider la 
formation d'un complexe entre la β-CD et l'azépinone 8. Les images en MEB ont montré une 
morphologie fibrillaire bien organisée pour le complexe, contrairement à l'azépinone 8 seule et 
à la β-CD seule, qui n'ont montré que des structures amorphes (Figure d). β-CD /8. 
 
Figure d: Images MEB de la β-CD seule (en haut à gauche), de l’azepinone 8 seule (en haut à 
droite), du complexe β-CD/8 avant irradiation (en bas à gauche), et après irradiation (en bas à 
doite). 
La stœchiométrie du complexe a ensuite été évaluée par spectroscopie UV en utilisant la 
méthode de variation continue. Une représentation graphique de l'évolution de l'absorption à 
254 nm pour des solutions aqueuses de composition molaire relative variée a suggéré la 
formation d'un complexe dans un rapport molaire de 1: 1, comme illustré à la figure e. 
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Figure e: Job’s plot de l’absorption UV (λ =254 nm) d’une solution β-CD:azepinone 8 à 
différents rapports molaires. 
 
Nous avons, par la suite, effectué des mesures spectroscopiques pour étudier le comportement 
du complexe en solution. Une expérience de titrage par RMN 1H a été réalisée dans laquelle la 
variation des déplacements chimiques des protons de la β-CD était mesurées avec l’augmentait 
progressivement de la concentration en l'azépinone 8. Les signaux correspondants aux protons 
H1, H2, H4 et H6, situés à l'extérieur de la cavité β-CD, ne présentaient aucun changement 
significatif. Par contre, les signaux correspondants aux protons H3 et H5, orientés vers 
l'intérieur de la cavité, présentaient un décalage vers les champs forts, avec des variations Δδ de 
0,03 et 0,07 ppm, respectivement, pour un rapport β-CD :8 de 1: 1, suggérant la présence d’un 
complexe d’inclusion à pénétration profonde (Figure f). 
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Figure f: Spectres RMN 1H de la β-CD montrant la variation de déplacement chimique de H3 
et H5 avec chaque addition d'azépinone 8 
Les données de titrage par RMN 1H pour le proton H3 de la β-CD, ont également été utilisées 
pour évaluer la constante de liaison, en utilisant l’équation de Benesi − Hildebrand. La valeur 
de Kb a été estimée à 35,4 (Figure g). 
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Figure g: variation de 1/ΔδH3 en function de 1/[azepinone 8]. 
La formation d’un complexe d’inclusion a également été validée par une expérience RMN 2D 
ROESY, réalisée sur une solution équimolaire de β-CD / 8 dans du D2O à 40°C. ous avons pu 
observer la présence de taches de corrélation, impliquant les protons vinyliques H4, H5, H6, H7 
de l'azépinone 8 et les protons internes H3 et H5 de la β-CD (Figure h). 
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Figure h: Agrandissement du spectre RMN ROESY à 600 MHz d’une solution 1:1 de β-CD/8 
(15 mM in D2O, 40 °C) (en haut). β-CD (en bas à gauche)et lactame 8 (en bas à droite). 
 
Photoélectrocyclisation de l'azépinone 8 en présence de β-CD 
Nous avons ensuite irradié le complexe β-CD / azépinone 8. La réaction de 
photoélectrocyclisation a été réalisée avec différentes proportions hôte/invité, en solution à 
chaud, en suspension à froid, sous forme de poudre solide, ainsi que sous forme de film mince 
solide. L'isolation du photocycloadduit 9 (Schéma 9), après l'irradiation s’est avérée très 
délicate. Ce dernier a donc été réduit en 2-azabicyclo[3.2.0]heptan-3-one 10 dans un processus 
« one pot ». Le produit 10 a ainsi été obtenu avec un rendement de 75% sur deux étapes. 
Aucune énantiosélectivité n'a été observée lors des réactions effectuées sur le complexe -CD/8 
en solution. L’irradiation du complexe -CD/8 1:1 à l'état solide en suspension dans l’eau ou en 
film mince, suivies d'une hydrogénation catalytique « one pot », a fourni le (1R,5R)-2-
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azabicyclo[3.2.0]heptan-3-one 10 avec des rendements allant jusqu'à 79% et avec excès 
énantiomériques allant jusqu'à 45%. (Schéma h, Tableau a). 
 
Schéma h: Préparation du composé 10 à partir du composé 4 
 
Entrée Conditions d’irradiation a étatb Rdt 10 (%) ee 10 (%) 
1 A, 45 °C, 2 h solution 40 0 
2 A, 20 °C, 2 h solutionc 65 0 
3 A, 5 °C, 2 h suspension 79 38 
4 A, 5 °C, 2 h suspensiond 75 45 
5 B, 25 °C, 7 h poudree 70 0-40f 
6 B, 25 °C, 20 h poudre 71 36 
7 C, 25 °C, 5 h film 77 41 
8 C, 25 °C, 5 h filmg 77 42 
9 C, 25 °C, 5 h filmc 78 41 
 
Tableau a: (a): Pour le détail des conditions A, B and C, voir la partie experimentael; (b): tous 
les écantillons ont été préparés à partir d’une solution aqueuse de 8 and de β-CD (1:1 ratio) à 
15 mM, sauf indication contraire; (c): les concentrations de 8 et de la β-CD étaient de 4 mM 
(1:1 ratio); (d): addition de 2 equivalents de β-CD solide; (e): les deux réactifs ont été 
mélangés directement, sans solvant ; (f): Pour 3 expériences idetiques, les ee étaient de 0%, 
29% and 40%; (g): La concentration de 8 était de 7.5 mM (1:2 ratio). 
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La configuration absolue du composé 10 
Toutes les expériences décrites ci-dessus ont conduit au même énantiomère majoritaire de 10. 
Pour déterminer la configuration de cet énantiomère majoritaire, un échantillon de 10 (avec ee 
= 42%) a été transformé en dérivé N-Boc 12 du cis-3,4CB-GABA, selon une procédure déjà 
décrite. La mesure du pouvoir rotatoire du composé 12 a donné une valeur []D + 33 (c 0,5, 
CHCl3 à 25
oC). Dans la littérature l’énantiomaire (R,R)-12 (ee = 97%) présente une valeur []D 
+ 68 (c 0,96, CHCl3 à 27
oC). Nous avons ainsi pu déduire que l'énantiomère majoritaire de 10 
avait une configuration absolue (1R,5R) (Schéma i). 
 
 
Schéma i: Transformation de 10 en 12. 
Dédoublement du ()-cis-3,4CB-GABA par HPLC 
Nos tentatives pour obtenir du cis-3,4 CB-GABA énantiomériquement pur par la 
photoélectrocyclisation énantiosélective de l'azépinone 8 en présence de β-CD en tant qu'hôte 
chiral, suivis d'une réduction du photoadduct, ont fourni des échantillons de 2-
azabicyclo[3.2.0]heptan-3-one 10 avec un excès énantiomérique au maximum de 45%. 
Afin de disposer d'une méthode d’accès plus appropriée à l'acide aminé cible cis-3,4CB-GABA 
sous une forme énantiomériquement pure, nous avons développé une stratégie de dédoublement 
de son dérivé racémique N-Boc 12 en utilisant une HPLC semi-préparative (Figure i). Une telle 
procédure présenterait plusieurs avantages par rapport à la méthode déjà décrite et qui repose 
sur la dérivatisation à l'aide d'une oxazolidinone chirale, comme nous l'avons mentionné 
précédemment.
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Figure i: Dédoublement par HPLC semi-préparative du N-Boc-cis-3,4CB-GABA 12 racémique. 
L’acide (±)-12 a pu être dédoublé grâce à une colonne Lux Cellulose-3 chirale, mais en raison 
de sa faible solubilité dans l'éluant, la séparation à l'échelle semi-préparative n'était pas 
efficace. 
Afin de contourner ce problème, nous avons effectué le dédoublement de l'ester benzylique (±)-
13, qui présentait une plus grande solubilité dans les solvants organiques (Schéma j). 
 
Schéma j: Synthèse de l’ester benzylique (±)-13 à partir de (±)-12 
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L'ester benzylique (±)-13 a été dédoublé sur une colonne Lux Cellulose-2 chirale en phase 
normale. La figure j montre le chromatogramme en HPLC analytique de (±)-13. 
 
 
Figure j: Chromatogramme en HPLC analytique de (±)-13 
Nous avons pu ainsi obtenir des fractions pures de chaque énantiomère de l’ester 13, comme le 
montre les chromatogrammes ci-dessous (Figure k). 
 
Figure k: Chromatogramme des énantiomères (+)-13 (en haut) and (-)-13 (en bas) purs. 
La configuration absolue de l’énantiomère (+)-13 a été déterminée par analyse par diffraction 
des rayons X comme étant (3R,4R). Nous avons donc déduit que l’énantiomère (-)-13 était de 
configuration (3S,4S) (Figure l). 
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Figure l: Structure par diffraction aux rayons X du (+)-(3R,4R)-13. 
 
Synthèse et structuration des peptides hybrides / 
Au cours des dernières années, le groupe du Pr. Aitken s’est spécialisé dans la synthèse 
d’acides aminés non naturels, contraints par un cyclobutane, et la préparation d’oligomères à 
partir de ces blocs de construction. Les oligomères de ces acides aminés contraints présentent 
des angles dièdres spécifiques qui leur confèrent la capacité de favoriser des structurations 
secondaires stables en trois dimensions. Bien que de nombreuses connaissances théoriques 
établissent une corrélation entre la structure des acides aminés et le schéma de repliement des 
peptides, il reste encore beaucoup à explorer expérimentalement avant de pouvoir établir une 
séquence peptidique afin d’anticiper un repliement spécifique dans une approche « bottom-
up ».
Les études théoriques ab initio effectuées par le groupe d’Hoffman ont suggéré que, dans un 
peptide hybride /γ, un angle dièdre θ d’environ 33°, sur le -amino acide, était idéal pour la 
formation d'une hélice 12/10. Sur la structure de l'ester (+)-(3R,4R)-13, nous avons pu mesurer 
un angle θ d'environ 27° (Figure m), ce qui en faisaitt un bloc de construction approprié pour 
un peptide α/γ qui pourrait se structurer en hélice 12/10. 
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Figure m: Structure cristalline du (+)-(3R,4R)-13 with the θ value. 
Ayant les deux énantiomères du cis-3,4CB-GABA en mains nous avons voulu voir l’effet de la 
stéréochimie du -aminoacide sur le repliement d’un peptide . Nous avons donc synthétisé et 
caractérisé des peptides hybrides  composés d’alternativement de la D- Alanine avec soit du 
(3S,4S)-, soit (3R,4R)-cis-3,4CB-GABA. La structuration tridimensionnelle de ces peptides a 
ensuite été étudiée. 
 
Procédure générale de synthèse des peptides hybrides γ/α. 
Nous avons débuté la synthèse des peptides cibles via une approche convergente impliquant le 
couplage de la D-alanine et l'un des énantiomères du cis-3,4CB-GABA en présence de l’agent 
de couplage HATU. 
Le dipeptide obtenu a ensuite été partitionné en deux ; une partie a été sélectivement déprotégée 
à l'extrémité N-terminale en présence de TFA, l'autre partie a été déprotégée sélectivement à 
l'extrémité C-terminale par hydrogénation catalytique en présence de Pd-C. Les deux dipeptides 
monoprotégés ont ensuite été couplés en présence de DIPEA et d'HATU pour conduire au 
tétrapeptide correspondant (Schéma k). 
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Schéma k: Schéma général de la synthèse convergente des Boc-cis-3,4CB-GABA-(R)-Ala]n-OBn 
di- and tetra-peptides. 
 
Analyses Structurale et Conformationelle en solution 
Par cette approche, les deux -dipeptides, Boc-S,S-GABA-R-AlaOBn et Boc-R,R-GABA-R-
AlaOBn, ainsi que les deux -tetrapeptides, Boc-(S,S-GABA-R-Ala)2OBn et Boc-(R,R-
GABA-R-Ala)2OBn, ont été préparés et par la suite entièrement cractérisé (Figure o). 
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Figure o: Les quatre peptides hybrides γ/α préparés, en série (S,S/R) (à gauche), en série 
(R,R/R) (à droite). 
Aucune liaison hydrogène intramoléculaire n’a pu être mise en évidence sur les deux séries de 
dipeptides. La structure par diffraction aux rayons X montre, elle, un réseau de liaisons 
hydrogènes intermoléculaires assurant un empilement parallèle pour le dipeptide p3 et 
antiparallèle pour p1 (Figure p and q).  
 
Figure p: Structure par diffraction aux rayons X du peptide p3 (enhaut), réseau de liaisons 
hydrogène intermoléculaires, vue de côté (à gauche), de face (au milieu), de dessus (à droite). 
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Figure q: Structure par diffraction aux rayons X du peptide p1 (enhaut), réseau de liaisons 
hydrogène intermoléculaires, vue de côté (à gauche), de face (au milieu), de dessus (à droite). 
Des expériences de NMR 2D ROESY ont été effectuées sur les tetrapeptides p2 et p4. Les 
corrélations ROE visibles pour le tetrapeptide p2 suggèrent la présence d'une alternance de 
pseudocyles à 12 et 10-atomes indiquant une tendance de ce peptide à adopter une structure 
secondaire hélicoïdale 12/10 en accord avec les prédictions d’Hoffmann(Figure r). 
 
Figure r: Corrélations ROE caractéristiques sur le tetrapeptide p2 (en haut) montrant la 
présence de pseudocycles (en bas) à 10 atomes (bleu) et à 12 atomes (vert). la flèche bleu 
claire correspond à une corrélation ROE faible. 
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Contrairement au tetrapeptide p2, les corrélations ROE observées pour le tetrapeptide p4 ne 
suggèrent pas la présence d'une hélice 12/10, mais plutôt la présence d’une alternance de 
pseudocycles 7/9 (Figure s). Ce type de structuration, qui n’a pas était décrite à ce jour et qui 
résulte d'interactions entre des liaisons peptidiques adjacentes, est une structuration compétitive 
suggérée par Hofmann. 
 
Figure s: Corrélations ROE caractéristiques sur le tetrapeptide p4 (en haut) montrant la 
présence de pseudocycles (en bas) à 9 atomes (orange) et à 7 atomes (rose). La flèche orange 
claire correspond à une corrélation ROE faible.\ 
Conclusion et Perspective 
Le but de ce travail était de préparer les deux -amino acides cyclobutaniques contraints, cis-
2,3CB-GABA et cis-3,4CB-GABA, par une transformation énantiosélective et de les utiliser 
comme blocs de construction pour la synthèse de peptides hybrides  susceptibles d'adopter 
une structuration hélicoïdale. La cyclodextrine a été choisi comme molécule hôte afin d’induire 
cette chirogénèse supramoléculaire lors de la formation du cyclobutane par voie 
photochimique. 
Dans ce but nous avons synthétisé le N-allyl-N- (4-méthoxyphényl) acrylamide 1 afin de le 
soumettre à une réaction de photocycloaddition [2+2] pouvant mener au lactame bicyclique 2, 
précurseur du cis-2,3CB-GABA. La complexation du composé 1 avec la cyclodextrine a été 
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évaluée grâce à des expériences en NMR 1H, 1D et 2D qui ont montré des interactions 
significatives entre les protons de l’hôte et de l’invité. Le ratio 1/CD du complexe a été identifié 
comme étant de 1:1 avec une faible constante de complexation Kb=14.7. 
La photocycloaddition réalisée sur le composé 1, en l’absence de -cyclodextrine n'a pas 
conduit au produit de cycloaddition photochimique [2 + 2] attendu, mais au 1-allyl-6-méthoxy-
3,4-dihydriquinoléine-2(1H)-one 5, résultant d'une électrocyclisation 6 photochimique suivie 
d'un réarrangement sigmatropique 1,5. 
D’autre part, nous avons étudié la photoélectrocyclisation de la 1,3-dihydro-2H-azépine-2-one 
8 en présence de β-cyclodextrine, pouvant mener à un photocycloadduit 9 énantiomériquement 
enrichi, précurseur du cis-3,4CB- GABA. La complexation du composé 8 avec la -
cyclodextrine a été évaluée par des expériences en NMR 1H 1D et 2D 1H RMN qui ont montré 
des interactions significatives entre les protons de l'hôte et de l'invité. Le complexe a été 
identifié comme présentant un rapport 1: 1 (β-CD / 8) et une constante de complexation 
modérée (Kb=35,4). 
L’irradiation du complexe -CD / 8 en solutions aqueuses, en suspensions dans l’eau ou à l’état 
solide, a provoqué l’électrocyclisation de l’azépinone 8 pour donner le photocycloadduit 9. Ce 
dernier ayant une très faible solubilité dans les solvants organiques, à été immédiatement réduit 
par une hydrogénation « one-pot » en 2-azabicyclo[3.2.0]heptan-3-one 10 avec des rendements 
allant jusqu'à 79% à parti de l'azépinone 8. L'excès énantiomérique le plus élevé (45%) a été 
obtenu lorsque l'irradiation a été réalisée sur le complexe β -CD / 8 en suspension dans l’eau. 
Poursuivant nos efforts pour accéder au (R, R)- et (S, S)-cis-3,4CB-GABA, nous avons établi 
une méthode de dédoublement de son dérivé N-Boc ester benzylique 13 racémique, par HPLC 
semi-préparative équipé d’une colonne chirale. Par cette technique nous avons pu obtenir les 
deux énantiomères sous forme pure et à l'échelle du gramme. 
Les dérivés énantiomériquement purs (-)- et (+)-cis-3,4CB-GABA ont ensuite été utilisés pour la 
synthèse deux séries de peptides diastéréoisomères. Ces peptides hybrides étaient composés 
d'une alternance de (-)-cis-3,4CB-GABA ou de (+)-cis-3,4CB-GABA et de D-Alanine. Deux -
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dipeptides, Boc-S,S-GABA-R-AlaOBn p3 et Boc-R,R-GABA-R-AlaOBn p1, ainsi que deux 
-tétrapeptides, Boc-(S,S-GABA-R-Ala)2OBn p4 et Boc-(R,R-GABA-R-Ala)2OBn p3 ont été 
préparés selon une synthèse convergente, et entièrement caractérisés. 
L'analyse de cristaux des deux dipeptides diastéréoisomères, par diffraction des rayons X, n'a 
révélé aucune interaction intramoléculaire, mais un réseau de liaisons hydrogène 
intermoléculaires. Des expériences de RMN 1D et 2D ont montré qu’en solution, le tétrapeptide 
Boc-(S,S-GABA-R-Ala)2OBn p4, adopte une conformation en hélice 12/10, alors que son 
diastéréoisomère Boc-(R,R-GABA-R-Ala)2OBn p3, présente une structuration inédite en hélice 
7/9. 
Une des perspectives de ce travail, est d’obtenir la photocycloaddition [2+2] du N-
allylacrylamide. Cette réaction pourrait être favorisée en remplaçant le groupement aryl 
(pMeO-phényle) par un groupement benzyle sur l’atome d’azote de l’amide, le système 
conjugué à 6 électrons π responsable de l’électrocyclisation n’étant plus là. 
La complexation -CD / azépinone 8 pourrait être renforcée par l'utilisation d'un groupement 
benzyle ou tertio-butyloxycarbonyle sur l’atome d'azote et ainsi améliorer l’énantiosélectivité 
lors de l'électrocyclisation de l'azépinone 8. 
Des -tétrapeptides, Boc-(S,S-GABA-R-Ala)nNHBn, pourraient être préparés et leurs 
préférences conformationnelles étudiées, car l'hydrogène de la fonction amide C-terminale 
pourrait fournir une liaison hydrogène supplémentaire, pouvant renforcer une structuration 
seconda. 
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Résumé : Le but de ce travail était la préparation de 
dérivés cyclobutaniques du GABA optiquement purs et 
leur utilisation dans la préparation de γ/α-peptides 
pouvant adopter une structure tridimensionnelle bien 
définie. Pour cela, deux stratégies ont été développées. 
La première consistait en l’utilisation de la β-
Cyclodextrine comme hôte supramoléculaire chirale 
lors de cyclizations photochimiques énantioséléctives. 
La tentative de cyclisation [2+2] intramoléculaire du 
N-allyl-N-(4-methoxyphenyl)acrylamide n’a conduit 
qu’à un δ-lactame issu d’une électrocyclisation 6π. 
L’électrocyclisation de la 1,3-dihydro-2H-azepin-2-one 
nous a permis d’obtenir le γ-latame bicyclique 
précurseur du (+)-cis-3,4CB-GABA avec un excès 
énantiomérique de 45%. La deuxième stratégie était 
basée sur une synthèse racémique du N-Boc-cis-
3,4CB-GABA suivi d’une séparation des deux  
énantiomères par CLHP semi-préparative avec une 
colonne chirale. 
Les (-) et (+)-cis-3,4CB-GABA  optiquement purs ont 
ainsi été obtenu à l’échelle du gramme. Ces deux 
énantiomères (-) et (+)-cis-3,4CB-GABA  ont ensuite été 
utilisés pour la préparation de deux séries de peptides 
mixtes-γ/α, diastéréoisomères [(S,S/R) et (R,R/R)] à 
courtes chaines contenant alternativement le cis-3,4CB-
GABA et le D-Alanine. L'analyse des conformations des 
dipeptides des deux séries par Diffraction des Rayons X, 
n'a montré aucune interaction intramoléculaire mais plutôt 
un assemblage de liaisons d'hydrogène intermoléculaires 
entre les molécules du dipeptide. D'autre part, les études 
RMN 1D et 2D (en solution) ont montré que le 
tétrapeptide des séries (S,S/R) pourraient avoir une 
structure hélicoïdale 12/10, tandis que son analogue 
diastéréoisomères des séries (R,R/R), a montré, en 
solution, une nouvelle structure sous forme de ruban 7/9. 
 
 
Title : New Enantioselective Transformations Induced by Cyclodextrins: Applications in the Preparation of Molecular 
Building Blocks of Biological Interest 
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peptide coupling. 
Abstract : This work revolves around the synthesis of 
ennatiomerically pure cyclobutane derivatives of 
GABA, and their use in the preparation of hybrid γ/α-
peptides that could adopt a well-defined three 
dimensional secondary structure. In this aim we 
developed two strategies. The first one employed native 
β-Cyclodextrin as a supramolecular chiral host to 
achieve enantiodifferentiating photochemical 
cyclizations. Attempting to perform an intramolecular 
[2+2] cyclization of N-allyl-N-(4-
methoxyphenyl)acrylamide, we  only obtained a δ-
lactam resulting from a 6π; electrocyclization, whereas 
the electrocyclization of 1,3-Dihydro-2H-azepin-2-one 
allowed access to a 45% enantiomerically enriched 
bicyclic γlactam precursor of (+)-cis-3,4CB-GABA. The 
second strategy was based on a racemic synthesis of N-
Boc-cis-3,4CB-GABA followed by a separation of the 
two enantiomers using a semi-preparative HPLC  
fitted with a chiral column. This allowed access to 
optically pure (-) and (+)-cis-3,4CB-GABA, on a gram 
scale. Furthermore, the enantiomerically pure (-) and (+)-
cis-3,4CB-GABA, were used to synthesize, and fully 
characterize two series [the (S,S/R) and the (R,R/R)] of 
short diasteriomeric hybrid γ/α-peptides composed of 
alternating cis-3,4CB-GABA and D-Alanine. Analysis of 
the conformational behavior of the dipeptides from both 
series by X-Ray diffraction on a single crystal, showed 
no intramolecular interactions but rather an array of 
intermolecular hydrogen bonding between the dipeptide 
molecules. On the other hand, a series of 1D and 2D 
NMR experiments showed that the tetrapeptide of the 
(S,S/R)-series could attain a 12/10 helical structuration, 
whereas its diasteriomeric analog of the (R,R/R)-series, 
displayed evidence of an  unprecedented 7/9 folding 
pattern in solution. 
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